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Abstract 
Although the first bacterial genome sequence was published almost 20 years ago, there 
is still no generalizable method for automatically assigning natural products to their 
cognate biosynthetic gene clusters (BGCs). This thesis describes the development of a 
mass spectrometry-based parallel stable isotope labeling (SIL) platform, termed 
IsoAnalyst, which automatically associates metabolite stable isotope labeling patterns 
with BGC structure prediction in order to connect natural products to their cognate 
BGCs. The parallel SIL experiments were optimized for small scale and a custom tool 
written in Python was developed for the untargeted detection and interpretation of SIL 
labeling patterns. This approach was validated in the industrial production strains 
Saccharopolyspora erythraea and Amycolatopsis mediterranei demonstrating that the 
compounds erythromycin A and rifamycin SV respectively, could be associated with the 
proper BGCs based on the distribution of isotopomer labeling patterns. The method was 
further validated by connecting known biosynthetic intermediates of these compounds to 
their associated BGCs and the identification of various siderophores through a 
combination of SIL labeling patterns and MS/MS fragmentation data. Extension to 
environmental organisms using a sequenced Micromonospora sp. from our 
Actinobacterial isolate library led to the discovery of lobosamide D, a new member of the 
lobosamide family of natural products, and an update to the lobosamide BGC to include 
relevant tailoring enzymes. This discovery illustrates the power of the IsoAnalyst 
platform for identifying new compounds, linking molecules to BGCs, and generating new 
knowledge about biosynthesis.  
Keywords:  Metabolomics; Mass Spectrometry; Stable Isotopes; Biosynthetic Gene 
Clusters; Natural Products 
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Chapter 1.  
 
Modern Natural Products: Interdisciplinary 
Approaches in the Multi-Omics Era 
1.1. Introduction  
The relationship humanity shares with chemistry produced in nature has been 
central to not only to our health but also to our indulgence in food, color, and aromas for 
as long as humans have had the capacity to value such pleasures.1,2 The oldest 
recorded uses of natural products come from plants, as they are a plentiful and 
accessible source of chemistry. Records of humans using plants for medicinal purposes 
dates back as far 2900 B.C., with the Ebers Papyrus, an Egyptian pharmaceutical record 
documenting over 700 plant-based medicines.1 Willow bark, for example, has been 
utilized as a medicinal treatment for pain and fever in traditional cultures around the 
world for thousands of years, due to the presence of a compound salicin, which is 
metabolized to the active component, salicylic acid, in the human body.1,3 In the 
nineteenth century, salicylic acid was further developed into acetylsalicylic acid, more 
commonly known as aspirin, and is still one of the most popular drugs for treating 
common maladies.3  
Since the advent of natural product chemistry as a modern scientific discipline, 
we have been continually inspired by the complexity and specificity of natural product 
structures. Compounds evolved to solve problems encountered by plants, fungi, and 
bacteria in the natural world have had an undeniably massive effect on human health.4,5 
Biological sources from every corner of the planet have been studied for their capacity to 
produce bioactive chemistry.1,6 Single-agent approaches to drug discovery have not only 
advanced therapeutic applications, but also provide researchers with chemical probes 
and tools for studying mechanism of action.7,8 While the question of how many truly 
novel natural product scaffolds remain to be discovered in nature is still contended,9–11 
the ecological functions of many known natural products are still not understood.5,6 In the 
last century there have been significant advances in our ability to study these 
compounds, which are often produced in incredibly small quantities due to their potency 
2 
and the energy required to produce them.12 Genomics has further changed the face of 
natural products by revealing immense metabolic diversity in the genomes of 
microorganisms.13,14 Genetic and environmental factors contribute to the chemical 
phenotype of plant and microbial sources,15 suggesting more complex questions 
surrounding the biological production and ecological functions of natural products. 
In the post-genomic era, natural products research has moved beyond drug 
discovery to other applications in human health such as the complex interactions and 
immunity conferred by the microbiome.16,17 There is no doubt that natural product 
research has had a massive impact on modern medicine,4 but historical, traditional, and 
cultural knowledge of natural sources of medicines are still making their mark on human 
health.18 The Nobel laureate, Tu Youyou, was acknowledged in 2015 for her work 
towards the discovery of the anti-malarial natural product artemisinin, which she 
famously extracted by interpreting ancient Chinese medical texts.19,20 According to the 
World Health Organization (WHO), traditional and complementary medicines are a 
significant source of primary and complementary health care globally.21 WHO 
emphasizes the importance of researching of naturally derived medicines which will 
continue to play a significant role in global health.21 Developing a more holistic 
understanding of natural products and their roles in nature and human health is finally 
possible under the culmination of decades of biological and chemical research in multi-
omics disciplines.18  
1.1.1. The Omics Family 
Twenty years ago, William Bains wrote in regards to the field of genomics:22  
The genome has turned out the be a relatively poor source of explanation 
for the differences between cells or between people. 
This was something of a bitter revelation that took the scientific community 
decades to come to understand. The discovery of the genetic code led to ever growing 
excitement over promises the ‘blueprint for life’ offered to revolutionize medicine by 
revealing a genetic source for every disease. Over time, the sequencing of genes 
became faster, cheaper, and more efficient, and the field of genetics grew into 
genomics. Certainly if genetic sequences could provide the instructions for cellular 
functions, whole genome sequences would reveal every gene and its function in the 
3 
diversity of life. However, the one gene one enzyme model began to unravel as full 
genome sequencing revealed far fewer genes than could account for all characterized 
proteins.  
At the turn of the century, the field of genomics had reached a pivotal moment. 
The genetic determinism that had dominated the past 50 years of biology was no longer 
sufficient to describe biological variation. In his 2001 commentary “The parts list of life”, 
Bains underpins the significant need to transition towards a systems biology approach in 
order to apply different levels of explanation, such as genomics or proteomics, to higher 
levels of understanding disease, human health, and basic phenotypic variations.22 In an 
earlier commentary, he compares this systematic thinking to a more obvious scenario:23 
Saying that a gene ‘causes’ hypertension or depression is similar to saying 
that a flat tire ‘causes’ a car to slow down. In a few pathological situations, 
the two are causally linked, but most cars traveling slowly do not have flat 
tires. A ‘tire knockout car’ would tell us little about traffic lights or driving 
skills or speed cameras.  
It seems a bit ridiculous to take the tires off of a car in order to answer questions 
about the car’s speed, but this does demonstrate the nature of genetic knock-out 
experiment with a narrow outlook on how the genetic knock-out actually changes the 
system. The speed of the car is not only determined by the tires but also inherently by 
the engine and circumstantially by the driver, traffic, weather, and route. Likewise, a 
gene’s function is determined by many more factors than just its sequence. A researcher 
interested in applying the knowledge of genomics to a biological system needs a toolbox 
of approaches at many explanatory levels, or else risk mistaking a traffic light stuck on 
red with a nail in the tire. Proteomics, transcriptomics, and metabolomics were young 
fields twenty years ago, but they were already being applied in innovative ways to 
explain phenotypes and metabolic processes.24 Genomics, and the daughter 
technologies that have come subsequently, arose from a need to functionally understand 
the connection between genotype and phenotype.  
 Transcriptomics looks at a snapshot of mRNA transcripts present in the cell as 
evidence to account for genes that are actively being transcribed, while proteomics 
provides evidence for enzymes and other proteins that are actively being translated. All 
stages, including genomics, are subject to a variety of factors that regulate and control 
the flow of information through each level.25 Epigenomics is a growing area looking at 
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factors influencing gene expression that has added yet more complexity to the whole 
picture of gene expression.26 Metabolomics is the only omics technology that looks 
directly at output of all the aforementioned biochemical processes. Metabolomics is the 
most direct way to study phenotypic output and has proven to be much more powerful in 
clinical diagnostics than genomics.25,27  The main bottleneck in metabolomics studies is 
still the difficulty in quickly and definitively identifying compounds, as well as 
differentiating unknown from known metabolites.12,25,28 
Today, multi-omics approaches are advancing quickly and becoming the 
standard for understanding biological systems. As our knowledge of biological systems 
deepens, there is an ever greater need to incorporate large datasets together to draw 
meaningful conclusions and many reviews are now available on technological advances 
allowing for the combination of this information.26,29–31 In this thesis I focus on the 
development of a mass-spectrometry based metabolomics tool to connect chemical 
phenotypes to genomic information. The motivation for this work is grounded in the 
unique position of metabolomics to galvanize a more holistic view of systems biology 
through its relationship to other omics technologies. 
1.1.2. The Genomic Era of Natural Product Discovery 
Genome sequencing has fundamentally changed the paradigm of natural 
products research and discovery. By the 1980s, natural product chemistry as a field was 
already focused on the chemical phenotype of cells, but had yet to fully dive below the 
surface of the genomic origin of these metabolites.14 Classical genetic techniques were 
used to establish biosynthetic logic and understand the genetic basis for specialized 
metabolism, but most natural product discoveries in bacteria and fungi were applied in a 
chemistry-focused manner.14 Bio-assay guided fractionation was the dominant technique 
that focused on identifying chemistry in terms of its structure and function.1 Bacterial 
natural products had been a fruitful area of research for a number of decades but around 
the 1990s many industrial research programs were turning away from natural products 
research as it was believed we were reaching a plateau of discovery.1,18 Model 
actinobacterial species such as Streptomyces coelicolor were known to produce a few 
compounds and an organism that produced 5 or 6 compounds was considered a 
privileged producer (Figure 1.1). However, when S. coelicolor was sequenced in 2002 it 
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was found to have a plethora of identifiable BGCs without distinct products known to be 
produced.14,32 This observation became a trend as more bacterial genomes were  
 
Figure 1.1 Natural Products Produced by Streptomyces coelicolor 
Structures of natural products produced by S. coelicolor which were discovered prior to the 
publication of the full genome in 2002 (top), and those products discovered after the genome was 
sequenced (bottom).  
sequenced and initiated a genomics revolution in natural products research. Like genetic 
determinism, genomics-driven natural products research at first promised to generate 
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fast and high-throughput workflows to discover novel chemistry by drawing direct 
connections between BGCs and compounds.13 As databases fill with BGC sequences, 
the influx of novel chemistry discovery has not followed, and the idea that every new 
BGC would also produce novel chemistry was soon shown to be flawed.33 Just as one 
gene does not produce one enzyme, BGCs likewise do not produce singular chemical 
entities.34,35 The levels of explanation of BGC diversity and evolution are still being built 
through the development of computational and analytical tools discussed throughout this 
chapter.  
1.2. Advances and Challenges in Genomic Discovery of 
Natural Products 
1.2.1. Tools for Sequencing and Analyzing Biosynthetic Gene 
Clusters 
With advancing technology and decreasing costs, the accessibility of high-quality 
genome information has increased exponentially.36,37 Over the last decade, this 
accumulation of genome sequence data has inspired the development and refinement of 
computational tools for identifying biosynthetic gene clusters (BGCs),38 predicting 
structural elements of the compounds they produce,39,40 prioritizing novel BGCs,41 or a 
combination thereof.42 Technological advances in sequencing have been a major driver 
in that ability of researchers to access genetic sequences of BGCs. BGCs are made up 
of large multi-modular domains resulting in long repetitive genetic sequences that are 
difficult to align due to high overlap.43 Second and third generation sequencing 
technologies have complementary strengths, in terms of read length compared to error 
rate.44 Third generation single molecule real time (SMRT) sequencing produces average 
read length of over 10 kb, compared to the 250 bp maximum read length of Illumina 
HiSeq, but suffers from a higher error rate.44 For the application of assembling the large 
multi-domain BGCs that produce natural products, the tradeoff of a higher error rate for 
longer read lengths offered by SMRT is necessary to align large BGC sequences. Even 
laboratories that are not equipped to work with genomic sequencing technology can 
access genomic data and analysis of published BGC sequences through public 
databases such as the atlas of biosynthetic gene clusters within the Integrated Microbial 
Genomes system (IMG-ABC),45 the Minimum Information about a BGC database,46 and 
the antiSMASH database47 (Figure 1.2). These databases will continue to grow in both 
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size and value to the scientific community as annotations and experimental validation of 
chemical structures are updated. Community efforts such as the Natural Products Atlas48 
and Lotus49 databases also enhance our understanding of the “specialized metabolome” 
by providing curated records linking structures to the taxonomy of their producing 
organisms. 
 
Figure 1.2 Overview of Genomics, Metabolomics, and SIL Tools 
This thesis focuses on the intersection of genomics, metabolomics, and SIL, which have 
complementary technologies and have been integrated in various ways. The center of this figure 
shows the technologies and advantages of each technique and the lines connecting genomics, 
metabolomics, and SIL show current integration of each technique. Genomics tools for BGC 
identification include antiSMASH for bacterial genomes, as well as related programs for fungi, 
plants, and intestinal microbiome sources, large-scale comparative genome analyses (BiG-
SCAPE52), and open source BGC databases such as MIBiG46 and IMG/ABC.45 In metabolomics, 
growing metabolite databases facilitate the extension of both targeted and untargeted studies. 
SIL has proven to be a versatile technique, which is applied in different ways to both genomics 
and metabolomics.  
Because of the increasing availability of full genome data, there have also been 
important advances in computational tools for the identification of BGCs, and for 
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prioritizing them based on novelty or relatedness.50 High confidence/low novelty tools 
that utilize hidden Markov models (HMM) and training sets to identify BGC Pfams are 
now standard for identifying non-ribosomal peptide synthase (NRPS) and polyketide 
synthase (PKS) BGCs.36 Computational tools such as antiSMASH42 and PRISM37  apply 
HMMs to identify BGCs and represent a significant advance in the accessibility of BGC 
analysis to natural product chemists who do not typically have the background or 
resources to work with large genomic datasets. These tools rely on training sets of 
sequence alignments from well-characterized biosynthetic domains and therefore have a 
bias towards finding BGCs related to known classes. Although this is very effective for 
identifying new BGCs of known classes, two novel algorithms that prioritize novelty over 
confidence have been developed. The ClusterFinder algorithm uses an HMM to identify 
regions of the genome containing Pfam domains that resemble the overall organization 
and frequency of a BGC, as opposed to specific domains related to biosynthetic 
transformations.38 ClusterFinder is available within the antiSMASH platform and can be 
run alongside the more traditional profile HMM algorithm for detecting known 
biosynthetic classes. Another approach, termed EvoMining, searches for additional 
copies of genes for primary metabolic enzymes, on the basis that specialized 
metabolism evolves from divergent copies of primary metabolic genes.41 EvoMining 
prioritizes novelty by searching for genes known to derive from primary metabolism, but 
which may have novel biosynthetic activity compared to relying on training sets derived 
from known biosynthesis.41  
The growing accessibility and versatility of these BGC analysis tools has 
transformed genome mining towards a more global approach. Large-scale comparison 
of genomic datasets and sequence alignment has enabled BGC discovery and 
classification across phyla, and deepened our understanding of gene cluster 
families.14,33,36 The sequencing and characterization of hundreds of BGCs over that past 
ten years has opened new opportunities to look at the global diversity of BGCs across 
phyla. Comparisons of BGC families across multiple genomes have proven to be 
powerful tools in leveraging these large dataset for natural product discovery.38,51 
Bacterial genome analysis is rapidly changing from an effort directed towards a handful 
of strains, to one focused on thousands of sequences. Large-scale comparisons of BGC 
families have proven to be powerful tools in leveraging these large datasets for natural 
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product discovery and for associating shared biosynthetic capacity with natural product 
production.31,52 
1.2.2. Connecting Molecules to Biosynthetic Gene Clusters 
The highest standard of evidence for connecting a BGC to the metabolite(s) 
produced is through heterologous expression, or a combination of promoter and knock-
out studies to validate compound production when the BGC is being expressed. Pre-
genomic era approaches relied on reverse genetics and heterologous expression to 
painstakingly assign BGCs to known chemistry.14 Modern techniques for heterologous 
expression53,54 and silent BGC activation55 have re-invigorated biochemical approaches 
for natural product discovery. However, the massive accumulation of genomic data is 
further enabling analytical techniques for making connections between BGCs and 
compounds on a larger scale.31 New BGCs are discovered with a higher frequency than 
new natural products due to a lack of tools for systematically connecting chemistry with 
BGCs.31,56 It is a much more standard procedure to detect and compare BGCs across 
genomic datasets than it is to fully characterize the chemical potential of a single 
organism.  
Two major bottlenecks in identifying chemistry from BGCs are the inaccuracy of 
compound structure prediction from BGC sequences, and the detection and 
dereplication of known and unknown compounds in metabolomics datasets.31 Structure 
prediction from BGC sequences does not currently have a high enough accuracy to be 
fully automated.31 Although domain sequences can be leveraged to predict enzyme 
substrates, especially for PKS and NRPS gene clusters, tailoring reactions, 
modifications, and cyclization reactions are not as predictable.31 This precludes the 
ability to predict the exact structure, fragmentation, and molecular formula of a natural 
product from its BGC. Research on co-evolving sub-clusters are advancing our ability to 
predict shared structural features among gene cluster families,40 however literature 
review remains necessary for accurate BGC substrate analysis.  
One of the most significant challenges is that not all BGCs are expressed under 
laboratory conditions.33  There are many techniques that can assist in the expression of 
cryptic or silent BGCs, including media experiments (one strain many compounds), 
challenge agents such as antibiotics, and co-culturing have all been used to encourage 
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expression of BGCs.57 Many innovative approaches have been developed to elicit 
compound production including high-throughput elicitor screening58 and CRISPR-Cas9 
strategies for activating BGCs in the native host.55 However, these powerful tools for 
compound elicitation still require advanced analytical techniques to identify target 
compounds.  
To address analytical challenges, there are two main types of approaches for 
connecting molecules to BGCs using MS metabolomics data. Feature-based methods 
use pattern matching of molecular networks generated from MS/MS fragmentation data 
to structural predictions from BGCs. The molecular networking approach employed by 
the Global Natural Products Social Molecular Networking (GNPS) knowledge base uses 
MS/MS spectra to visualize MS features with related fragmentation spectra59 (Figure 1.2) 
Algorithms that predict BGC substrates, particularly for NRPS gene clusters, can be 
associated with molecular families identified by MS/MS networks.34,60,61 This is effective 
for discovering compounds of specific classes, especially those that have distinct 
MS/MS fragmentation patterns. Correlation-based methods look at links between gene 
cluster families and molecular families across many strains harboring related 
BGCs.31,35,62 Correlation-based methods can associate shared chemistry produced 
across many strains without MS/MS data, although the fragmentation spectra often plays 
an important role. A recent preprint by Eldjárn et al. details a novel computational 
approach which applies both feature and correlation based linking of compounds to 
BGCs systematically.63 It is clear that all of these approaches have powerful ongoing 
applications in natural product discovery by genome mining. However, the over-reliance 
on MS/MS fragmentation for identifying and characterizing chemistry is a weakness that 
biases these approaches towards compounds that fragment well and BGCs that have 
predictable structures. Indeed, substrate predication is not nearly as automated as 
MS/MS fragmentation or BGC correlation across strain libraries, so orthogonal analytical 
methods to identify products of BGCs would greatly enhance these approaches.  
In this chapter I describe the context of the development of such an analytical 
method which relies on genomics, metabolomics, and SIL tracers to identify natural 
products in association with the producing BGC. This method relies on the strengths of 
each area, and the modern technological advances that have galvanized the opportunity 
to draw connections between BGCs and chemistry in a systematic manner.  
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1.3. Natural Product Characterization in Metabolomics 
1.3.1. Primary and Specialized Metabolomics 
Natural products are generally understood to be small compounds (< 1500 Da) 
produced in nature that do not serve any primary biological function, but may serve 
important biological roles under environmental pressures. For this reason, natural 
products have been referred to as ‘secondary metabolites’, implying that they are not 
required for the organism’s survival.64,65 Our understanding of what constitutes a 
secondary metabolite remains unclear as many molecules traditionally categorized as 
natural products have been shown to serve essential biological functions in niche 
environments. Consequently, the term ‘specialized metabolite’ is often used to indicate 
that these molecules serve specialized but still essential functions. While the monomeric 
units of proteins, sugars, DNA, and lipids remain nearly ubiquitous across domains of 
life, specialized metabolites are distributed according to varying ecological and 
evolutionary pressures.65  
In reality, all structural classes of compounds are differentially subject to 
metabolomics-based investigation, and do not divide neatly into primary and specialized 
metabolites based on physical and chemical characteristics alone.28 Primary and 
specialized metabolism also share pools of monomers and are biochemically structurally 
related evolutionary relatedness between metabolic processes.66 For example, even 
though they are often structurally modified and contain non-canonical amino acids, 
NRPS compounds can be analyzed by fragmentation patterns using the same physical 
and chemical principles that define how protein sequences are derived from predictable 
fragmentation in proteomics.67 Similarly, terpenes and fatty acids come from completely 
different biosynthetic classes, but both are characterized by hydrocarbon backbones. 
Although derived from different biosynthetic pathways and serving different biological 
roles, these classes of compound can both be detected and quantified by standard 
GCMS methods due to their volatility, availability of standards, and abundance of 
published protocols.68,69  
Within this body of work I will henceforth use the terms specialized metabolite 
and natural product synonymously. This is done with the intention of distinguishing 
primary and specialized metabolomics studies, not by the compounds detected in the 
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experimental system, but rather by the experimental design and proposed data analysis. 
Primary metabolic pathways that are central to proliferation and growth have been 
studied through metabolomics to establish pathway sequences, compare altered 
metabolism is different disease states, and as disease markers.25,28 Primary 
metabolomics often goes beyond looking at a snapshot of metabolite levels, towards the 
study of fluxomics, which aims to observe metabolic flux in biological systems.70 
Systems biology and fluxomics studies can inform natural product applications, 
especially in chassis optimization for production of the primary building blocks necessary 
for heterologous expression. However, secondary metabolomics studies typically aim to 
characterize the final product of a pathway, rather than assess the overall metabolic 
processes at play.12  
Both primary and specialized metabolomics aim to characterize the final products 
of gene expression however the prioritization of detected compounds differs significantly. 
Primary metabolites can be studied in a very targeted manner, focusing only on 
compounds with known identities, to derive biological insight.12 For example, routine 
metabolomics methods targeting central metabolites are used to characterize glycolysis, 
pentose phosphate pathway, and the TCA cycle as well as amino acid metabolism.25 
Many specialized metabolomics experiments aim to discover unknown or novel 
metabolites and identify known compounds only in order to deprioritize them.12 The 
value of natural products in human medicine drives this field to focus heavily on the 
discovery of new chemistry, for applications in drug discovery. The differences in aims is 
what sets apart primary and specialized metabolomics studies more than the target 
metabolites, as there is often overlap between primary and specialized metabolite pools. 
Annotation of chemistry associated with BGCs has implications across many disciplines 
in both medicine and chemical ecology.13 
1.3.2. Traditional Compound Isolation and Characterization 
Compound identification and characterization techniques have changed 
significantly throughout the history of studying natural products. In the earliest period of 
natural product discovery, from the 1940s through the 1970s, relatively simple analytical 
techniques were frequently rewarded with the discovery of novel compounds with 
powerful biological activities.64 Extracts were typically profiled using a simple but 
powerful screening technique known as TLC-bioautography. Biological extracts were 
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applied as mixtures to agar plates inoculated with target organisms as whole-cell 
live/dead assays. Hits were determined by a zone of inhibition around the spot where the 
extract was applied. Extracts demonstrating activity were then further separated using a 
TLC solvent system, and applying TLC-separated extracts to the same agar assays in 
order to track the active component in the mixture. In this iterative manner, the active 
component was identified and purified from large scale fermentations for further 
characterization.64,71 Prior to HPLC, isolation methods were less precise and often 
resulted in mixtures of isomeric compounds. Similarly, chemical characterization 
methods such as IR, NMR, and degradation analyses were less precise and required 
large quantities of compound. Because of these limitations, this period is defined by the 
discovery of compounds often produced in high titer under laboratory conditions, and 
compounds which have strong identifiable activity in whole-cell antibacterial assays.  
In the 1980s, HPLC revolutionized natural product research through the 
development of the bio-assay guided fractionation approach.1,64 Bio-assay guided HPLC 
fraction workflows were essentially a result of multiple technological advances in both 
chromatography and biological activity determination. HPLC separations of extracts are 
slow due to their time-consuming and serial nature compared to TLC which is relatively 
quick and easily run in parallel conditions.71 Despite this, the improvement in 
chromatographic precision achieved with HPLC allowed for more complete separation of 
isomers, confidently purified compounds on a micro-scale, and all around more efficient 
workflows. Automated fraction collection systems were a major driver in the throughput 
of this fractionation process, which was necessary to keep up with the advances in 
biological screening. By the mid-2000s, high throughput screening campaigns were 
becoming more available for applying large libraries of compounds made from HPLC 
separated extracts from natural sources.1 Developments in NMR and MS technologies 
further drove this field to isolate and characterize more compounds.72 
Bioactivity guided fractionation by HPLC quickly became a dominant workflow in 
natural products and it is still relied on heavily today. However, even carefully planned 
HTS and metabolomics experiments often lead to the rediscovery of compounds that 
were just as easily discovered in the TLC-bioautography workflows of the 60s and 70s.1 
Technological advances certainly drove natural products discovery over the last several 
decades, by improving the purification and analysis of natural products, but the 
challenge of deconvolution remains as a complex problem in metabolomics today as it 
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was in early discovery workflows. Indeed, databases with Rf values in numerous solvent 
systems and bioactivity profiles of natural products were used to dereplicate TLC-
bioautography results much in the same way MS/MS fragmentation comparison has 
become essential to the dereplication toolbox of modern natural products 
researchers.59,71 Advancing technology is continually met with the infinite complexity of 
nature.  
Modern metabolomics is done using MS or NMR based approaches and both 
have advantages and challenges associated with them. NMR is inherently quantitative 
but this advantage also biases the technique towards compounds produced in higher 
concentrations.65 Various techniques have been developed for compound identification 
by NMR metabolomics of complex extracts,73 however, the work presented in this thesis 
focuses on MS-based metabolomics approaches.  
1.3.3. Mass Spectrometry Metabolomics 
Technological Advances in MS have motivated the application of metabolomics 
to many different biological systems. Although it is sample destructive, MS is a highly 
sensitive technique for many compound classes and for this reason is often preferred 
over NMR for metabolomics applications. Improvements in MS resolution have 
culminated in the ultra-high resolution of the Fourier transform ion cyclotron resonance 
(FTICR) (resolution >500,000, accuracy <1ppm).65 The increase in mass accuracy has 
greatly improved our ability to predict molecular formulae and identify compounds by 
database matching. Still, a sub-1 ppm mass error is not sufficient to eliminate all 
possible molecular formulae.74 Advances in ultra-high-pressure liquid chromatography 
(UPLC) technology has allowed for sub-2 µm particle size, pressures above 500 bar, 
and effective runtimes under ten minutes. UPLC-MS is ideal for high throughput of 
metabolomics samples due to the short runtimes and excellent reproducibility in peak 
retention. No single hyphenated MS technique is ideal for complete coverage of all types 
of metabolites, however orthogonal chromatography methods (reverse phase, HILIC, 
GC, super critical fluid chromatography) and ionization techniques (ie EI, ESI, APCI, 
MALDI, DESI, etc) facilitate customized workflows for diverse metabolite coverage. 
Protocols for specific classes of compounds have become standardized for targeted 
metabolomics studies, especially of primary metabolism.25 
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In terms of natural products research and discovery, MS/MS molecular 
networking has become the gold standard for dereplication and has invigorated many 
creative MS metabolomics applications.75 The GNPS community has contributed over 
70,000 annotated MS/MS spectra for known compounds, allowing a more 
comprehensive and streamlined process for dereplication than ever before. The strength 
and sensitivity of modern MS technologies combined with the accessibility of the GNPS 
database has changed the face of natural products discovery. Beyond dereplication, the 
layering of multi-informational data such as bioactivity, taxonomy, geographical location, 
genomics, epigenetics, and SIL have greatly enhanced opportunities to apply molecular 
networking to complex problems and large datasets.75 Imaging MS has also invigorated 
new natural products discovery approaches by allowing for spatial resolving power and 
in situ detection of metabolites. There are many different ionization techniques for 
imaging MS that can be applied to different types of samples and target compounds.76 
Imaging MS can also be paired with different detection systems to allow for high mass 
accuracy, ion mobility separation, and MS/MS fragmentation.76  
These developments have led researchers to move towards a more global 
outlook on metabolomics. The sensitivity and throughput of modern MS technology 
allows for the acquisition and analysis of hundreds of thousands of mass features, many 
of which are not able to be identified by database searching.25,28 As our experimental 
snapshots of the metabolome become more complete, it is clear that our current view of 
metabolism is insufficient to account for the complexity observed in the metabolome. 
These observations demonstrate that targeted metabolomics studies will only take us so 
far in advancing our understanding of metabolism, and consequently untargeted 
metabolomics workflows have become more popular and standardized.25 While targeted 
metabolomics studies can be said to be ‘hypothesis-driven’, untargeted metabolomics 
studies are better viewed as ‘hypothesis-generating.’ A more global view of the 
metabolome promises an incredible potential for discovery, but is accompanied by new 
experimental and computational challenges. Untargeted MS metabolomics approaches 
have been mainly limited by compound identification which precludes the ability to draw 
significant biological conclusions.25 Untargeted approaches are still limited by compound 
identification, however there are a growing number of tools available to analyze MS 
metabolomics data in an untargeted manner, and databases.  
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1.4. Stable Isotope Labeling 
There is no doubt that isotopic labeling has shaped and driven our understanding 
of metabolism. The radioactive isotope 14C was used by Krebs to elucidate the TCA 
cycle77 and soon became established as the primary technique for following the fate of 
carbon atoms through biological transformations. Even stable isotopes such as 13C and 
2H were detected by chemical degradation prior to the availability of MS to elucidate the 
biosynthesis of cholesterol.78 Since heavy isotopes were first used in substrates to be 
fed into a biological system and traced to determine their metabolic fate, many advances 
have been made in both applications of SIL feedings, and detection of downstream 
metabolites. MS in particular has allowed for the efficient detection of stable isotopes, 
which have effectively replaced radioactive isotopic tracing in biosynthesis studies due to 
the considerably safer and more sensitive detection of stable isotopic tracers. SIL is the 
cornerstone of natural product biosynthesis, however, SIL applications are far from old-
fashioned, and are continually being adapted for use with innovative applications.70  
1.4.1. SIL Approaches for Genome Guided Natural Product Discovery 
Because SIL precursor feeding has been so successful in the area of elucidating 
biosynthesis, it is a natural addition to the toolbox of genome-based discovery. 
Information about the domain specificities within BGCs allow for substrate predictions, 
which are particularly well-studied for NRPS and PKS gene clusters. The genomisotopic 
approach coined in 2007, led to the discovery of the lipopetides, orfamides A-C.79 In this 
study the authors identified an NRPS BGC and used computational tools to predict the 
amino acid sequence of the peptide product79 (Figure 1.3) They used 15N labeled 
leucine, which was selected because it was predicted to occur in the product structure 
four times, ensuring more robust MS and NMR signals. This was a highly targeted but 
effective approach, which relied on selecting SIL precursors specific to a single target 
BGC.  
Similar approaches have been successful in targeting compound discovery 
based on substrate specificity analysis of enzymatic domains of cryptic BGCs.80,81 This 
however often requires the use of advanced precursors which target the BGC of interest 
selectively compared to other BGCs present in the genome. Compounds that are 
tailored to predicted enzyme specificity are more expensive and it is common to use 
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precursors containing multiple labeled positions to clarify instances of direct 
incorporation from labeling derived from metabolic processing of the SIL precursor prior 
to incorporation80 (Figure 1.3) Although the genomisotopic approach is powerful for 
targeted discovery, these limitations impede the development of an easily generalizable 
approach for isotopically labeling natural products globally. 
 
Figure 1.3 SIL Tracers and Common Biological Applications 
Examples of SIL tracers that are commonly used in SIL feeding experiments to study primary 
(orange boxes) and specialized (blue boxes) metabolism. Most groups of metabolites used as SIL 
tracers may be applied to both primary and specialized metabolism. Because metabolic flux 
experiments look at the full metabolic landscape, they tend to rely on central primary pathways 
while specialized SIL metabolomics tend to use more targeted SIL tracers.  
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1.4.2. Stable Isotope Labeling in MS Metabolomics 
SIL has many versatile applications in MS metabolomics. In particular, SIL 
assists in molecular formula assignment74 and in differentiating biologically derived 
compounds from background ions.70 Fully labeled extracts can be paired with unlabeled 
extracts as reference standards to assist in compound identification.70 SIL MS 
metabolomics is also applied to detect the biotransformations of xenobiotics82 as well as 
in metabolic flux analysis to determine metabolic fluxes under steady-state or dynamic 
conditions.83 Metabolic flux is a measure of metabolite turnover over time and provides 
an orthogonal view of cellular metabolic phenotype to metabolomics (Figure 1.3).   
Metabolomics is an attempt to observe the complete metabolic phenotype of an 
organism at a given moment in time.70 Although this static view of the metabolome is rich 
and informative, it is not sufficient to gain a complete biological understanding of 
metabolism. Fluxomics is an adjacent field to metabolomics that is often used in 
conjunction with other ‘omics’ techniques to build systems level models of biological 
systems. SIL compounds, typically labeled by 13C, are used to trace the flux through 
different metabolic pathways over time. Advanced computational analysis of SIL 
incorporation across the metabolome can determine pools of metabolites that are 
enlarged or depleted, and illuminate the metabolic pathways responsible based on 
layered omics information that underlies the constructed metabolic network.83 Metabolite 
levels and fluxes provide complimentary and essential pieces of information in 
understanding the underlying metabolic system.70 For example, a metabolomics 
experiment may detect a significant increase of a certain metabolite in a disease state 
model, but the metabolite level alone will not tell you if the pathway that consumes it has 
been downregulated, or if a reaction that produces it has been upregulated. Complex 
computational models are used to interpret these data but intuitive interpretation of 
untargeted SIL metabolomics data can be used to complement fluxomics. Because 
metabolic flux analysis is constraint based and requires exact inputs to the system, it is 
not ideal for natural product discovery which relies on changing environmental conditions 
and genetic manipulations to encourage compound production. In natural products, 
fluxomics analyses are most often applied to microbial factory and chassis optimization 
as opposed to compound discovery. However, because fluxomics aims to look at the full 
metabolic system of an organism, many powerful orthogonal data analysis tools have 
been developed for untargeted SIL detection across the metabolome.84  
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1.4.3. Untargeted Metabolomics 
Untargeted SIL metabolomics present a very exciting outlook on the future of 
metabolic studies. These approaches have great potential for discovery of new 
metabolites, pathways, and genes.84 As I have covered throughout this chapter there 
have been significant advances in MS technologies, and SIL approaches that facilitate 
researchers’ ability to access massive amounts of data about biological systems. 
Despite the exciting perspective these approaches can bring to studying metabolism, 
untargeted SIL metabolomics is still quite intractable due to the great difficulty in 
analyzing the data.84 Without knowing ahead of time which compounds to look for, MS-
metabolomics datasets are intimidating in the sheer number of ions to interrogate. 
Advances in automated processing and database information about known compounds 
are assisting in the progress of dereplicating known compounds in both primary and 
secondary metabolism. Most of these methods are focused on fluxomics, and primary 
metabolism, but there are powerful implications these approaches can have in 
specialized metabolite discovery.  
In natural products discovery, truly untargeted SIL MS metabolomics approaches 
are not common. Although it is true that all metabolomics studies aim to find the 
metabolic phenotype of a particular genotype, natural product metabolomics has a 
particularly strong focus on final metabolite discovery. Many untargeted approaches aim 
to identify metabolites in the context of their biological role in metabolism and often 
generate hypotheses about the biological system being studied.84 In these kinds of 
metabolomics approaches statistical analyses are used to determine differences in 
metabolite flux and concentration under a biological context, while novel compound 
isolation is de-prioritized. In natural products, metabolomics is most often used as a 
discovery tool to identify compounds of interest for further isolation and characterization 
and application to an unrelated system.12 Natural product metabolomics innovation is 
marked by the integration of orthogonal biological data from high-throughput screening 
with MS metabolomics data to facilitate compound discovery. This distinction in aims is 
likely why SIL MS metabolomics studies involving natural products are nearly always 
targeted.  
The culmination of knowledge in the areas of genomics, BGC analysis, MS 
metabolomics, and systems biology has created a unique opportunity to better 
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understand the relationship between genes and molecules. I have developed an 
untargeted SIL metabolomics platform which aims to facilitate specialized metabolite 
discovery by genome mining and is flexible enough to apply to any microbial culture and 
compound class. The central principle of this technique it to bring together knowledge of 
both the genome and metabolome to characterize the complex chemical phenotypes of 
BGCs.  
1.5. Overview of IsoAnalyst Approach  
The research described in this thesis brings together the strengths and weakness 
of current approaches in genomics, MS metabolomics, and SIL tracers to produce a 
systematic method for the untargeted discovery of compounds produced by BGCs. This 
platform employs parallel stable isotope labeling (SIL) to categorize specialized 
metabolites in liquid fermentations based on biosynthetic precursor incorporation, and 
connects these molecules to candidate BGCs using annotated genome sequence data. 
Parallel fermentation of the test organism is performed in the presence of either an 
isotopically labeled precursor or a control culture containing the corresponding unlabeled 
precursor for a panel of SIL tracers (Figure 1.4a). In Chapter 2 I describe the 
development of this fermentation protocol and describe the results of optimizing the 
growth media and SIL tracer selection. Following workup and UPLC-MS analysis of all 
samples, the IsoAnalyst pipeline identifies unique MS features present in each condition, 
and compares mass isotopologue distributions between unlabeled and labeled 
conditions to determine the degree of labeling by each precursor (Figure 1.4b). In 
Chapter 3 I describe the IsoAnalyst program itself, including the input data requirements, 
statistical analysis, and validation. I further validate the application of IsoAnalyst in 
Chapter 4 using model organisms with well-characterized biosynthetic pathways. The 
experimental precursor incorporation patterns determined by IsoAnalyst are then 
manually compared against the theoretical precursor incorporation rates derived from 
BGC annotations (Figure 1.4c) to yield candidate BGC(s) responsible for the production 
of each labeled metabolite. This approach streamlines the categorization of analytes by 
their biosynthetic origin and reduces MS metabolic profiles to quickly delineate the 
complex phenotypes of BGCs. In Chapter 5, I demonstrate the full application of the 
IsoAnalyst platform and BGC analysis on a sequenced environmental isolate, 
Micromonospora sp., from our Actinobacterial isolate library. This complete workflow 
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culminated in the association of both known and unknown compounds originating from 
the same BGC and the discovery of a new analogue belonging to the lobosamide family 
of macrolactams. There are many exciting and innovative applications for the IsoAnalyst 
platform to facilitate novel compound discovery and complete characterization of 
complex chemical phenotypes. In this thesis, I lay the foundation for this technique and 
demonstrate the utility of IsoAnalyst to understanding biosynthetic potential in 
microorganisms. 
 
Figure 1.4 Overview of the IsoAnalyst Workflow 
(a) SIL and unlabeled extracts are grown in parallel for four days, extracted, and analyzed by 
UPLC-MS. (b) IsoAnalyst program identifies SIL incorporation in MS features aligned across all 
samples. (c) IsoAnalyst profiles generated for all MS features are compared to curated genomic 
information from antiSMASH and MIBiG.  
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Chapter 2.  
 
Design and Optimization of Parallel SIL Fermentation 
Method 
2.1. Introduction  
 Stable isotope labeling (SIL) is a versatile technique that is utilized in many 
different biological and chemical applications. There are two main ways to apply SIL 
treatments to biological samples. You could replace an essential nutrient completely with 
a labeled version to generate a fully labeled metabolome. For example, replacing the 
sole carbon source in a minimal media with U-13C6 glucose for multiple generations 
results in a metabolome fully labeled by 13C. Replacing an essential nutrient entirely with 
an SIL compound is powerful in that it allows the researcher to trace all metabolic 
processes involving that nutrient. This approach is used for metabolic flux 
measurements, quantification of known compounds, and untargeted discovery of novel 
metabolic pathways, however it is expensive to fully replace an essential nutrient with an 
SIL version.1 It is also not necessary to fully label a pool of metabolites in order to gain 
insights from an SIL experiment.1  Another approach is to add an SIL tracer molecule as 
a supplement to a culture medium which already contains all essential nutrients. This 
allows the researcher to add more specialized or expensive SIL precursors to target 
specific pathways as opposed to fully replacing a light element for a heavy one 
throughout the metabolome. Stable isotope labeling using amino acids in cell culture 
(SILAC) is commonly used where labeled amino acids are supplemented to the growth 
medium for applications in both metabolomics and proteomics.2,3 Whether fully replacing 
an essential nutrient, or supplementing the culture with an SIL tracer, carefully controlled 
media conditions are used to ensure proper calculations of isotopic incorporation and 
reduce dilution of the SIL precursor by complex media constituents.  
 Although these studies do often use minimal media, not all SIL studies require 
knowledge of the exact isotopic ratios to draw useful biological conclusions. SIL has 
been used in the elucidation of specialized biosynthetic pathways that produce natural 
products by supplementing an excess of SIL tracer in complex growth media.4 There is a 
balance between providing a medium that is rich enough to elicit compound production 
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but simple enough to not interfere with the incorporation of the SIL precursor. Studies in 
polyketide biosynthesis for example often use a semi-rich media with aliquots of [1-
13C]acetate or [1,2-13C]acetate supplemented into the media throughout the growth 
phase.5 This is necessary to produce a sufficient amount of labeled material to fully 
purify the target compound and determine the positions of 13C incorporation by NMR. 
There is no one set of media conditions and SIL precursors that will work for all target 
organisms or all BGCs. Metabolism by definition is highly flexible, and chemical 
phenotypes are known to be influenced more by small environmental changes than by 
genomic differences. In this chapter I discuss the preliminary experiments I used to 
develop the experimental design of the IsoAnalyst approach. This experimental design 
may be generally applicable to Actinobacteria, however, these experiments also 
demonstrate the overall considerations needed to optimize the IsoAnalyst method for 
any microorganism.  
2.1.1. Considerations for Experimental Design 
 The purpose of this method is to label natural products on the basis of their 
biosynthetic pathways. Natural product structures are highly complex and are often 
derived from multiple specialized biosynthetic pathways. Microorganisms can harbor 
many different classes of BGCs, but most draw from the same pool of metabolites as 
primary metabolism for biosynthetic building blocks. The substrates of common 
biosynthetic classes such as NRPS, PKS, and terpenes can be partially deduced from 
the sequence of the BGC. I aimed to develop a generalizable method that could be 
adapted to cover many biosynthetic pathways, without expensive or multiply labeled 
tracer compounds. The main factors that went into developing this method were the 
media conditions, selection of SIL precursors, and selection of microorganisms to use for 
the optimization of this technique.   
 Three microorganisms are used throughout this chapter to test different media 
conditions and the SIL precursors. Two of these are model organisms that have been 
studied extensively for their natural product biosynthesis and one is a sequenced 
environmental isolate from our marine Actinobacteria isolate library. I performed SIL 
experiments in a variety of additional type strain organisms during the development of 
this fermentation protocol. The examples selected here generally demonstrate the 
factors that need to be considered when applying the IsoAnalyst technique to any target 
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organism, and the basis for the optimized protocol used throughout the rest of this 
thesis.  
 Streptomyces coelicolor M145 was selected due to it’s well-studied metabolism 
and known production of a variety of natural products. S. coelicolor is a popular 
organism to test different environmental conditions due to the production of the colorful 
pigments actinorhodin and prodigiosin, which allow for the easy visual evaluation of 
metabolic changes. Four compounds produced by S. coelicolor are described in this 
chapter. Dihydrokalafungin (2.1) is the biosynthetic precursor to the polyketide 
actinorhodin including g-actinorhodin (2.2), streptorubin B (2.3) is a PKS-NRPS hybrid, 
and desferrioxamine (2.4) is a common hydroxymate siderophore produced by many 
Actinobacteria (Figure 2.1). Other known compounds produced by S. coelicolor such as 
calcium dependant antibiotic, and coelimycin were not observed under any of the media 
conditions tested. Saccharoplyspora erythraea NRRL 23338 was used to test SIL 
incorporation into the macrolide antibiotic erythromycin A, and this model organism is 
used throughout this thesis as a proof-of-concept for the entire IsoAnlayst workflow. S. 
erythraea produces the polyketide antibiotic, erythromycin A (2.5, Figure 2.1), which has 
been studied extensively as a model for polyketide biosynthesis6 and antibiotic drug 
discovery.7 Finally, a Micromonospora sp. from the Linington Lab’s marine 
Actinobacteria isolate library was used in the development of this method. This isolate 
was selected due to the fact that it produced a family of polyketides previously 
discovered in our lab, and this had prompted the complete sequencing of it’s genome.8 
Having the full genome sequence of an organism is an important prerequisite for the 
development of this tool and offers discovery potential through genome mining. In this 
chapter I will only discuss the previously characterized lobosamide A (2.6, Figure 2.1) 
produced by Micromonospora sp. The complete strain designations for all microbial 
strains are indicated in the methods at the end of this chapter.  
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Figure 2.1 Natural Products Produced by Model Organisms 
Structures of natural products discussed throughout this chapter and names of the producing 
organisms. Dyhidrokalafungin (2.1), g-actinorhodin (2.2), streptorubin B (2.3), and 
desferrioxamine B (2.4) are produced by S. coelicolor. Erythromycin A (2.5) is produced by S. 
erythraea. Lobosamide A (2.6) is produced by Micromonospora sp.  
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2.2. Media Optimization  
 Media conditions for growing bacteria isolated from marine sources have been 
tested extensively since the 1960s, including both complex and minimal media.9–13 The 
main objectives of these experiments were to selectively isolate marine bacteria that had 
a high likelihood of producing natural products, and to optimize for the production of 
natural products. I am also aiming to enhance the production of different natural 
products, however, my central objective is to optimize the incorporation of SIL tracers 
into the natural products that are produced. Because there is no one growth medium that 
will optimize the production of all natural products an organism is capable of making, it is 
important to test a variety of conditions both for compound production and SIL 
incorporation. Specialized and primary metabolism are intricately connected, and those 
media constituents which are known to modify specialized metabolism also affect the 
central metabolic processes which govern transformations of the SIL tracer prior to 
incorporation into a natural product.14,15 
 The three major essential nutrients that need to be considered in a minimal 
media are carbon, nitrogen, and phosphate. Other essential nutrients include 
magnesium (MgSO4) and iron (FeSO4), but additional heavy metals and salts are often 
included as well. The Actinobacteria strains in our strain library were all isolated from 
marine sediments and were initially grown in a media made with a high salt 
concentration from a product called ‘Instant Ocean’ which contains the approximate salt 
mixture found in ocean water. This was intended for the isolation of marine obligate 
bacteria, however we cultivate many strains that are adaptable to more standard media 
without marine salts. The Micromonospora sp. isolated from our library was known to 
grow in GNZ media which does not contain Instant Ocean, so I aimed to develop a 
standard minimal media recipe with low salinity that could be generalized for all of the 
organisms discussed in this thesis. The ingredients for all media discussed are 
described in the last section of this chapter.  
 All of the experiments discussed in this section test the incorporation of [1-
13C]acetate into polyketide and NRPS compounds. I used this simple SIL tracer for the 
development of this technique due to its high applicability to a variety of natural products 
and its affordability as a simple and commonly used SIL tracer. [1-13C]Acetate can be 
incorporated directly into polyketide products via malonyl-CoA, but can also be 
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incorporated into other biosynthetic monomers such as amino acids through primary 
metabolism recycling (Figure 2.2). This makes [1-13C]acetate a valuable feedstock for 
labeling a wide cross-section of natural product classes but it also complicates data 
interpretation, as I will discuss further in Chapter 4. Briefly, [1-13C]acetate enters the TCA 
cycle as [1-13C]acetyl-CoA resulting in 13C incorporation into all TCA intermediates 
(Figure 2.2). When a 13C labeled succinyl-CoA is converted to succinate, the position of 
the 13C label becomes ambiguous due to the symmetry of succinate. Because of this, 
two positions have an equal chance of being labeled in the subsequent TCA cycle 
intermediates (Figure 2.2). Labeled oxaloacetate re-enters the TCA cycle resulting in up 
to two 13C incorporation events in citrate, isocitrate, and a-ketoglutarate. The 
interconversion of succinate and succinyl-CoA leads to the indirect incorporation of 13C 
into the C1 position of methylmalonyl-CoA as indicated by an open red circle while the 
direct labeling of the C4 position of methylmalonyl-CoA is lost to decarboxylation during 
the PKS condensation of methylmalonyl-CoA units (Figure 2.2). Some amino acids are 
derived from TCA cycle biosynthetic precursors, and therefore are able to be labeled by 
[1-13C]acetate. [1-13C]Acetate incorporation into amino acids was not detected in any of 
the experiments described in this chapter, and will therefore be discussed in more depth 
in Chapter 4.  
 Initially I optimized the media conditions to promote [1-13C]acetate incorporation 
into polyketides due to the expected promiscuity of this SIL precursor incorporation into 
central pathways connected to the TCA cycle. I expected that the media conditions that 
significantly altered central metabolism would result not only in different natural product 
biosynthesis, but also different amounts of SIL tracer incorporation. The experiments 
presented in this chapter are not likely to produce the same results for every organism in 
every media. Media selection is an important part of optimizing and SIL tracer study to 
the test organism’s metabolism, and the media conditions tested in this section 
represent a good starting place for applying SIL feeding to any microorganism. 
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Figure 2.2 TCA Cycle Labeling by [1-13C]Acetate 
Red filled circles represent 13C derived from [1-13C]acetate following its direct transformation to 
acetyl-CoA. Open circles represent labeled carbon positions which are ambiguous due to 
compound symmetry. Molecules depicted with two open circles may have labeling in either 
position but not both. Groups of amino acids that are derived from TCA cycle biosynthetic 
precursors are indicated.  
2.2.1. Carbon and Nitrogen Sources 
Many members of the Actinobacteria phylum that are known for producing 
diverse natural products are found in soil environments. These environments are 
typically rich in different carbon sources from plant debris but are limited in nitrogen and 
phosphate.14 Actinobacteria from both terrestrial soil and marine sediment are known to 
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utilize a wide variety of simple and complex carbohydrates.14 Carbon source influences 
antibiotic production, most notably by carbon catabolite repression which is known to 
repress the production of many natural products while the microorganism is consuming 
glucose as a preferred carbon source.16 Many papers have been published looking at 
the selective use of carbon sources by microorganisms, and the influence of carbon 
source on the production of natural products.10,17  
Nitrogen source also has a significant impact on natural product production and 
overall metabolism. Unlike carbon however, nitrogen is a limited resource in the natural 
soil environment of Actinobacteria. Streptomyces in particular are known to lack 
repression of amino acid biosynthesis pathways, such that most amino acids are being 
produced at all times in the bacterial lifecycle.14 It has been suggested that the tight 
regulation of specialized metabolism allows for the catabolism of amino acids when a 
natural source of amino acids or other nitrogen source becomes available.14 Because 
these bacteria have lost their ability to regulate much of the amino acid production, a 
sudden influx of a nitrogen source can result in the overproduction of certain amino 
acids. Without the ability to repress some of these pathways, natural product 
biosynthesis can act as a metabolic sink for the excess of specific amino acids. The tight 
regulation of specialized metabolism makes up for the lack of regulation of the primary 
metabolic pathways, and therefore can be heavily influenced by the availability of 
specific nitrogen sources. 
2.2.2. Effects of Carbon and Nitrogen Sources on Micromonospora 
sp. Metabolism 
The very first question I pursued as a graduate student was, ‘what minimal media 
conditions induce compound production and facilitate [1-13C]acetate incorporation into 
polyketides produced by Micromonospora sp.?’ I began with the assumption that 
Micromonospora sp. may not produce lobosamides or any other natural product in most 
media, and so I aimed to test nutrients that were shown to influence natural product 
production. I grew Micromonospora sp. in a variety of media conditions with different 
carbon and nitrogen sources and screened for lobosamide A production using LCMS. I 
selected the media that were exhibiting the production of lobosamide A in 
Micromonospora sp., and performed an experiment testing how these media conditions 
influenced [1-13C]acetate incorporation into lobosamide A. Five types of media were 
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tested using [1-13C]acetate, and the full list of ingredients is given in Table 2.1 in the 
methods section at the end of this chapter. Four types of carbon sources were tested 
including glucose, maltose, sucrose, and soluble starch. All of these carbon sources 
were paired with (NH4)2SO4 as a nitrogen source, while starch was tested with both 
(NH4)2SO4 and glutamate due to the fact that both combinations produced lobosamide A. 
The basal media in all conditions was the same (Table 2.1). Observationally, I noticed 
that the starch media enhanced the growth of Micromonospora sp. regardless of which 
nitrogen source it was paired with, while the other carbon sources seemed to induce 
growth and lobosamide A production more when paired with the ammonium nitrogen 
source.  
In this first experiment, I used the Linington Lab’s standard extract library building 
protocol to extract and prepare the SIL samples for UPLC-MS analysis. Briefly, the 
bacterial cultures were grown in 60 mL of liquid minimal media and supplemented with 
12 mM of either unlabeled acetate or [1-13C]acetate. Unlabeled control cultures were 
grown in parallel with SIL supplemented cultures for each media condition. Cultures 
were grown for seven days while shaking at 200 rpm and extracted on the seventh day. 
A standard C18 column chromatography protocol was used to generate prefractionated 
extracts on the basis of polarity as described in the methods at the end of this chapter. 
Previous work done on lobosamide A production by this Micromonospora sp. strain had 
demonstrated that lobosamide A was present in the 80% and 100% methanol fraction 
and so these fractions were further processed for UPLC-MS analysis.  
Figure 2.3 shows the MS results for lobosamide A in an unlabeled sample and in 
each of the five media conditions when labeled by [1-13C]acetate. Clearly observable SIL 
incorporation was detected in the media with glucose and maltose carbon sources 
paired with (NH4)2SO4 (Figure 2.3b,c) as well as in starch paired with glutamate (Figure 
2.3f). The sucrose and starch carbon sources paired with (NH4)2SO4 appeared to have 
very minor SIL incorporation when compared to the unlabeled condition (Figure 2.3d,e).  
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Figure 2.3 [1-13C]Acetate Incorporation in Lobosamide A (2.6) 
MS spectra of the [M+H-H2O]+ ion (m/z 466.29) of 2.6 in media containing different carbon and 
nitrogen sources. (a) Unlabeled MS spectrum of 2.6. MS spectra of 2.6 labeled by [1-13C]acetate 
in media containing (NH4)2SO4 and one of four carbon sources (glucose (b), maltose (c), sucrose 
(d), starch (e)), and an additional media containing glutamate and starch (f).   
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These results show that carbon source affects the incorporation of [1-13C]acetate 
into lobosamide A, but the difference between starch media containing glutamate or 
(NH4)2SO4 indicates that nitrogen source influences [1-13C]acetate incorporation as well. 
[1-13C]Acetate incorporation was higher in the starch media containing glutamate 
compared to the starch media containing (NH4)2SO4 (Figure 2.3e,f). Like other bacteria, 
Actinobacteria are known to prioritize nutrient consumption based on availability. This is 
central to carbon catabolite repression, which prioritizes glucose and other accessible 
carbon sources over more complex carbohydrate sources. Because starch is broken 
down into glucose, starch is also known to induce carbon catabolite repression, which 
may not be ideal for the production of many natural products. However, starch is used in 
many of the common growth media used for Actinobacteria and induced observably 
better growth in Micromonospora sp. and SIL incorporation in lobosamide A. Glutamate 
is readily used as a carbon source as well as a nitrogen source, and feeds directly into 
the TCA cycle by conversion to a-ketoglutarate. Media containing glutamate has been 
used to elicit natural product production, and the supply of two carbon sources that feed 
into the TCA cycle from different pathways improves overall growth and natural product 
production.18 Labeling studies using S. coelicolor grown on media containing glucose 
and glutamate indicated that glutamate is a preferred carbon source, which heavily 
dominates the TCA cycle, while glucose-derived carbon dominates the pentose 
phosphate and glycolysis intermediates.19 Because the starch-glutamate growth medium 
feeds carbon sources into the TCA cycle from two different pathways, a surplus of TCA 
cycle intermediates are likely generated. This surplus of TCA cycle intermediates may 
modify the central metabolic processes such that the [1-13C]acetate tracer remains 
available for specialized metabolism. 
Relying only on qualitative analysis, the glucose-ammonium, maltose-
ammonium, and starch-glutamate media had essentially the same results, but the 
starch-glutamate medium may have slightly more SIL incorporation due to the fact that 
heavier isotopologues were detected with a relatively higher abundance (Figure 2.3f). I 
selected the starch-glucose medium moving forward because Actinobacteria are known 
for growing well and producing natural products in media containing complex 
carbohydrates such as starch10 and because I observed more robust and consistent 
growth in the cultures containing starch. Starch is also present in both low salinity (GNZ) 
and high salinity media recipes used in our lab, indicating that starch is often an 
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important nutrient for encouraging both bacterial growth and natural product 
biosynthesis.  
2.2.3. Effects of Nitrogen Source on S. coelicolor Metabolism 
The initial experiment performed with Micromonospora sp. indicated that a 
starch-glutamate minimal medium produced sufficient [1-13C]acetate incorporation in 
lobosamide A, but changing the nitrogen source to (NH4)2SO4 decreased [1-13C]acetate 
incorporation. I aimed to test a starch-based minimal medium with different nitrogen 
sources in another microorganism to determine whether this growth medium was 
generalizable for [1-13C]acetate incorporation in other Actinobacteria. Streptomyces 
coelicolor is a model organism that is known to produce a variety of natural products 
including blue and red pigments, actinorhodin and prodigiosin respectively.  
In the subsequent experiments, I adopted a 24-well plate fermentation protocol 
that was optimized for Streptomyces strains to allow for screening of more conditions,20 
and simplified the extraction protocol. The well plates contain 2 mL of growth medium in 
each well, effectively decreasing the amount of SIL required and allowing for more 
media conditions and replicates to be tested. The complete optimized fermentation 
protocol is described in methods at the end of this chapter. For the extraction of the 24-
well plate cultures, after five days of fermentation, I added an equal volume of methanol 
to each well, resulting in a 1:1 water:methanol extract. Each sample was sonicated and 
centrifuged prior to analysis by MS. This simplified protocol allows for a higher 
throughout of samples, at the cost of less compound coverage. As with any 
metabolomics experiment there will always be some bias in the compounds that are 
extracted and detected. I opted for a simple workup that would retain compounds of 
relatively low and high polarity, from the cells and the supernatant. It is important to note 
that although this general extraction method will work for many natural products, it 
should be optimized on the basis of target compound classes.  
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Figure 2.4 Photos of S. coelicolor Cultures in Different Minimal Media 
S. coelicolor cultures grown in minimal media containing the same core ingredients but varying 
nitrogen sources. Three replicates of each media are shown. (a) Media containing limited 
nitrogen but excess phosphate. (b) Media containing excess nitrogen but limited phosphate. 
Initially, I performed a qualitative experiment growing S. coelicolor in a starch 
based media with different nitrogen sources. S. coelicolor growth and natural product 
production is visually modified in different growth conditions, allowing for facile screening 
of media or other environmental changes. I tested S. coelicolor in 12 different minimal 
media with six different sources of nitrogen and either nitrogen or phosphate limitation. 
All of the minimal media contained starch as a carbon source (Table 2.2). Both nitrogen 
and phosphate limitation have both been shown to elicit different natural product 
production in various organisms.9,11 This experiment was evaluated visually in order to 
narrow down ideal conditions to test [1-13C]acetate incorporation. Figure 2.4 is a 
photograph showing the visual changes in S. coelicolor growth in response to both the 
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nitrogen source, and the limiting nutrient in the media. Figure 2.4a shows the six 
different media when nitrogen is a limited nutrient, meaning the growth medium will run 
out of nitrogen before running out of phosphate. Figure 2.4b shows media containing the 
same ingredients, but with phosphate limitation and an excess of nitrogen. Generally, 
the nitrogen-limited media all induced varying pigmentation and sufficient growth, while 
most of the phosphate-limited conditions resulted in lower growth and little to no 
pigmentation (Figure 2.4). The phosphate-limited medium containing glutamate, 
however, did result in observable red pigmentation and significantly more biomass than 
the other phosphate-limited conditions (Figure 2.4). I selected three nitrogen-limited 
media from this panel to move forward and test [1-13C]acetate incorporation with S. 
coelicolor. I selected the (NH4)2SO4, glutamate, and asparagine media, due to the fact 
that these three media resulted in visual differences in pigment production in the initial 
screening (Figure 2.4a).  
I performed an experiment using the 24-well plate protocol and addition of 12 mM 
of [1-13C]acetate in these three media and analyzed the samples by UPLC-MS according 
to the protocol described at the end of this chapter. The glutamate media again showed 
the best results across all the compounds detected in this experiment. Figure 2.5 shows 
the [1-13C]acetate incorporation into the three putatively identified products g-
actinorhodin(2.2), streptorubin B (2.3), and desferrioxamine B (2.4) in the nitrogen-
limited glutamate medium. Although the nitrogen-limited glutamate medium in Figure 
2.4a was clearly dominated by blue pigmentation, both prodigiosin and actinorhodin 
were putatively identified with substantial labeling by [1-13C]acetate (Figure 2.5).  
The actinorhodins are dimeric benzoisochromanequinone polyketide antibiotics 
which are made up of 16 subunits of malonyl-CoA. There are various related 
actinorhodin analogues, but they are all biosynthesized by the dimerization of the 
octaketide dihydrokalafungin (2.1).21 The only actinorhodin compound I was able to 
putatively identify in the nitrogen-limited glutamate media was g-actinorhodin (2.2, Figure 
2.5a). Although substantial incorporation of [1-13C]acetate was detected (Figure 2.5a), 
the heaviest detectable isotopologue peak was M9, indicating that not all sixteen 
available positions had SIL incorporation. Streptorubin B (2.3, Figure 2.5b) is an NRPS- 
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Figure 2.5 Mass Spectra of S. coelicolor Natural Products 
Structures and mass spectra of (a) g-actinorhodin (2.2), (b) streptorubin B (2.3), and (c) 
desferrioxamine B (2.4) in unlabeled and [1-13C]acetate labeled extracts. Red circles represent 
positions which are expected to be labeled by [1-13C]acetate. The open circles in 2.4 (c) represent 
alternate positions which can be labeled due to the symmetry of succinate (Figure 2.2).  
PKS hybrid molecule which contains seven units of malonyl-CoA in the cyclized alkyl tail 
and one in the backbone.22 There are eight carbon positions in streptorubin B (2.3) that 
are derived from malonyl-CoA and may be labeled by [1-13C]acetate, but M5 was the 
heaviest isotopologue detected (Figure 2.5b). Like g-actinorhodin, streptorubin B had 
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substantial incorporation of [1-13C]acetate, but did have complete SIL incorporation in 
every available position. Desferrioxamine B (2.4) is a hydroxamate siderophore which 
also had detectable labeling by [1-13C]acetate in one position (Figure 2.5c), likely 
corresponding to the acetyl-CoA subunit. Desferrioxamine B also contains succinyl-CoA 
subunits which can be labeled by [1-13C]acetate indirectly through the TCA cycle, 
however these positions did not appear to have detectable SIL incorporation (Figure 
2.5c).  
Surprisingly, no streptorubin B or any other related prodigiosin compound was 
identified in the nitrogen-limited (NH4)2SO4 medium despite the fact that this medium did 
clearly produce red pigmentation which can be observed visually (Figure 2.4a). Similarly, 
the nitrogen-limited asparagine medium did not produce detectable amounts of any 
desferrioxamines, prodigiosins, or actinorhodins. This was less surprising due to the 
overall less consistent growth and pigmentation observed in these cultures (Figure 2.4a), 
but does complicate the ultimate goal of comparing SIL incorporation across the different 
media conditions. 
One compound was identified in all three media conditions (Figure 2.6). 
Dihydrokalafungin (2.1) is a biosynthetic precursor to the polyketide actinorhodin. 
Although g-actinorhodin was only putatively identified in the glutamate medium (Figure 
2.5a), other actinorhodin analogues were likely produced in the (NH4)2SO4 and 
asparagine media due to the fact that the precursor 2.1 was produced. I was not able to 
detect any actinorhodin compounds in the (NH4)2SO4 or asparagine media, which could 
be accounted for by multiple factors. A single extraction technique was used on all 
samples which may not be ideal for all actinorhodin analogues and the overall titer of 
actinorhodin production in the (NH4)2SO4 and asparagine media may not be sufficient for 
detection by MS. There are additional biological factors such as the regulation of the 
biosynthetic pathway or degradation of the final product. Due to these inconsistencies, 
2.1 was the only compound for which I was able to directly compare [1-13C]acetate  
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Figure 2.6 Mass Spectra of 2.1 in Minimal Media 
Mass spectra of dihydrokalafungin (2.1) in minimal media containing (NH4)2SO4 (a), glutamate (b), 
or asparagine (c) as a nitrogen source. The red circles represent positions that are expected to 
be labeled by [1-13C]acetate through malonyl-CoA or acetyl-CoA.  
incorporation (Figure 2.6). More SIL incorporation was detected in 2.1 in the glutamate 
medium than either the (NH4)2SO4 or asparagine media (Figure 2.6). This is clear from 
two observations. The M1 isotopologue peak is the base peak in the labeled spectrum of 
2.1 in the glutamate medium, compared to the other media which maintain a higher 
relative intensity of the monoisotopic M0 peak compared to the M1 isotopologue peak 
(Figure 2.6). Additionally, isotopologue peaks up to M5 were detected in the glutamate 
medium, indicating a higher degree of labeling than the other conditions. Interestingly, 
the (NH4)2SO4 medium produced a DHKF spectrum with the M2 isotopologue as the 
base peak. This highlights the importance of observing the unlabeled control MS 
spectrum side-by-side with the labeled spectrum. The M2 isotopologue peak also had a 
higher intensity in the unlabeled control (Figure 2.6), indicating that this isotopologue 
peak is overlapped with the monoisotopic M0 peak of a related analogue, likely the 
reduced form of 2.1. The overall isotopologue distribution in the labeled spectrum of 2.1 
in the (NH4)2SO4 medium indicates that both the oxidized and reduced forms of 2.1 have 
some [1-13C]acetate incorporation. However, the overlap of these signals complicates 
the interpretation of the SIL incorporation. It is likely that the mixture of oxidation states 
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in this medium results from the ammonium content in the media, making this medium 
less ideal for interpreting [1-13C]acetate in this class of compounds. [1-13C]acetate 
incorporation was also observable in 2.1 in the asparagine condition, but the lower signal 
to noise and smaller distribution of isotopologue peaks indicates that this medium is also 
not ideal for [1-13C]acetate detection in 2.1. The incorporation of [1-13C]acetate into three 
additional compounds in the glutamate condition (Figure 2.5) supports the selection of 
this media because of the consistency of SIL incorporation across three different natural 
products. Although none of these compounds exhibited full [1-13C]acetate incorporation 
into all available positions, the consistency of these results was encouraging evidence 
that the nitrogen-limited media containing glutamate as the sole nitrogen source was a 
good general medium for conducting SIL studies in other Actinobacteria besides 
Micromonospora sp.  
These results also indicated that S. coelicolor is not an ideal model organism for 
use in this study because its growth in the minimal media was highly inconsistent in 
follow-up experiments. Following these experiments, I struggled to maintain consistent 
growth with the S. coelicolor cultures. Figure 2.4 shows the clumpy sort of growth 
observed across these cultures, which is common for S. coelicolor but appeared to be 
exaggerated in the minimal media recipes compared to rich media. This observation 
paired with the inconsistent production of the target compounds led me to move away 
from using S. coelicolor as a model organism. Still, the results here support the notion 
that media selection has a significant influence on the experimental outcome, and that 
the nitrogen-limited media containing starch and glutamate enhanced [1-13C]acetate 
incorporation into polyketide compounds.  
2.2.4. Phosphate and Nitrogen Limitation in Micromonospora sp.  
In the preliminary media experiment using S. coelicolor, I observed significant 
differences in metabolism and growth between nitrogen and phosphate limited 
conditions (Figure 2.4). I selected the nitrogen-limited media to test [1-13C]acetate 
incorporation because nitrogen limitation induced more consistent production of 
observable natural products in S. coelicolor, however phosphate limitation has also been 
shown to improve natural product production in other cases.11 Excess of either nitrogen 
or phosphate tends to delay and decrease the production of most natural products.9 
Many different combination and concentrations of nutrients have been tested in terms of 
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optimizing natural product production, and limiting nitrogen or phosphate is commonly 
applied to influence specialized metabolism. Phosphate in particular controls many 
aspects of central metabolism including RNA, DNA, and protein synthesis as well as 
cellular respiration and ATP levels.11 Testing different combinations of nitrogen sources 
with both nitrogen and phosphate as the limiting nutrient can not only induce different 
natural product biosynthesis as shown with S. coelicolor, but also influences central 
metabolism and therefore the efficiency of [1-13C]acetate incorporation.  
I tested the effect of phosphate and nitrogen limitation on [1-13C]acetate 
incorporation into lobosamide A. I also tested glutamate and glutamine as different 
nitrogen sources. Glutamine is metabolically related to glutamate, but keeping the molar 
amount of nitrogen equal in the media results in a smaller molar amount of carbon 
coming from glutamine as opposed to glutamate. I qualitatively tested how the 
combination of nitrogen source and nitrogen or phosphate limitation affected [1-
13C]acetate incorporation into lobosamide A. I also increased the concentration of [1-
13C]acetate in the cultures to 30 mM in order to increase the SIL incorporation compared 
to the previous experiment shown in Figure 2.3. The basal media for this experiment 
contained starch as the primary carbon source and the same salt and metal content as 
the previous experiment (Table 2.2). 
Both of the media containing glutamate as the nitrogen source demonstrated a 
slightly higher degree of [1-13C]acetate labeling compared to the media containing 
glutamine (Figure 2.7). This observation is based on the general shift of the isotopologue 
distribution towards heavier isotopologues in the glutamate condition compared to 
glutamine, although all four media conditions had detectable intensity for the M9 
isotopologue peak of lobosamide A. The phosphate limited conditions generally had less 
SIL incorporation that the nitrogen limited media containing the same nitrogen source 
(Figure 2.7). However, the phosphate limited media containing glutamate has a more 
intense M0 peak than the nitrogen limited media containing glutamine, indicating that the 
total SIL incorporation is actually less in the nitrogen limited - glutamate media. Even 
though the whole pool of lobosamide A ions in the phosphate-limited glutamine media 
have more SIL incorporation, the extent of [1-13C]acetate incorporation is lower in the 
heavy isotopologues M6, M7, M8, and M9 (Figure 2.7). This is an important observation to 
consider in terms of the aims of the experiments presented here. Many SIL studies focus 
on the flux of an SIL tracer through a system or the fraction of labeled carbon present in 
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a pool of labeled compounds. However, in this work I aim to use SIL precursors to infer 
the number of biosynthetic building blocks derived from that precursor. The optimization 
of this experiment aims to detect the heaviest labeled isotopologue peak, regardless of 
the overall efficiency of SIL incorporation. When comparing the phosphate-limited 
glutamate condition and the nitrogen-limited glutamine condition, the phosphate-limited 
glutamate condition is more optimal because it results in a high extent of labeling even 
though the pool of ions has a lower overall percentage of 13C incorporation. 
 
Figure 2.7 [1-13C]Acetate Incorporation in 2.6 in Nutrient Limited Media 
Mass Spectra of lobosamide A (2.6) in minimal media containing either glutamate or glutamine as 
a nitrogen source, and limitation in either nitrogen or phosphate. The filled red circles represent 
positions that are expected to be labeled by [1-13C]acetate through malonyl-CoA or acetyl-CoA. 
The open red circles represent positions that may be indirectly labeled by [1-13C]acetate through 
conversion to methylmalonyl-CoA (Figure 2.2).  
Overall, these experiments show that the nitrogen-limited starch-glutamate media 
was optimal for both Micromonospora sp. and S. coelicolor in terms of compound 
production and [1-13C]acetate incorporation into target polyketide products. I use this 
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minimal growth medium in the subsequent SIL experiments described throughout this 
thesis, further demonstrating that this media recipe is generally effective for SIL 
incorporation in a variety of Actinobacteria. Although this medium is a good option, 
generally speaking, for the Actinobacteria presented in this thesis, the data presented 
here indicate that optimizing minimal media conditions for the test organism in terms of 
both compound production and SIL incorporation is crucial to success.  
2.3. SIL Precursor Selection  
In addition to [1-13C]acetate, I selected three other SIL precursors to allow for 
association of MS signals with BGCs. IsoAnalyst was developed to permit flexibility in 
terms of SIL precursor selection. Any type of SIL tracer can be used in the IsoAnalyst 
method, but the goal of this approach is to minimize the cost of SIL tracers by using 
simple building blocks that are isotopically labeled in a single position. Theoretically, 
multiply labeled precursors can be used in IsoAnalyst, however, algorithms for detecting 
multiply labeled precursors already exist and are well-established. One novel aspect of 
IsoAnalyst is to detect the number of SIL precursors incorporated into a natural product 
structure, rather than identify SIL incorporation by large mass shifts associated with 
specific functional groups. I will discuss this aspect of the data analysis more in Chapter 
3, but the SIL precursors selected here reflect this objective. With the ultimate goal of 
detecting the number of biosynthetic units in a compound, ideal SIL tracer molecules are 
those which are incorporated directly into natural product pathways but are not so 
specific that they only target a few BGCs. The SIL tracers described here were selected 
based on their general applicability to the model organisms used and can be used for 
first-pass screening of biosynthetic potential in any organism, but are by no means 
optimized for the full coverage of all classes of BGCs.  
 To demonstrate the scope of IsoAnalyst across a broad cross section of 
biosynthetic classes, I selected four SIL precursors; [1-13C]acetate, [1-13C]propionate, 
[methyl-13C]methionine, and [1-15N]glutamate. [1-13C] Propionate is predominantly used 
for identifying polyketide pathways, due to its conversion to methylmalonyl-CoA, a 
common building block in type I and type II polyketide biosynthesis. [methyl-
13C]Methionine was selected in order to label compounds methylated by S-adenosyl 
methionine (SAM). Methylation by SAM is encountered relatively frequently in natural 
product biosynthesis and therefore assists in prioritizing compounds which have a high 
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likelihood of being natural products, especially if they are also labeled by one or more of 
the other SIL precursors. Finally, [1-15N] glutamate was selected to constitutively label all 
products containing nitrogen atoms. To accomplish this, 50% of the total available 
nitrogen was labeled in the form of [1-15N] glutamate, with the remainder deriving from 
standard unenriched glutamate. The growth medium and procedures used in this 
experiment are described in the methods section at the end of this chapter.  
2.3.1. Parallel SIL Incorporation in Erythromycin A 
The biosynthesis of erythromycin A has been studied extensively as a model 
system for modular polyketide synthases.23 The macrolide core is formed by the 
condensation of one propionyl-CoA and six methylmalonyl-CoA units followed by 
glycosylation with the saccharides desosamine and mycarose (Figure 2.8). [1-
13C]Propionate is directly converted to the substrates propionyl-CoA and methylmalonyl-
CoA, however the latter may also be labeled by [1-13C] acetate through conversion to the 
TCA cycle intermediate succinyl-CoA (Figure 2.2). The indirect labeling of 
methylmalonyl-CoA by [1-13C] acetate is included in the labeling prediction as we cannot 
differentiate analytically between direct and indirect SIL incorporation (Figure 2.8a). 
Desosamine contains a tertiary dimethylamino group which is expected to be labeled by 
a single position in the [1-15N]glutamate condition, and two positions in the [methyl-13C] 
methionine condition. The mycarose unit has a single methylation position and is later 
methylated by an O-methyltransferase following attachment to the macrolide core 
(Figure 2.8a).  
I optimized the concentration of each SIL precursor by testing a range of 
concentrations as described in the methods section at the end of this chapter. The final 
concentrations used for precursor were 30 mM [1-13C]acetate, 30 mM [1-13C]propionate, 
5 mM [methyl-13C]methionine, and 10 mM [1-15N]glutamate. The expected labeled 
positions of erythromycin A and the MS spectra in each SIL condition are shown in 
Figure 2.8b. Substantial labeling was observed in all four conditions. In particular, [1-
13C]propionate, [methyl-13C]methionine, and [1-15N]glutamate qualitatively appear to 
have complete SIL incorporation in every available position (Figure 2.8b). [1-13C]Acetate 
did not label erythromycin A as extensively as anticipated, however [1-13C]acetate is only 
incorporated into erythromycin A indirectly through the conversion of succinyl-CoA to 
methylmalonyl-CoA (Figure 2.2).  
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Figure 2.8 Biosynthesis and SIL Tracer Incorporation in 2.5 
(a) The erythromycin BGC, expected biosynthetic precursors, and the expected SIL incorporation 
in those precursors. (b) Structure of erythromycin A (2.5) with positions of SIL incorporation 
indicated. Mass Spectra of 2.5 showing labeling by [1-13C]acetate, [1-13C]propionate, [methyl-
13C]methionine, and [1-15N]glutamate. Arrows indicate the heaviest isotopologue peak that 
visually appears to have SIL enrichment. (c) Comparison of expected SIL incorporation on the 
basis of the BGC to observed SIL incorporation. Although visual inspection implies sufficient 
labeling, a statistical technique for determining the true SIL incorporation will be described in the 
next chapter.  
The heaviest isotopologue peaks that are clearly enriched are indicated in Figure 
2.8b by arrows, however it is not possible to tell by observation alone if these peaks are 
enriched with heavy isotopes derived from the SIL precursor, or from naturally occurring 
13C. Figure 2.8c shows the expected labeling on the basis of interpreting the BGC, but 
comparable information cannot be derived from observing the MS spectra alone. In 
Chapter 3 I will discuss the statistical approach used to interpret these data, however 
this fermentation and SIL precursor addition protocol were successfully optimized on the 
basis of this qualitative data analysis.  
52 
2.4. Optimized Parallel SIL Feeding Experiments in Minimal 
and Rich Media 
Having optimized this experiment for the labeling of erythromycin A, and 
confirmed that the SIL incorporation qualitatively matched what was expected on the 
basis of the BGC, I aimed to test the full SIL panel in Micromonospora sp. I performed 
the same SIL experiment described previously for S. erythraea using Micromonospora 
sp. in the nitrogen-limited starch-glutamate minimal media. I looked at lobosamide A 
again to assess the outcome of this SIL experiment. Lobosamide A is a polyene 
macrolactam polyketide, which is biosynthesized from six units of malonyl-CoA, three 
methylmalonyl-CoA, and a 3-aminobutryate starter unit which is derived from glutamate.8 
I performed an additional experiment with Micromonospora sp. using the rich media 
GNZ which was previously used for the large-scale fermentation of this organism in 
order to isolate lobosamide A and related analogues.8 The ingredients for the GNZ 
media are described in the last section of this chapter. I used higher concentrations of 
each SIL tracer in the GNZ media to ensure sufficient incorporation (100 mM [1-
13C]acetate, 100 mM [1-13C]propionate, 16.5 mM [methyl-13C]methionine, and 100 mM 
[1-15N]glutamate). 
Both the minimal medium and rich medium resulted in substantial labeling in the 
[1-13C]acetate, [1-13C]propionate, and [1-15N]glutamate conditions. Surprisingly, the [1-
13C]acetate incorporation was lower in the rich medium, while [1-13C]propionate 
incorporation was higher in the rich medium. These results demonstrate that this parallel 
SIL feeding approach can not only be applied in rich media, but in some cases may 
result in more complete incorporation of certain SIL precursors. This underscores the 
importance of testing a variety of media conditions and the utility of applying this 
technique in combination with different environmental stimuli to induce natural product 
biosynthesis.  
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Figure 2.9 SIL Incorporation in 2.6 in Mimimal and Rich Media 
Mass Spectra showing SIL Incorporation in lobosamide A (2.6) in nitrogen-limited starch-
glutamate minimal medium (a) and the rich growth medium GNZ (b). More SIL incorporation was 
observed for [1-13C]acetate in the minimal media, while more SIL incorporation was observed for 
[1-13C]propionate in the rich media, indicating that there is not likely a single media condition that 
will be optimal for every SIL tracer used.  
2.4.1. Significance of Fermentation Optimization 
In this chapter I showed the importance of testing how major nutrients affect 
target compound production, as well as influence SIL incorporation into target 
compounds as an initial optimization step. The results of these experiments indicate that 
the minimal medium and SIL conditions developed in this chapter are generally 
applicable to my model organisms. Because of these promising results, I used the 
nitrogen-limited starch-glutamate minimal media and the SIL tracer concentrations 
described in this chapter throughout the remainder of this thesis. However, from working 
with minimal media and testing various conditions it was clear to me that the process of 
making and testing media conditions is tedious and often leads to discouraging results. 
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Particularly in the case of S. coelicolor, I was not able to induce detectable natural 
product biosynthesis in many of the media conditions. Even in the model organisms 
used, minimal media does not result in the production of more than one or two 
compound families. Furthermore, screening fermentation conditions typically involves 
rich media to induce compound production, and a method which relies solely on minimal 
media may not have the same potential for discovery due to this limitation. Still, the 
flexibility of this approach allows for many fermentation systems to be tested for 
compound discovery in parallel, and further optimized following identification of labeled 
MS signals.   
When screening for unknown compounds, a variety of media conditions may be 
necessary in order to find the optimal conditions for the organism, compound, and 
selected SIL precursors. Alternatively, a starch-glutamate based media may be a good 
starting point, especially for labeled acetate incorporation, which is involved in many 
central metabolic processes. Beginning with a simple medium one can also perform a 
series of challenge experiments using heavy metals or antibiotics to induce different 
natural product biosynthesis while ensuring observable SIL incorporation. Complex 
media can be used as well however this requires a higher concentration of SIL tracers 
due to the high availability of different nutrients including amino acids, nucleic acids, and 
carbohydrates. Complex media are also likely to result in less reproducibility between 
batches because the ingredients are not exactly specified. Despite these caveats, a 
combination of minimal and rich media can easily be tested in parallel to optimize this 
method for any microorganism. 
The data in this chapter were analyzed qualitatively for the purpose optimizing 
the fermentation conditions and SIL tracers. This was adequate for screening media and 
SIL conditions, however, in Chapter 3 I will describe the analytical platform I developed 
using Python 3 to statistically determine the number of SIL precursors incorporated into 
every MS feature in the parallel SIL metabolomics experiments presented here. 
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2.5. Methods 
2.5.1. Strain Designations 
Saccharopolyspora erythraea ATCC 11635 (NRRL 2338) and Streptomyces 
coelicolor ATCC BAA-471 (A3(2) / M145) were purchased from ATCC (USA). 
Micromonospora sp. RL09-050-HVF-A was isolated and sequenced as described in 
Schulze et al.8 The Micromonospora sp. RL09-050-HVF-A genome was uploaded to 
NCBI under the accession number JAGKQP000000000 and the BioProject ID 
PRJNA718589. 
2.5.2. Media Recipes 
The minimal media recipes used for SIL experiments in this chapter are shown in 
Table 2.1 and Table 2.2. Variation in phosphate, nitrogen, and carbon sources and 
concentrations are also indicated. Table 2.1 shows the media recipes used in section 
2.2.1 for preliminary experiments with Micromonospora sp. The basal medium in Table 
2.2 was used with the microtiter plate protocol for the remainder of the experiments in 
this chapter.   
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Table 2.1 Minimal Media for Nitrogen and Carbon Sources 
Basal Medium Concentration 
MgSO4 2.0 g/L 
CaCO3 1.5 g/L 
FeSO4 1.5 mg/L 
CuSO4 1.5 mg/L 
ZnSO4 1.6 mg/L 
Phosphate  
K2HPO4 1.5 g/L 
Carbon  
Starch 40 g/L 
Glucose 40 g/L 
Maltose 40 g/L 
Sucrose 40 g/L 
Nitrogen  
Glutamate 5 g/L 
(NH4)2SO4 5 g/L 
The complex medium GNZ (10 g glucose, 20 g starch, 5 g N-Z-amine, 5 g yeast 
extract, 1 g CaCO3, and 14 g agar per liter of water) was used to grow Micromonospora 
sp. seed cultures in all experiments, and as the primary growth medium in the SIL 
experiment in section 2.4. The complex medium ISP (3 g yeast extract, 5 g acid 
hydrolyzed casein, and 14 g of agar per liter of water) was used to grow seed cultures of 
S. coelicolor and S. erythraea. Both GNZ and ISP culture plates were made using 15 g/L 
of agar for streaking frozen stocks of all bacterial strains.  
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Table 2.2 Minimal Media for Nitrogen and Phosphate Limitation 
Basal Medium Concentration 
NaCl 2.0 g/L 
MgSO4 1.0 g/L 
CaCO3 1.0 g/L 
FeSO4 0.01 g/L 
CuSO4 1.5 mg/L 
ZnSO4 3.0 mg/L 
CoSO4 0.15 mg/L 
MnSO4 0.15 mg/L 
Na2MoO4 1.0 mg/L 
Carbon  
Starch 10 g/L 
Phosphate 4 mM 10 mM 
KH2PO4 0.16 g/L 0.41 g/L 
K2HPO4 0.49 g/L 1.22 g/L 
Nitrogen 60 mM 20 mM 
Glutamate 10.2 g/L 3.38 g/L 
Asparagine 7.93 g/L 2.64 g/L 
(NH4)2SO4 3.96 g/L 1.32 g/L 
2.5.3. Medium Scale Fermentation and Extraction 
Initial experiments testing nitrogen and carbon source with the Micromonospora 
sp. were carried out using the standard growth and extraction protocol used for building 
the Linington Lab’s marine Actinobaterial natural product extract library. 
Micromonospora sp. was grown in culture flasks containing a metal spring and 60 mL of 
each type of media indicated in Table 2.1. Every carbon source was paired with 
(NH4)2SO4, but only starch was paired with glutamate as a nitrogen source. The 
selection of these media for fermentation with [1-13C]acetate was made on the basis of 
preliminary time-course experiments done in small scale for the detection of lobosamide 
A. Each culture flask also contained 1.2 g of Amberlite XAD-16 adsorbant resin to assist 
with the extraction of natural products from the culture medium. Each 60 mL culture was 
inoculated with 3 mL of seed culture grown in GNZ media for three days. An unlabeled 
control culture containing 12 mM of unlabeled acetate was grown in parallel to 
experimental cultures containing 12 mM of [1-13C]acetate. Cultures were shaken at 200 
rpm for seven days and then extracted and fractionated by polarity.  
58 
Each 60 mL culture was first filtered by vacuum filtration and the cell debris and 
resin were then extracted in a 1:1 mixture of methanol and dichloromethane for one 
hour. The organic extract was collected by vacuum filtration and dried by rotary 
evaporation. The crude organic extract was initially separated into seven fractions by a 
stepwise methanol/water elution (10, 20, 40, 60, 80, 100 vol/vol) and an additional ethyl 
acetate wash step on a RediSep Rf C18 cartridge (Teledyne Isco) using a Teledyne Isco 
CombiFlash Rf flash chromatography system. Lobosamide A is found in the 80% 
methanol and 100% methanol fractions, so these fractions were prepared for UPLC-MS 
analysis for each media condition control and [1-13C]acetate culture. Samples were 
prepared by first dissolving each pre-fractionated extract in 1 mL of methanol and 
diluting the sample by 1:200 into 50% (vol.vol) methanol/water.  
2.5.4. Microtiter Plate Fermentation with SIL Tracers 
The SIL feedstock compounds, [99% 1-13C]acetate, [99% 1-13C]propionate, [99% 
methyl-13C]methionine, and [98% 1-15N]glutamate, and unlabeled version of each 
compound were prepared as stock solutions in Milli-Q water and sterilized by filtration 
(0.2 uM filter). Bacterial inoculum was prepared by first streaking a frozen stock on a 
GNZ agar plate (10 g glucose, 20 g starch, 5 g N-Z-amine, 5 g yeast extract, 1 g 
CaCO3, and 14 g agar per liter of water) for Micromonospora sp. and ISP agar plate (3 g 
yeast extract, 5 g acid hydrolyzed casein, and 14 g of agar per liter of water) for S. 
erythraea. Single colonies were selected to inoculate a 7 mL liquid culture of either GNZ 
or ISP media. Once turbid growth was observed in rich media, 50 µL of this culture was 
used to inoculate a 7 mL culture of the same minimal media to be used in the SIL 
experiment. After 24 hours of growth, this culture was used for the inoculation of the 
microtiter plates. The same culture was used as inoculum for all replicate wells of every 
feedstock condition in a given experiment. The 24-well microtiter plates and sandwich 
covers used for micro-scale bacterial cultures were purchased from Enzyscreen B.V. 
(The Netherlands) and the protocol for microtiter well plate fermentations was adapted 
from Duetz et al.20  
The 24-well microtiter plates were cleaned and sterilized according to Duetz et 
al.,20 and 2 mL of minimal media was added to each well. The first and last columns in 
each 24-well plate were left with sterile media and the inner 16 wells were inoculated 
with 80 µL of bacterial inoculum. Following inoculation, either an SIL compound or the 
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corresponding unlabeled compound was added to each well by sterile filtration. Four 
replicate wells were prepared and inoculated for each condition, including unlabeled 
controls. Unlabeled control cultures were included for each feedstock condition to 
account for metabolic changes that may occur as a result of adding the precursor 
compound. The SIL feedstock compounds were tested at various concentrations as 
indicated in the following sections. Stock solution concentrations were adjusted 
according to the final desired concentration of each SIL or unlabeled precursor in the 
culture so that a minimal volume of 20-100 µL of stock solution was added to each well. 
The replicate cultures were fermented and analyzed separately and therefore account 
for technical variation in both the fermentation experiment as well as the analytical 
variation in the MS data.  
Microtiter plates containing SIL supplemented bacterial cultures were shaken at 
200 rpm and maintained at 23.0 °C for five days. On the fifth day the cultures were 
extracted by adding 2 mL of Optima methanol to each well. The contents of each well 
were then transferred to Eppendorf tubes, sonicated for 5 minutes, and centrifuged for 1 
minute at 16,000 g. Methanol/water extracts were injected directly onto the UPLC-qTOF 
system, or diluted to maintain the most intense signals in the chromatogram in an 
optimal range for both sensitivity and mass accuracy.  
2.5.5. Optimization of SIL Tracer Incorporation in Erythromycin A 
In order to determine the optimal concentration for each of our SIL precursors, I 
performed an experiment using S. erythraea as described above with replicates of the 
following concentrations of each SIL: (100 mM, 10 mM, 1 mM, 0.1 mM) [1-13C]acetate, 
(100 mM, 10 mM, 1 mM, 0.1 mM) [1-13C]propionate, (16.5 mM, 10 mM, 1 mM, 0.1 mM) 
[methyl-13C]methionine, and (20 mM, 10 mM, 2 mM) [1-15N]glutamate. In all conditions 
the total concentration of glutamate is 20 mM, as glutamate is the only nitrogen source in 
the minimal media. For the [1-15N]glutamate labeling condition we tested three ratios of 
[1-15N]glutamate and unlabeled glutamate, so that the total available nitrogen was the 
same in every condition. Unlabeled controls were performed as four replicates with 
matching concentrations of unlabeled acetate, propionate, methionine, and glutamate 
respectively. Erythromycin A (2.5) was used as a test case to determine the optimal 
concentrations of each SIL precursor (Figure 2.10).  
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Figure 2.10 Mass Spectra of 2.5 with Varying Concentrations of SIL Tracers 
Mass spectra of erythromycin A (2.5) from S. erythraea extracts supplemented with [1-13C]acetate 
(a), [methyl-13C]methionine (b), [1-13C]propionate (c), and [1-15N]glutamate (d) at the 
concentrations indicated.   
2.5.6. UPLC-MS Methods 
The samples that were prepared from the pre-fractionated extracts of 60 mL 
bacterial cultures were processed and ran at UC Santa Cruz using an Agilent 1260 
binary pump and an Agilent 6230 time-of-flight mass spectrometer with a Jetstream ESI 
source. A 2 uL sample was injected onto a 1.8-um particle size, 50 x 2.3 mm i.d., 
ZORBAX RRHT C18 column. A gradient from 10 to 90% acetonitrile over 4 min with a 
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1.5  min hold at 90% and 3 min re-equilibration. Flow rate 08 mL/min. 0.02% formic acid 
in solvents. Positive mode, 100 – 1700 m/z, source temp 350 C, 11L/min drying gas.  
All other samples were prepared and analyzed by the following procedure. 
Biological samples were diluted with an equal volume of methanol and the supernatants 
were subjected to chromatographic separation and mass spectrometric analysis. 
Chromatography was performed on a Waters I-Class Acquity UPLC system (Acquity 
HSS T3 1.8 µm, 2.1 x 100 mm) using a linear gradient (solvent A: H2O + 0.01% formic 
acid, solvent B: acetonitrile + 0.01% formic acid) of 5-98% B over 5.8 minutes, a hold a 
98% B for 0.3 min followed by a 1.8 minute re-equilibration at 5% B. All mass spectra 
were acquired using a Waters Synapt G2Si qTOF MS run in data-independent 
acquisition (DIA) mode. The MS detector range was set to 50-1500 m/z in positive 
mode, with a capillary voltage of 3.5 kV, and a desolvation temperature of 200 ºC.  
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Chapter 3.  
 
IsoAnalyst: An MS Metabolomic Platform for the 
Detection of Stable Isotopic Label Incorporation in 
Natural Products 
3.1. Introduction 
Advances in MS technology have driven a surge in the development of 
innovative metabolomics approaches. As discussed in Chapter 1, targeted 
metabolomics methods are now streamlined for many general classes of metabolites 
such as amino acids, and central carbon metabolism. This was achievable due to an 
increase in accessible methods to quickly acquire high resolution MS datasets and 
advances in compound identification databases, especially those that use fragmentation 
data such as GNPS.1,2 Untargeted metabolomics is an appealing approach to expand 
upon metabolomics for novel pathway and compound discovery. Coupling untargeted 
metabolomics studies with SIL precursors has powerful implications but there are 
challenges associated with such an approach. Many biologically relevant SIL tracers are 
commercially available, and MS facilitates the sensitive detection of their incorporation 
into metabolites, however dedicated and intuitive software for the interpretation of 
untargeted SIL MS data is lacking.3 Still, there have been some exciting developments in 
this area as there are wide reaching applications of untargeted SIL MS metabolomics.  
A recent study demonstrated how the complete 15N labeling of a cyanobacterial 
culture using Na15NO3 can be employed to associate peptide natural products with their 
NRPS BGCs.4 The authors focused on NRPS BGCs because adenylation domains can 
be identified in the genome sequence to predict the amino acid sequence and therefore 
the total number of expected nitrogen atoms in the product. By providing Na15NO3 as the 
sole nitrogen source, any nitrogen-containing natural product that the cyanobacteria 
produced may be labeled and detected. This was a rare untargeted study that aimed to 
detect all natural products in a given extract that demonstrated 15N incorporation, 
however the authors did not use any statistical analysis.4 Rather, they manually 
compared SIL incorporation in the experimental samples to the unlabeled controls to 
determine the number of 15N atoms present in each compound. They successfully 
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identified four compounds from four different BGCs by matching the mass difference 
between unlabeled and labeled isotopologue peaks with the expected number of 
nitrogen atoms in the predicted BGC products.4 Two of the compounds identified were 
new natural product structures, highlighting the ability to discover novel compounds and 
quickly generate hypotheses about their biosynthetic origin. This promising example of 
untargeted SIL metabolomics demonstrates the need for powerful and flexible tools for 
the detection of SIL tracers in complex datasets.  
Another recent study used [13C6]-phenylalanine in plants to detect compounds 
derived from this precursor, termed the ‘phenylalanine derived metabolome’. This study 
aimed to detect the entire phenylalanine derived metabolome of a wild type Arabidopsis 
thaliana and various mutants to identity genes associated with variation in phenylalanine 
derived metabolites.5 Like many other SIL tracer studies, these authors used an amino 
acid with multiple labeled atoms because this makes the detection of incorporation much 
more straightforward. In paired samples, the mass shift of 6 Da can be detected by mass 
searching and confirmed as a full incorporation of the entire SIL tracer. The use of a 
tracer like [13C6]-phenylalanine increases the ease of detecting target compounds but at 
a high financial cost. Cheaper SIL tracers are preferable when designing experiments 
with parallel labeling conditions. Interpretation of singly labeled tracers is not as 
straightforward due to isotopic contributions from natural 13C and the complex 
distributions of isotopologue peaks that occur when an SIL precursor is incorporated into 
the same compound multiple times. These recent publications show that there is a 
strong need across different biological systems to identify compounds associated with 
BGCs in a systematic way. Detection of SIL tracer incorporation in MS metabolomics is 
highly applicable across different systems and computational tools that allow for flexible 
SIL experimental designs are in high demand. 
3.1.1. Computational Tools For Untargeted SIL MS Metabolomics 
Untargeted SIL analyses have grown in popularity as they are better suited to 
novel pathway discovery and a number of tools have been developed for this purpose. 
Many of these tools can be used in conjunction with fluxomics analyses to discover 
novel pathways and metabolites, or to associate metabolites that are co-regulated under 
drug pressure or disease conditions.2,3 XCMS is a common MS data processing platform 
that was originally developed in R but now in its online version has become highly 
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accessible to researchers around the world.6 Supplemental programs that work with the 
XCMS output to further process metabolomics data are used for many different 
applications, including untargeted SIL analysis. In particular, X13CMS has become a 
useful tool for comparing isotopic incorporation in m/z features across different 
conditions.7,8 Other algorithms such as mzMatch-ISO9 and geoRge10 also rely on XCMS 
and mzMatch.R11 for data pre-processing. XCMS is most often used to process LCMS 
data although it can handle GCMS data as well. Dedicated algorithms such as non-
targeted tracer fate detection algorithm (NTFD)12,13 and mass isotopolome analyzer 
(MIA)14 were designed specifically for low resolution GCMS data. These tools have 
demonstrated effective deconvolution of low resolution SIL MS data and the ability to 
account for natural SIL abundances in bulky derivatization groups used for GCMS. The 
datasets generated by these tools have high potential for novel pathway discovery in 
global metabolic studies and in conjunction with fluxomics or other systems level 
modeling.15–17 Although these methods are all applicable to novel natural product 
discovery, they are limited in that they typically require a high degree of labeling such as 
from a fully labeled carbon source and aim to compare changes in labeling across the 
metabolome as a result of a perturbation. Because they aim to look globally at the 
central metabolome, these tools can be applied to synthetic biology and optimization of 
compound production, but are too promiscuous in the SIL design for easy identification 
of novel compounds. 
An R package, Miso, was recently developed specifically to handle the detection 
multiple SIL conditions in parallel experiments.18 Miso automatically detects SIL 
incorporation in isotopologues across different SIL precursor conditions and aligns them 
with an unlabeled dataset. The output of Miso contains a complete list of all isotopologue 
pairs detected, and the number of labeled atoms in each condition. Miso was originally 
created for a particular experimental design published by the same group termed Dual 
Labeling of Metabolites for Metabolome Analysis (DLEMMA).19,20 This approach requires 
parallel isotopic labeling conditions containing the same metabolite precursor with 
different SIL compositions (ie tyrosine-2H4 and tyrosine-13C915N1). The aim of this 
analysis is to assist in sub-structure searching and molecular formula assignment for 
metabolite identification, but requires multiply labeled tracers to target a specific 
pathway. The novelty of this approach is in its ability to align labeling data from parallel 
SIL conditions, however the particular requirements of the SIL selection make these 
67 
experiments somewhat inflexible. The Miso package has been developed to allow for 
additional flexibility in SIL precursor selection outside of the DLEMMA workflow.18 The 
Miso algorithm and workflow are a powerful new tool for investigating natural product 
biosynthesis and facilitating discovery in microbial natural products, although it was 
developed initially as an application in plant metabolomics.  
Like the untargeted SIL data analysis approaches described above, Miso 
compares isotopologue intensities between labeled and unlabeled conditions to 
statistically determine the enrichment of heavy isotopologue peaks in the labeled 
sample. Many of these methods give relative isotopologue ratios as outputs, but Miso 
gives a very specific output indicating the number of labeled atoms present in each 
detected molecule. This is possible because the published examples of the Miso 
analysis involve SIL precursors with multiple labeled atoms, and assumes that for 
biological relevance, the precursor will be fully or partially incorporated into the 
compounds of interest with two or more labeled atoms. This works well for the 
application of substructure searching of a specific metabolite or group of metabolites that 
are derived from a common precursor. Like Miso, IsoAnalyst aims to identify the number 
of SIL tracer molecules incorporated into metabolites across a set of SIL conditions. 
However, a method for interpreting isotopologue ion intensities that accurately detects 
iterative incorporations of a singly labeled SIL tracer is beyond what is currently available 
in untargeted MS metabolomics.  
All of the algorithms discussed so far apply similar processing and statistical 
analyses of isotopologue peaks by comparing relative isotopologue intensities between 
unlabeled and labeled samples. Peaks that are determined to be labeled are typically 
displayed as mass isotopomer distributions (MID), or isotopologue distributions 
depending the resolving strength of the mass spectrometer. MID patterns can be used 
for statistical association between features showing similar labeling patterns or 
visualized for manual comparison. Miso differs from this type of output by providing the 
number of heavy isotopes detected in each compound. IsoAnalyst aims to generate an 
output similar to Miso, but uses relative isotopologue ratios within a single labeled 
sample to determine the number of SIL tracers incorporated into the structure. This 
approach allows for the more sensitive detection of SIL incorporation beyond the most 
intense isotopologue peak in the mass spectra. 
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3.1.2. The IsoAnalyst Approach to Untargeted SIL MS Metabolomics 
Analysis  
While other approaches aim to interpret the SIL incorporation information directly 
for structure determination, IsoAnalyst focuses on the biosynthetic profile of molecules 
labeled under different conditions to generate hypotheses about the genomic origin of 
that molecule. To facilitate the use of various singly labeled precursors I developed the 
novel algorithm, IsoAnalyst, to determine the number of detectable SIL incorporation 
events in each feature under every SIL conditon. In Chapter 2 I covered how the 
IsoAnalyst approach is based on the flexibility of SIL precursor selection to identify 
different pathways. Here I will describe how IsoAnalyst determines the number SIL 
atoms in every mass feature across all experimental conditions.  
IsoAnalyst processes mass spectrometry data in three stages. Initially, the raw 
data are pre-processed using third party software to generate peak and feature lists as 
input files. MS features are then aligned across all unlabeled control samples in the first 
processing step to generate a ground truth feature list containing the monoisotopic m/z 
value (M0) for every MS feature detected across the entire experiment (Figure 3.1a). The 
next step uses the M0 peak of each feature in the master list to identify and scrape the 
associated isotopologue peak data (M1, M2, M3, etc.) for every feature in each SIL 
condition (Figure 3.1b) Finally, IsoAnalyst determines the degree of isotopic labeling for 
each analyte by comparing the relative isotopologue ratio M1:M0 of a feature in the 
unlabeled dataset with sequential pairs of peaks (e.g. M1:M0, M2:M1 etc.) in the labeled 
dataset. For every position where this ratio is significantly greater than the M1:M0 ratio of 
the unlabeled feature, we assume that at least that many positions are enriched in that 
given condition. The final output of IsoAnalyst is a summary of the number of SIL 
incorporations detected for each feature under every SIL condition (Figure 3.1b). 
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Figure 3.1 IsoAnalyst MS Data Processing Workflow  
(a) Required data pre-processing steps to generate input files for IsoAnalyst. Files are 
indicated as tilted rectangles and those highlighted with a light gray box are required input 
files. Requirements described in the software documentation are available in the GitHub 
repository. The ground truth feature list of features aligned across samples is highlighted 
in a dark gray box and may be generated by the ‘Prep’ step of the IsoAnalyst program 
(highlighted in green) or by third party tools. (b) IsoAnalyst performs the following steps: 
all isotopologue peak information for every feature is first scraped from the centroided 
peak lists in the ‘Scrape’ step (highlighted in blue). In the ‘Analyze’ step (highlighted in 
orange), the isotopologue ratios are compared for every feature in each SIL condition to 
determine the extent of labeling. Finally, a summary file is generated containing all of the 
SIL incorporation profiles for every feature that contains labeling in two or more 
conditions.  
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3.2. Standard Processing: Feature Detection and Alignment 
3.2.1. Peak Picking and Feature Detection 
Mass spectrometry generates complex multi-dimensional datasets, and pre-
processing of these datasets greatly affects the quality of downstream statistical results. 
There are many freely available tools and vendor specific software packages for this 
purpose, which typically involve processes such as noise filtering, baseline correction, 
peak picking, and retention time alignment.6,21,22 Centroiding, sometimes referred to as 
‘peak picking’,  determines the m/z peak’s centroid (or center) and collapses it into a 
single data point representing the intensity of one peak in one scan.23 This is not to be 
confused with the subsequent pre-processing step, feature detection, or the 
chromatographic alignment of m/z peaks. Because the extracted ion chromatogram of 
an m/z peak is also often referred to as a ‘peak’, representing compound elution over 
time, there is some overlap in the terminology between these two pre-processing steps. 
Feature detection often involves various other processes for cleaning up the data such 
as smoothing, background subtraction, and noise filtering.24 A chromatographic mass 
feature is a determined m/z value and retention time pair which represents a unique ion 
detected in an experiment. Isobars have the same mass but can elute at different times, 
highlighting the importance of accurate feature detection in order to determine individual 
analytes detected in an experiment even if they have the same mass. 
The confusion around this terminology is often disregarded because the majority 
of MS metabolomics studies apply statistical analyses to only the deconvoluted MS 
features. The centroided peak lists are typically considered as raw data files and are 
disregarded in the downstream analysis, except to follow up on specific analytes and to 
check data quality parameters such as peak shape and overlap. IsoAnalyst differs from 
other statistical analyses in that it requires separate input files with centroided m/z peak 
information for every sample and deconvoluted MS features for the unlabeled control 
samples only (Figure 3.1). Throughout this chapter I use the term ‘peak’ to refer to the 
centroided m/z peaks detected in each scan performed by the MS detector, and the term 
‘feature’ to refer to unique m/z and retention time pairs that were deconvoluted from the 
total ion chromatogram of the sample. When discussing the elution profile of an MS 
feature I will specify it as a ‘chromatographic peak’.  
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3.2.2. Considerations for Data Independent Acquisition 
All of the MS data in this thesis were acquired on a Waters Synapt G2Si qTOF 
mass spectrometer in a data independent acquisition (DIA) mode, termed MSE. 
Generally speaking, DIA of MS data means that all ions detected in the MS1 spectra are 
equally subjected to fragmentation. This is in contrast to data dependant acquisition 
(DDA) where only the highest intensity ions, or ions in an inclusion list will be 
fragmented. While more fragmentation information is retained in DIA methods, greatly 
reducing bias towards more abundant ions, the deconvolution of matching fragment ions 
to the corresponding parent mass is more complicated than in DDA. Waters MSE 
technology uses alternating low and high energy scans throughout the chromatogram to 
acquire full profile data across the entire dynamic range in both MS1 and MS2 mode for 
precursor and fragment ion detection respectively (Figure 3.2a) 
An in-house pre-processing pipeline which is specialized to handle MSE data 
from our Waters Syanpt G2Si was used for peak picking and feature detection. First, a 
centroiding algorithm is applied, to produce scan-by-scan peak lists for every sample in 
a csv format (Figure 3.2b). This centroiding algorithm is applied to the high and low 
energy scan separately to create two centroided peak lists for each sample. These peak 
lists are then deconvoluted in the pre-processing pipeline to produce feature lists for 
each sample. The analysis takes into account the chromatographic peak shape of each 
feature and determines the center (retention time) as well as the low and high scans 
indicating the beginning and end of the chromatographic peak. Importantly, this step 
includes de-isotoping, which is essential to the downstream processes because the 
feature lists are used to identify the monoisotopic M0 mass for every feature. The final 
step of feature detection that is specific to DIA MS data is to align the MS2 features with 
their parent MS1 ions and generate one file per sample which contains all parents and 
fragment ions (Figure 3.2c).  
IsoAnalyst is currently only designed to handle MS1 data, so although I perform 
the entire process shown in Figure 3.2 on every sample, I only keep the MS1 centroided 
peak list and disregard the MS2 peaks lists. I also disregarded the MS2 data in the final 
feature lists in order to simplify the initial development of the algorithm. Fragmentation 
data are investigated for SIL incorporation on a case-by-case basis to aid in structural 
assignment in the following chapters. Future development of this work could retain the 
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MS2 data in the processing pipeline however significant work remains in developing tools 
to automate the comparison of SIL labeled MS fragment ions across large datasets.  
 
Figure 3.2 Overview of DIA MS data acquisition and pre-processing 
(a) Cartoon diagram of DIA MS data acquisition, where alternating MS1 and MS2 continuum 
scans are acquired across the chromatographic run. (b) Centroiding of continuum data collapses 
peaks into a single intensity in each scan, which is then written to a .csv file  containing the full 
centroided peak lists. (c) Feature detection aligns the MS1 and MS2 data, and writes the data to a 
.csv file containing all MS1 features and their aligned MS2 features. 
3.2.3. Generating the MS Feature Master List  
The first step of the IsoAnalyst workflow is to align the features detected in the 
unlabeled control samples by retention time (0.03 min window) and m/z (15 ppm error) 
to generate a master list of all features present across the experiment (Figure 3.1a). 
IsoAnalyst contains a module which can perform this step, however other programs such 
as XCMS6 and MZmine21 can also align features across samples. This step may be 
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performed within IsoAnalyst, or by a third party tool (Figure 3.1a) The final ground truth 
list of features for the experiment contains the m/z value, retention time, charge state, 
low and high scan numbers, and the conditions the feature occurs in. This information is 
used in the following steps to guide the isotopologue data extraction.  A unique identifier 
is assigned to each feature and the m/z value recorded in the master list is assumed to 
be the monoisotopic M0 mass for that analyte due to the de-isotoping algorithm applied 
during feature detection. The scan ranges vary slightly between replicates, but are highly 
reproducible in retention time as expected from a UPLC system. IsoAnalyst takes the 
highest and lowest scan numbers from the list of replicates of each feature and uses this 
scan range to scrape isotopologue peaks from all of the experimental scan-by-scan data 
for that feature in the next step.  
The ground truth list of MS features is filtered to include only those features 
present in at least three of four replicate samples, and to exclude features present in 
solvent blanks. Doubly charged ions (ie [M+2H]2+) are observed in our experiment and 
retained in the ground truth feature list, however these ions are not analyzed in the 
subsequent steps of IsoAnalyst. The doubly charged ions observed in these experiments 
were all found to correspond to singly charged adducts and so I opted to focus on the 
statistical analysis of only the singly charged species for the development of this tool. 
Additional considerations should be made for interpreting SIL incorporation into high 
molecular weight doubly charged ions, which often correspond to large peptides. 
IsoAnalyst can easily be modified to detect and analyze these isotopologues, however 
the statistical approach presented here may not be ideal for the interpretation of SIL 
enrichment in such ions. Software currently exists that is more suited for the analysis of 
SIL incorporation into large peptides for proteomics applications.25 
3.3. Isotopologue Detection and Determination of SIL 
Incorporation 
3.3.1. Interrogation of SIL Experimental Data for All Isotopologue 
Peaks 
Isotopologues are isotopic homologs that contain the same number of light and 
heavy isotopic elements, but the isotopically enriched positions may differ.26 A mass 
spectrometer cannot differentiate the position of isotopic enrichment, but identifies 
74 
isotopologue peaks by their mass.27 The qTOF-MS system used in this study operates at 
about 25,000 FWHM resolving power, allowing for accurate mass determination. 
However, the resolving power of the qTOF mass spectrometer is not sufficient to 
differentiate between the natural occurrence of 13C and the enrichment of 15N in the [1-
15N]glutamate condition used in my experiment. These isotopologues are detected 
together as a single mass isotopomer peak27 as opposed to a pure isotopologue peak 
representing ions corresponding to the incorporation of an individual isotope. This 
complicates the detection of the isotopologue peaks in the [1-15N]glutamate condition 
slightly because the combined mass contribution of 15N and 13C skews the detected 
mass of the heavy isotopologue peaks in comparison to SIL conditions supplemented 
only with 13C.  
For identifying isotopologues in the unlabeled datasets, and in the SIL conditions 
containing only 13C enrichment, the mass difference of 1.00335 m/z is used to identify 
isotopologue peaks. For labeled features in the [1-15N]glutamate condition, the mass 
isotopomer peaks M1, M2, etc each represent a mixture of isotopologues containing 
either 15N, 13C, or some combination of both isotopes. For clarity, throughout this text I 
refer to all isotopically enriched peaks as ‘isotopologues,’ with the understanding that 
these peaks represent mixtures of isotopologues only in the [1-15N] glutamate condition. 
IsoAnalyst uses the mass difference between 14N and 15N (0.99704 m/z) to search for 
isotopologue peaks in the [1-15N] glutamate condition. The contribution of 13C to the 
isotopologue peaks in the [1-15N] glutamate condition is accounted for in the next step, 
where isotopologue ratios are compared directly between labeled and unlabeled 
conditions.  
The first challenge in analyzing the isotopologue peaks in this experiment was to 
attain the complete group of isotopologue peaks for every MS feature in the labeled 
samples. Because isotope distribution patterns vary significantly between analytes, I 
found that existing MS analysis software could not correctly identify the M0 peak of 
extensively labeled features in the SIL conditions. With the iterative incorporation of 
singly labeled precursors, my aim is to identify the heaviest isotopologue mass with 
detectable SIL incorporation even if it is not the most abundant isotopologue peak. The 
accurate and complete detection of the isotopologue distributions of every feature in the 
dataset is critical to the sensitivity and accuracy of the downstream analysis. The scrape 
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step in IsoAnalyst looks for all of the isotopologue peaks for every feature in the master 
list of feature aligned across the experiment in every sample (Figure 3.1b).  
To overcome the challenge of accurately aggregating this isotopologue data, 
IsoAnalyst uses the monoisotopic mass (M0) of each MS feature from the ground truth 
feature list as an anchor point to interrogate the labeled MS data for relevant MID 
patterns. This was accomplished using a custom data processing script that interrogated 
the centroided MS data from each experimental condition for the presence of each 
isotopologue peak (M0, M1, M2, etc) for every feature in the master list (Figure 3.1b). 
Starting from the M0 mass of each feature, the mass difference between the heavy and 
light isotope is iteratively added to obtain the theoretical masses of the isotopologue 
peaks M1, M2, M3, etc. IsoAnalyst then scrapes the scan-by-scan centroided data for 
every peak corresponding to the calculated isotopologue mass using a 15 ppm error 
window. The scan range used for obtaining the isotopologue peak data is determined by 
the initial feature detection step. Isotopologue data is interrogated this way for both 
unlabeled and labeled samples and written to a single file containing the full scan-by-
scan isotopologue data for all replicate samples in each feedstock condition (Figure 
3.1b).  
3.3.2. Calculating the Isotopologue Ratio 
The isotopologue distribution of a molecule can be theoretically calculated on the 
basis of the charge, molecular formula, and relative isotopic abundances of the elements 
present in the molecule.28 It is determined primarily by the natural abundance of 13C 
(1.07%) and the number of carbons present in the molecule, but smaller isotopic 
contributions from other elements such as nitrogen and oxygen are often incorporated 
into theoretical isotopologue distribution calculations.28 The measured isotopologue 
distribution of an analyte can be leveraged for molecular formula prediction and assist in 
compound identification.29 Complete isotopologue distributions can reduce candidate 
molecular formulas by >95% compared to accurate mass alone.28,30 Although this 
information is useful in compound identification, it is computationally time consuming to 
predict molecular formulas for hundreds to thousands of features. The ratio of the first 
isotopologue (one 13C; M1) to the monoisotopic mass (all 12C; M0) provides a more 
straightforward if less information rich way to measure isotopic abundance. This ratio 
(M1:M0) is not always sufficient for complete molecular formula predication but is a 
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molecule-specific measurement of natural isotopic abundance.31 The natural M1:M0 
isotopologue ratio for every feature in the unlabeled control data plays a special role in 
the IsoAnalyst workflow as this calculated ratio is the basis for statistically determining 
whether that feature is labeled in the SIL conditions. 
Mass accuracy has been a major focus in modern HRMS technological 
developments, however spectral accuracy is a companion concept that is often 
overlooked.32 In MS, spectral accuracy typically refers to the ability of the MS to 
accurately measure isotopic distributions. A common measurement of spectral accuracy 
is to calculate the percent error of the measured M1:M0 isotopologue ratio of a standard 
from its theoretical calculated M1:M0 isotopologue ratio.31 The M1:M0 ratio is usually 
calculated as a ratio of the integrated intensities of the M1 and M0 peaks across the 
chromatographic region.29,31,33 In IsoAnalyst I took a different approach to determine the 
M1:M0 isotopologue ratio by plotting the intensity values of the M1 and M0 peaks in each 
scan and plotting a linear regression function to determine the slope (Figure 3.3). The 
slope of this function is used as the experimentally determined M1:M0 ratio for the natural 
isotopic distribution of each MS feature detected in the unlabeled control data. These 
isotopologue intensity values are compared for a single analyte in a sample and the 
slopes of each intensity ratio plot are then averaged across replicates. The mean M1:M0 
ratio calculated for an MS feature in the unlabeled control samples is later used for 
statistical comparison to the isotopologue ratios in the labeled condition to determine the 
number of SIL precursors incorporated in the analyte. Centroid data are not preferable 
for  
 
Figure 3.3 MS data centroiding and isotopologue ratio plotting 
(a) Diagram of LC-MS data acquisition showing mass spectra collected at regular time intervals 
across a chromatographic peak. Each orange line represents a single mass spectrum, or scan 
containing m/z values across the instrument’s range. Data are first centroided, or peak picked, to 
give a single data point corresponding to the intensity of every m/z value in a scan. (b) All centroided 
scan data for a given feature plotted together as single points. (c) All centroided scan data for the 
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first two isotopologue peaks, M1 and M0, plotted by matching scans. The slope of the linear trend 
line in (c) is the isotopologue ratio used in the analysis step of the IsoAnayst workflow. 
spectral accuracy measurements as much of the spectral peak information is lost in the 
centroiding process.30,32 However, by plotting the centroided peak intensities by each 
scan I can assess the quality of the observed M1:M0 ratio in terms of linearity as well as 
spectral accuracy.  
To assess the variability of the naturally occurring M1:M0 isotopologue ratio for 
known analytes in our qTOF system, I analyzed erythromycin A at different 
concentrations (Figures 3.4, 3.5). Eight concentrations of erythromycin A, 500 nM, 100 
nM, 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM,  and 0.1 nM, were prepared and analyzed 
according to the methods at the end of this chapter. An additional higher concentration 
of 1 µM was tested, however the signal was highly saturated resulting in such a low 
mass accuracy that the isotopologue peaks could not be accurately detected and this 
sample was removed from the statistical analysis. Data was acquired for five replicate 
injections of each sample. Figures 3.4 and 3.5 show the calculated slope of the M1:M0 
intensity ratio for the [M+H]+ ion (m/z 734.4694) in the replicates for all eight 
concentrations. The linear regression statistics were computed using the linear 
regression function in the scipy.stats package. The slopes calculated from the linear 
regression of the M1:M0 intensity plot were then averaged to get the mean slope and 
standard deviation calculated across the five replicate sample injections (Figures 3.4, 
3.5). I refer to the mean slope and the M1:M0 ratio interchangeably throughout this 
section depending on the context. This value is used as the experimentally determined 
M1:M0 isotopologue ratio in comparison to the theoretical M1:M0 isotopologue ratio as 
calculated from a molecular formula. 
The standard error of regression (SER) values shown in figures 3.4 and 3.5 are 
similar to the commonly used R2 value indicating the linear fit of the data, but provide the 
error in the same numerical scale as the slope of the linear regression trend line rather 
than as a percentage. These SER values represent how well the data points in a single 
sample fit the linear regression model. The overall linear fit of these data is good across 
all concentrations, however the standard errors for the 500 nM replicates (Figure 3.4a) 
are notably an order of magnitude higher than the other concentrations. The lowest SER 
values were found for the intermediate concentrations 50 nM, 10 nM, and 5 nM (Figures 
3.4c,d, 3.5a). These statistics alone indicate that the data fit a linear model relatively well 
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across all concentrations, except 500 nM which demonstrated other systematic errors as 
discussed below.  
 
Figure 3.4 M1:M0 Isotopologue ratio plotting for commercial standard of 
erythromycin A (10 nM – 500 nM) 
Mass isotopologue distributions plotted by m/z versus intensity (left), linear plots of the M1:M0 
isotopologues of erythromycin A (center), and the individual and mean slopes of each replicate 
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linear graph, standard error (SER) of each linear model, and the standard deviation of the mean 
slope (right). Data shown for four concentrations 500 nM (a), 100 nM (b), 50 nM (c), 10 nM (d).   
 
Figure 3.5 M1:M0 Isotopologue ratio plotting for commercial standard of 
erythromycin A (0.1 nM – 5 nM) 
Mass isotopologue distributions plotted by m/z versus intensity (left), linear plots of the M1:M0 
isotopologues of erythromycin A (center), and the individual and mean slopes of each replicate 
linear graph, standard error (SER) of each linear model, and the standard deviation of the mean 
slope (right). Data shown for four concentrations 5 nM (a), 1 nM (b), 0.5 nM (c), 0.1 nM (d).   
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The mean slope and standard deviation were also calculated for each 
concentration. The standard deviation represents the variability of the mean slope 
calculated across the five replicates, whereas the SER values indicate how well the 
M1:M0 isotopologue intensity ratio plot of each replicate fits a linear model. The standard 
deviations of the mean slope are low across all concentrations, except the lowest 
concentration (0.1 nM) which was an order of magnitude higher than the other 
concentrations (Figure 3.5d). The SER values for the 0.1 nM data were also slightly  
higher than the higher concentrations. This indicates that although the overall precision 
of determining the M1:M0 ratio by linear regression is high, there is a lower limit in signal 
intensity where it is not ideal for measuring the isotopologue intensity ratio. 
3.3.3. Accuracy and Variability of the Isotopologue Ratio 
The theoretical M1:M0 ratio for the [M+H]+ ion of erythromycin A was calculated 
as 0.417 using the online tool enviPat Web 2.4.34 Table 3.1 indicates the relative percent 
error of the experimentally determined M1:M0 ratio for each concentration, from the 
theoretical ratio M1:M0 calculated by the equation 3.1: 
!1:!0	&''('	(%) = !1:!0(exp. ) −!1:!0(2ℎ&('. )!1:!0	(2ℎ&('. ) 	× 	100	 
This calculation has been used previously to assess spectral accuracy of MS 
systems, or how faithfully the MS signals demonstrate the true isotopic abundance.31–33  
 A percent error of 2-5% is often cited as the optimal range for spectral accuracy 
as measured by the M1:M0 ratio of known compounds.28,30,31 All of the experimentally 
derived M1:M0 ratios for the erythromycin A standard were within 10% of the true M1:M0 
ratio, except 500 nM which was much higher (64.5%) (Table 3.1). The mean M1:M0 
ratios and standard deviations for all eight concentrations of the erythromycin A standard 
are plotted together in Figure 3.6a. The dotted line in Figure 3.6 is drawn at the 
theoretical value 0.417. There is an apparent trend in these data that the M1:M0 ratio 
tends to decrease as concentration, and therefore signal intensity, decreases. This is 
true up to a point, as the lowest concentration (0.1 nM) demonstrated a higher average 
and larger standard deviation (Figure 3.6a). 
 
(3.1) 
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Table 3.1 Statistics for the natural M1:M0 isotopologue ratio of erythromycin A  
Sample 
Mean 
Slope 
(M1:M0) 
Slope      
RSD 
(%) 
Percent Error 
± stdev 
(Spectral 
Accuracy)* 
Average 
High 
Intensity 
Intensity 
RSD (%) 
Shapiro-Wilk 
p-value 
erythromycin A 
commercial 
standard 
500 nM 0.686 0.44 64.5 ± 0.6 1.3E+07 0.52 0.183 (n=5) 
100 nM 0.426 0.94 2.08 ± 1.06 5.9E+06 0.89 0.476 (n=5) 
50 nM 0.407 1.97 -2.34 ± 1.88 5.0E+06 1.14 0.473 (n=5) 
10 nM 0.402 1.49 -3.70 ± 1.44 8.8E+05 5.11 0.780 (n=5) 
5 nM 0.392 1.53 -5.79 ± 1.46 4.9E+05 2.07 0.102 (n=5) 
1 nM 0.381 0.79 -8.69 ± 0.66 8.2E+04 3.88 0.531 (n=5) 
0.5 nM 0.387 1.81 -7.11 ± 1.55 3.7E+04 5.38 0.752 (n=5) 
0.1 nM 0.416 5.53 -0.295 ± 5.41 7.1E+03 4.54 0.225 (n=5) 
S. erythraea 
extract 
unlabeled acetate 0.356 2.81 -14.6 ± 2.38 8.2E+05 47.7 0.046 (n=4) 
unlabeled propionate 0.346 1.45 -17.0 ± 1.28 4.7E+05 17.3 0.668 (n=4) 
unlabeled methionine 0.352 1.14 -15.5 ± 0.86 4.5E+05 6.14 0.786 (n=4) 
unlabeled glutamate 0.345 2.03 -17.2 ± 1.77 3.6E+05 26.4 0.223 (n=4) 
All unlabeled 0.350 2.29 -16.1 ± 1.86 5.2E+05 49.8 0.238 (n =16) 
*Based on theoretical  M1:M0 0.417 
Most of the percent errors calculated were negative, which aligns with published 
work showing that most HRMS systems including qTOF tend to underestimate the M1:M0 
ratio.31,32 The exception being the two highest concentrations, 500 nM and 100 nM which 
both have M1:M0 ratios with positive percent error. The 500 nM concentration in 
particular has a very high percent error despite having low standard deviation and SER 
values (Table 3.1, Figure 3.4a). This strongly indicates that the signal intensity in this 
condition has saturated the detector. When the monoisotopic mass (M0) is saturated, the 
first isotopologue (M1) may continue to show increasing signal intensity before it too 
reaches saturation at a high enough concentration. Because of this, saturated signals 
give erroneous M1:M0 values that cannot be detected by linear regression or variation 
statistics alone. The 100 nM concentration also has a positive percent error, however it 
is within the expected 5% error28 from the theoretical value (Table 3.1).  
The ideal signal range for the Synapt G2Si is an ion intensity of approximately 
1.0e3 – 1.0e6. Signal intensities of 1.0e6 and higher are near saturation and often result 
in a decrease in mass accuracy, while signals higher than 8.0e6 are highly saturated 
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and not guaranteed to meet the specifications for mass accuracy. The average signal 
intensity for the highest intensity scan is shown for each concentration of erythromycin A 
in Table 3.1. The signal intensities in the standard erythromycin A samples were highly 
consistent due to the fact that the five replicates were sample injections from the same 
vials. In the fermentation experimental design, I include unlabeled control samples that 
are matched to every SIL precursor condition. This means that for each SIL precursor 
there are four control wells to which an unlabeled version of that biosynthetic precursor 
is added. These four replicates are inoculated from the same starter culture, but are 
fermented, worked up, and analyzed separately. These are technical replicates that 
account for variation in the wells of the microtiter plate, extraction technique, and MS 
analysis and so the variability in signal intensity was expected to be higher in these 
samples.  
 
Figure 3.6 Average natural M1:M0 ratios measure for erythromycin A 
Dotted line at 0.417 represents the theoretical M1:M0 ratio of erythromycin A as calculated using 
enviPat Web 2.4.34 Error bars are standard deviation of the mean where n = 5 for the commercial 
standard of erythromycin A and n = 4 for each unlabeled extract condition. 
I calculated the same statistics for the variability and accuracy of the M1:M0 ratios 
in the unlabeled control samples for a full S. erythraea experiment including acetate, 
propionate, methionine, and glutamate. The full experimental conditions can be found at 
the end of this chapter. Table 3.1 and Figure 3.6b include the statistics for the M1:M0 
ratios of the [M+H]+ ion of erythromycin A in the unlabeled control extracts of S. 
erythraea. The mean slopes in this table are generated from four replicate sample 
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extracts of cultures that were supplemented with the unlabeled precursor. Each 
unlabeled precursor control condition is processed separately, however the M1:M0 ratio is 
expected to be identical in these samples as they are all subject to the natural 
abundance of 13C and analyzed by MS on the same day. The variability (Slope RSD; 
Table 3.1) is low within these conditions and remains low when the M1:M0 ratio is 
averaged across all sixteen control samples (‘All unlabeled’). It is notable however that 
the percent errors calculated for the M1:M0 ratio of erythromycin A in the extracts were 
considerably larger in magnitude than in the standard samples (Table 3.1). The fact that 
the M1:M0 ratio was consistently smaller in the unlabeled extracts compared to the 
standard samples suggested that the signal intensity may be lower and potentially 
biasing the measurement towards a lower M1:M0 ratio. The average upper signal 
intensities for these samples were in the 3.0e5 - 9.0e5 range, which is within the ideal 
signal range according to Waters and based on the results using the standard of 
erythromycin A (Table 3.1). As expected, the relative standard deviation (RSD) of these 
signal intensities were much higher than in the standard samples (Table 3.1), however 
this did not translate to a higher variability in the M1:M0 ratio itself (Figure 3.6b).  
Although the M1:M0 ratio measured by qTOF-MS and calculated by the approach 
presented here is not reliably accurate to the literature standard28, it is clear that within a 
single experiment we can expect the detected isotopologue ratio to be precise if not very 
accurate. Because there was low variability in the M1:M0 ratio across the full set of 
sixteen unlabeled control samples, I expect that the factors that contributed to a larger 
deviance from the theoretical M1:M0 value were systematic and affected the entire 
sample set, including the labeled samples, with the same bias. The 2-5% accuracy 
suggested by Kind and Fiehn28 was intended for using the M1:M0 ratio to assist in the 
reduction of potential molecular formulas. This application requires objective accuracy of 
the M1:M0 ratio calculated for each molecular species, however my experiments use the 
M1:M0 ratio for internal comparisons so the overall precision is more important than the 
accuracy.  
 The subsequent statistical analysis described in the next section uses a Welch’s 
t-test which assumes that the sample sets being compared have a normal distribution. 
One informal way of assessing normality is to plot the data in a frequency distribution 
histogram or to use other methods of visual plotting. I am working with relatively small 
sample sizes that are not amenable to this assessment. There are also a variety of test 
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statistics used to determine is a sample set is normally distributed but the Shapirio-Wilk 
test is often cited as providing better power than other commonly used tests of 
normality.35 A Shapiro-Wilks test was employed using the scipy.stats package to test the 
normality of the unlabeled M1:M0 ratios for the [M+H]+ ion of erythromycin A in the 
standard samples and the unlabeled extracts. A significant p-value for a Shapiro-Wilk 
test (< 0.05) indicates that the data are not normally distributed. All of the M1:M0 ratios 
derived from standard and extract samples showed normal distribution according to this 
test except for the S. erythraea extract supplemented with unlabeled acetate (Table 3.1). 
This dataset was determined to include an outlier, as further indicated by the higher 
standard deviation in this condition. The Shapiro-Wilk p-value calculated for the full 
sixteen unlabeled control sample was also insignificant indicating an overall normal 
distribution of the M1:M0 ratios derived from linear regression slopes of these samples.  
3.3.4. Using Isotopologue Ratios to Determine the Extent of SIL 
Incorporation in MS Features 
Because all SIL precursors used in this method are singly labeled, incorporation 
of any SIL precursor will increase the M1:M0 intensity ratio for that condition. Starting with 
the M1:M0 ratio in the SIL condition, IsoAnalyst asks the question, 'is this isotopologue 
ratio significantly greater than the M1 to M0 ratio of the same chemical species having a 
natural isotopic distribution?' If the isotopologue ratio of M1:M0 for the feature in the SIL 
condition is statistically indistinguishable from the unlabeled feature, it is determined to 
have no isotopic enrichment in that condition. However, if it is significantly greater, the 
feature is determined to be labeled. IsoAnalyst then iteratively compares the intensity 
ratios for subsequent isotopologue pairs (e.g. M2:M1, M3:M2, etc) until the isotopologue 
ratio is no longer statistically distinguishable from the natural M1:M0 ratio. 
The heavy isotopologue ratios detected in the SIL conditions are expected to 
demonstrate a higher variability than the natural abundance M1:M0 ratios of features in 
the unlabeled conditions. The replicates in this experiment are derived from individual 
biological cultures maintained in separate sterile wells in 24-well plates. Although the 
media conditions are identical, and the culture inoculum for each well is derived from the 
same original colony, there will always be small variations that affect the metabolism of 
the SIL incorporation in each well. I looked at the variability of the heavy isotopologue 
ratios of erythromycin A in the [1-13C]acetate condition because this precursor is not 
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directly incorporated into the compound and therefore may demonstrate higher variability 
in SIL incorporation under minor environmental changes. Table 3.2 shows the mean 
slopes for each isotopologue ratio calculated for the [M+H]+ ion of erythromycin A in the 
[1-13C] acetate samples, with the RSD expressed as a percentage. The RSD values for 
the first three isotopologue ratios (M1:M0, M2:M1, M3:M2) were between 2-4% which is 
similar to the RSD of the M1:M0 isotopologue ratios calculated for the unlabeled 
conditions (Table 3.2). The heavier mass isotopologue ratios had increasing RSD values 
which could be explained not only by biological variability but the lower intensities of 
these heavy mass isotopologue peaks (M7:M6, M8:M7 in Table 3.2). Overall, the 
variability of the isotopologue ratios in the SIL conditions is slightly higher than the M1:M0 
isotopologue ratios in the unlabeled conditions.  
Table 3.2 Isotopologue ratio statistics for erythromycin A labeled by [1-
13C]acetate 
Isotopologue 
Ratio mean slope 
Slope RSD 
(%) 
Average High 
Intensity 
Intensity 
RSD (%) 
Shapiro-Wilk 
p-value 
M1:M0 2.074 2.25 3.0E+05 5.15 0.478 
M2:M1 1.032 3.71 3.1E+05 5.89 0.444 
M3:M2 0.664 1.68 2.0E+05 5.48 0.643 
M4:M3 0.446 4.06 9.2E+04 9.05 0.078 
M5:M4 0.323 7.57 3.0E+04 13.1 0.187 
M6:M5 0.268 4.65 8.2E+03 12.0 0.515 
M7:M6 0.262 10.0 2.1E+03 6.11 0.106 
M8:M7 0.212 21.8 4.9E+02 3.34 0.129 
 [1-13C]Acetate can be incorporated into erythromycin A in six positions, through 
the indirect transformation of methylmalonyl-CoA from the TCA cycle intermediate 
succinyl-CoA, as discussed in Chapter 2. Six carbon positions of erythromycin A can be 
labeled indirectly by [1-13C]acetate through malonyl-CoA (Figure 3.7a). The intensities of 
the isotopologue peaks of erythromycin A in each scan of the chromatographic peak are 
shown for one control replicate and one [1-13C]acetate experimental replicate (Figure 
3.7b). The M1:M0 ratio of the unlabeled control and all detectable isotopologue ratios in 
the [1-13C]acetate condition are then plotted as intensity ratios (Figure 3.7c). A single 
replicate is plotted for each isotopologue ratio for comparison (Figure 3.7c), however 
mean slope data (n=3) were used in the statistical analyses shown in Figure 3.7d.  
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The statistical comparison between isotopologue ratios of a compound in the SIL 
condition and the M1:M0 ratio in the unlabeled condition is done using a two-tailed 
Welch’s t-test with a p-value cut off of 0.05. Although IsoAnalyst performs a two-tailed t-
test in this analysis, it only determines an isotopologue peak to be enriched in an SIL 
precursor if the M1:M0 ratio is significantly greater than the natural M1:M0 ratio. This is 
effectively a one-tailed t-test (p-value cut off of 0.025), using a combination of the two-
tailed p-value (< 0.05) and the test statistic (< 0) to decide if a isotopologue is enriched 
with an SIL precursor. For erythromycin A labeled by [1-13C]acetate, the first four 
isotopologue ratios (M1:M0, M2:M1, M3:M2, and M4:M3) all have significant p-values and 
negative t-statistic values, indicating they are all significantly larger than the M1:M0 ratio 
in the unlabeled condition (Figure 3.7d). When plotted together, it is clear that these 
isotopologue ratios have larger slopes than the unlabeled M1:M0 ratio (Figure 3.7c). The 
M5:M4 isotopologue ratio does not have a significant p-value (Figure 3.7d), indicating that 
is statistically indistinguishable from the unlabeled M1:M0 ratio. Enrichment of SIL in the 
M5 isotopologue is therefore not detectable, as this isotopologue may have four positions 
enriched by 13C derived from the [1-13C]acetate tracer and one 13C position deriving from 
the natural abundance of 13C. Based on the statistical analysis shown in Figure 3.7d, the 
M4 isotopologue is the heaviest isotopologue that has statistically significant enrichment 
from the [1-13C]acetate tracer. The remaining isotopologues (M6:M5, M7:M6, and M8:M7) 
have significant p-values (< 0.05), but positive t-statistic values, indicating that they are 
all significantly smaller than the unlabeled M1:M0 ratio (Figure 3.7d).  
 Although various elements make small contributions to isotopologue abundance, 
the theoretical M1:M0 ratio for a compound depends primarily on the number of carbons 
in a compound’s structure. Larger organic molecules have a higher M1:M0 ratio because 
there are more carbon positions available in the molecule where 13C may occur. The M1 
isotopologue peak represents the same compound as the M0 peak, except with one 13C 
present somewhere in the structure. A molecule with more carbons will naturally have a 
higher probability of having a 13C present in its structure, consequently increasing the 
ratio of the M1 isotopologue peak in comparison to the monoisotopic peak. Likewise, 
when a molecule is enriched with an SIL precursor incorporated into its structure, the 
probability of the remaining carbons having a naturally occurring 13C is less than that of 
the whole molecule produced in unlabeled conditions. This is why we see significance in  
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Figure 3.7 Isotopologue ratios for erythromycin A labeled by [1-13C]acetate 
(a) Structure of erythromycin A with red circles representing positions where 13C can be 
incorporated into the structure via [1-13C]acetate. (b) Plot of the isotopologue peak intensities for 
erythromycin A in an unlabeled control (top) and an [1-13C]acetate labeled sample (bottom). (c) 
Isotopologue intensity ratios plots for M1:M0 ratio in the unlabeled control, and the first five 
isotopologue pairs in the labeled sample. (d) Table showing the mean slope of every isotopologue 
pair and the Welch’s two-tailed t-test results for each labeled isotopologue pair.  
the two tailed t-test beyond the isotopologue peak containing the most SIL atoms 
derived from the SIL precursor.  
This phenomenon is best illustrated when a compound has complete SIL 
enrichment in every available position. [1-13C]Propionate is a highly efficient SIL 
precursor for labeling erythromycin A, which uses six methylmalonyl-CoA units and one 
propionyl-CoA units in the biosynthesis of its polyketide backbone. In this experiment we 
observed complete labeling by [1-13C]propionate, which appears as a clear 7 Da shift 
from M0 to M7 (Figure 3.8b). Figure 3.8a shows the structure of erythromycin A 
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corresponding to the M1 peak in the unlabeled condition, with a single naturally occurring 
13C in its structure (open circle). The structure in Figure 3.8b represents the M8 
isotopologue in the [1-13C]propionate condition, which has seven 13C atoms derived from 
enrichment by the [1-13C]propionate (filled circles) and one position deriving from 
naturally occurring 13C (open circle). Erythromycin A has 37 carbon positions that may 
contain 13C derived from natural abundance to generate the M1 isotopologue structure 
shown in Figure 3.8a. The isotopologue of erythromycin A which has complete labeling 
by [1-13C]propionate (M7) has 30 remaining carbon positions that may contain 13C 
derived from natural abundance to generate the M8 isotopologue structure shown in 
Figure 3.8b. The ratio of M8:M7 is significant in the two tailed t-test (p = 1.6 x 106), but the 
graph in Figure 3.8c clearly shows that the M8:M7 ratio is significantly smaller than the 
M1:M0 ratio of the unlabeled feature. The M8:M7 ratio of erythromycin A in the [1-13C] 
propionate condition is significantly smaller than the M1:M0 ratio of erythromycin A in the 
unlabeled condition because there are less carbon positions remaining in the structure 
where natural 13C may occur. This trend of isotopologue ratios being a significantly 
smaller than the natural M1:M0 ratio was common for ions that had strong signal intensity 
for the heavy isotopologue peaks.  
This statistical analysis therefore assigns the degree of isotopic labeling detected 
for a given SIL precursor in every MS feature aligned across the experiment. IsoAnalyst 
evaluates every MS feature from the ground truth list in each SIL condition to determine 
whether or not the feature is isotopically enriched in that condition, and how many 
positions can confidently be assigned as labeled. These data create a profile for each 
MS feature indicating the extent of labeling in each SIL precursor tested. The final step is 
to combine the labeling information into a summary file with every feature from the 
ground truth feature list and the number of SIL precursors detected in each condition. 
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Figure 3.8 Isotopologue ratios for erythromycin A labeled by [1-13C]propionate 
(a) Structure of the M1 isotopologue of erythromycin A in the unlabeled sample. The open yellow 
circle represents 13C derived from the natural abundance of 13C. (b) Structure of the M8 
isotopologue of erythromycin A. Filled yellow circles represent 13C derived from [1-13C]propionate 
and the open yellow circle represents 13C from the natural abundance of 13C. (c) Isotopologue ratio 
plots from an unlabeled control and [1-13C]propionate labeled sample. (d) Table showing the mean 
slope and Welch’s two-tailed t-test results for the three heaviest isotopologue ratios of erythromycin 
A labeled by [1-13C]propionate.   
3.3.5. Complete SIL Incorporation in Erythromycin A 
The statistical approach presented in this chapter fulfils the need outlined in 
Chapter 2 to identify the heaviest isotopologue peak of a compound that is enriched by 
an SIL precursor. This analysis therefore identifies the number of singly labeled SIL 
precursors incorporated into a given ion, and aligns these data across parallel SIL 
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conditions. I have already shown that four 13C atoms from [1-13C]acetate and seven from 
[1-13C]propionate were detected in erythromycin A. This aligns well with the predicted 
incorporation of these SIL precursors (Figure 3.9a) because [1-13C]propionate is 
incorporated directly into all of the polyketide core substrates, while [1-13C]acetate only 
labels the methylmalonyl-CoA extender units indirectly through the TCA cycle. Four 
labeled methylation positions were detected in the [methyl-13C]methionine condition, 
corresponding to the dimethylamino group of desosamine, the methylation position of  
 
Figure 3.9 Full labeling prifle of erythromycin A by [1-13C]acetate, [1-
13C]propionate, [methyl-13C]methionine, [1-15N]glutamate 
(a) Erythromycin biosynthetic gene cluster, substrates used in the biosynthesis of erythromycin A, 
and the expected labeling of these substrates. (b) Structure of erythromycin A and the atoms that 
are expected to be labeled in the four SIL conditions, and MS data of erythromycin A in the four 
SIL conditons. (c) Comparison of expected and observed labeling of erythromycin A. 
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mycarose, and the O-methyl group of mycarose (Figure 3.9). Labeling of the single 
nitrogen present in desosamine was also detected in the [1-15N]-glutamate condition 
(Figure 3.9). This demonstrates that the IsoAnalyst MS data processing platform can 
accurately detect complete iterative SIL incorporation in erythromycin A, a compound 
with a well-established biosynthetic framework.  
 
Figure 3.10 IsoAnalyst labeling profiles for adducts and in-source fragments of 
erythromycin A 
(a) Diamonds represent MS features associated with erythromycin A plotted by m/z and retention 
time. Bar graphs show IsoAnalyst results for each features. (b) Chromatograms showing the peak 
shape and retention time of the MS features from (a).  
A common difficulty in MS metabolomics is the high number of mass adducts and 
in-source fragments that can inflate the number of detected features compared to real 
compounds present in a sample.36 A total of five features were detected for erythromycin 
A, corresponding to different fragments of the same compound (Figure 3.10). The 
dehydrated fragment ion m/z 716.4565 had labeling patterns that matched the [M+H]+ 
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ion, while smaller fragments showed decreased labeling from [methyl-13C]methionine 
due to the loss of the mycarose sugar subunit (Figure 3.10a). IsoAnalyst therefore not 
only accurately detects SIL incorporation in MS features across multiple conditions, but 
can also group adducts and fragments that derive from the same compound, simplifying 
interpretation of labeling data for complex samples. In the following chapters I will 
demonstrate how correlating labeling patterns between ions can not only relate 
fragments and adducts of the same molecule, but assists in the association of 
biosynthetically related molecules across the entire metabolome.  
3.4. Limitations of IsoAnalyst  
3.4.1. Signal Intensity and Variability 
Signal intensity is one of the main limiting factors in detecting compounds that 
are present in the extract, and has a known influence on accurate measurement of 
isotopologue ratios.37 The analysis of erythromycin A at different concentrations shows 
that the accuracy and variability of the M1:M0 isotopologue is affected at both low and 
high signal intensities. Signal saturation has a clear detrimental impact on the overall 
measurement of isotopologue ratios, that would significantly affect the downstream 
analysis. Because saturation overestimates the M1:M0 ratio, an ion that is saturated in 
the unlabeled condition would result in higher false negatives in SIL detection. Signal 
saturation is a common problem and optimizing sample concentration is always an 
important aspect of MS metabolomics. Signals in the upper intensity ranges may still be 
peak picked and processed in standard MS metabolomics workflows, however saturated 
signals may cause significant downstream problems in the statistical analysis employed 
in IsoAnalyst. For this reason, it is especially important to test sample concentrations 
ahead of time and maintain consistency in sample preparation techniques. 
At the lower end of signal intensity there are also limitations in data analysis. The 
main limiting factor is low concentrations of the compound in the sample either due to 
low production by the organism, ineffective extraction techniques, or inefficient 
ionization. The incorporation of singly labeled SIL compounds can exacerbate this by 
spreading the signal intensity across a larger number of isotopologue peaks, effectively 
lowering the signal intensity of individual isotopologue peaks compared to the unlabeled 
sample. In the case of erythromycin A, the ion intensity was consistently strong, all the 
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way up to the M8 isotopologue in the case of labeling by [1-13C] propionate. In this ideal 
case, I showed how t-test statistics beyond the heaviest labeled isotopologue can have 
results which show that the isotopologue ratio is significantly smaller than the M1:M0 ratio 
of the unlabeled compounds. While the statistics calculated beyond the heaviest labeled 
isotopologue help verify the SIL incorporation in ions with sufficient signal intensity, it is 
not required for the identification of labeling. Lower abundance ions may have more SIL 
positions that are labeled than are able to be detected, however I have shown that 
accurate detection of SIL incorporation is possible as low as 8.0e3 ion intensity (Table 
3.2, Figure 3.7d).  
 Another cause of low signal intensity that I have observed in these experiments 
is the inconsistent production of compounds across the panel of labeling conditions. The 
four SIL media conditions are fermented and analyzed separately, and this may 
influence the metabolism of the organism such that a compound is produced sufficiently 
in one SIL condition, but is not present or present in very small quantities in another. The 
purpose of growing paired controls with an unlabeled version of the precursor is to 
maintain similar nutrient environments so that the samples can be directly compared. 
Although this worked quite well for the compounds I observed and will discuss in the 
next chapter, this experimental design may be modified such that the medium used 
always contains unlabeled versions of every precursor. Doing so would potentially make 
the media conditions more consistent for compound production but, adds to the 
complication of setting up the experiment. This is a tradeoff that should be considered 
depending on the test organism.  
3.4.2. Incomplete SIL Incorporation 
A limitation of many studies that use SIL precursors is the interference of 
unlabeled nutrients which dilute the target biosynthetic precursor pools, and prevent 
complete labeling of target molecules. One approach to achieving compete labeling in 
the metabolome is to grow the organism in media containing a single carbon source of 
U-13C glucose, as is common in metabolic fluxomics studies. Since the aim of IsoAnalyst 
is to selectively label certain classes of molecules, it was not practical to supplement the 
media with fully labeled carbon sources. Overall the IsoAnalyst approach is limited by 
the efficiency of SIL incorporation. As discussed in Chapter 2, these challenges are 
mitigated mostly in the development of media conditions and SIL compounds as the rate 
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of SIL incorporation relies on the metabolic processes at play. This inherent limitation 
prevents IsoAnalyst from determining the true number of SIL precursors incorporated 
into any feature, but rather it identifies the number of SIL precursors that can be 
confidently detected in any given MS feature. This is important to consider when 
interpreting labeling data in terms of BGC information, as the absence of labeling cannot 
be conflated with the lack of particular substrate in the BGC structure prediction.  
3.4.3. BGC regulation 
IsoAnalyst only detects compounds which are produced under the media 
conditions used, and does not inherently elicit natural product production. The common 
challenges associated with silent BGCs apply to the IsoAnalyst experiments and 
workflow. One advantage of IsoAnalyst is that it is flexible and can be used in 
combination with other common methods for assessing genomic potential of micro-
organisms. IsoAnalyst can be applied to many different media conditions, co-cultures, or 
in combination with other elicitors such as antibiotics and heavy metals. It can also be 
applied to genetically manipulated organisms such as knock-outs or constitutive 
promoters, as well as to heterologous hosts. The flexibility of IsoAnalyst allows for its 
application to any experiment that aims to find chemistry produced in a biological 
fermentation, where the genome of the organism is known.  
3.5. Conclusion 
Many of the SIL MS metabolomics algorithms described in the introduction of this 
chapter retain only the most abundant isotopologue peaks in their analysis. This is why 
there is a great advantage to targeted approaches that utilize SIL precursors with 
specific biosynthetic targets and distinct isotopic combinations. In the IsoAnalyst 
approach, I aim to identify the iterative incorporation of multiple SIL precursors that are 
labeled in a single position in both known and unknown compounds. Rather than 
targeting a specific compound or group of compounds, IsoAnalyst allows for the efficient 
association of MS features by their biosynthetic origin. To achieve this, I aimed to 
develop a method that detects SIL incorporation, the number of SIL precursors present, 
and aligns the data across parallel labeling conditions. IsoAnalyst compares 
isotopologue ratios between unlabeled controls and labeled samples to leverage 
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information from the full isotopologue distribution, including highly labeled but low 
abundance isotopologue peaks. From this analysis it is possible to determine the 
minimum number of isotopic incorporation events for a given isotopically enriched 
feature. This analysis does not define the precise number of biosynthetic precursors in 
the structure, but rather the minimum number of detectable incorporation events, to 
provide overall labeling patterns for every feature under each SIL condition. In addition, it 
does not differentiate between direct biosynthetic incorporation and metabolic 
transformation of the feedstock prior to incorporation. Still, IsoAnalyst accurately 
detected SIL incorporation in all detected adducts and in-source fragment ions of 
erythromycin A across all four SIL conditions. In the subsequent chapters I will apply this 
method to the full metabolome of sequenced organisms to demonstrate how IsoAnalyst 
results relate to known biosynthetic pathways (Chapter 4) and discover novel chemistry 
from known biosynthetic pathways (Chapter 5).  
3.6. Methods  
3.6.1. UPLC-MS methods and data acquisition  
All solvents used for UPLC and HPLC were Optima grade, and water used for 
chromatography was purified by a Milli-Q water purification system.  All standard 
solutions and biological extracts were analyzed using a Waters Acquity I-class UPLC 
system coupled to a Waters Synapt G2Si qTOF mass spectrometer. Sample injections 
(5 µL) were subjected to chromatographic separation and mass spectrometric analysis. 
Chromatography was performed (Acquity HSS T3 1.8 µm, 2.1 x 100 mm) using a linear 
gradient (solvent A: H2O + 0.01% formic acid, solvent B: acetonitrile + 0.01% formic 
acid) of 5-98% B over 5.8 minutes, a hold a 98% B for 0.3 min followed by a 1.8 minute 
re-equilibration at 5% B. All mass spectra were acquired in MSE mode which is a data-
independent acquisition (DIA) mode (Figure 3.2). The MS detector range was set to 50-
1500 m/z in positive mode, with a capillary voltage of 3.5 kV, and a desolvation 
temperature of 200 ºC. A 0.4 second scan rate was used, with an alternating MS1 and 
MS2 scan acquisition. The MS2 data is acquired and processed by the method shown in 
Figure 3.2, however only the MS1 data is used in the IsoAnalyst processing workflow.  
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3.6.2. MS analysis of erythromycin A standard at varying 
concentrations 
Solutions containing a commercial standard of erythromycin A (Sigma-Aldrich) 
were prepared at the concentrations 500 nM, 100 nM, 50 nM, 10 nM, 5 nM, 1 nM, 0.5 
nM, and 0.1 nM in a 1:1 mixture of optima methanol and Milli-Q purified water. Five 
replicates of each concentration were analyzed. These data were pre-processed for 
peaking picking and feature detection by our in-house processing pipeline to produce the 
centroid peak lists and feature lists as shown in Figure 3.2. I then analyzed these data 
using the isotopologue scraping step of IsoAnalyst to detect all the naturally occurring 
isotopologues of the [M+H]+ ion of erythromycin A. I wrote a custom Python 3 script to 
calculate the linear regression of the M1:M0 isotopologue ratio and Shapiro-Wilk statistics 
for the M1:M0 ratio of the erythromycin A in the commercial standard samples. Linear 
regression and Shapiro-Wilk statistics were both calculated using the scipy.stats 
package in Python 3.  
3.6.3. IsoAnalyst program requirements 
IsoAnlalyst is a custom script written in Python 3. Additional information 
regarding input requirements and user guides for IsoAnalyst are available on the GitHub 
repository (www.github.com/liningtonlab/isoanalyst). The data presented throughout this 
thesis were pre-processed using an in-house custom tool, designed to handle Waters 
MSE data. This was done according to the workflow in Figure 3.2 to generate centroided 
peak lists and chromatographically aligned feature lists as .csv files for direct input to 
IsoAnalyst (Figure 3.1). IsoAnalyst also accepts generic data inputs that can be 
converted from most major vendor data types as described on the GitHub repository.  
3.6.4. Bacterial strain and inoculum preparation  
Saccharopolyspora erythraea ATCC 11635 (NRRL 2338) was purchased from 
ATCC (USA). Bacterial inoculum was prepared by first streaking a frozen glycerol stock 
on an ISP agar plate (3 g yeast extract, 5 g acid hydrolyzed casein, and 14 g of agar per 
liter of water). Single colonies were then selected to inoculate a 7 mL liquid culture of 
ISP media. Once turbid growth was observed in rich media, 50 µL of this culture was 
used to inoculate a 7 mL culture of the same minimal media to be used in the SIL 
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experiment. After 24 hours of growth, this culture was used for the inoculation of the 
microtiter plates.  
3.6.5. Parallel SIL experiment 
A minimal medium was used for all SIL fermentation experiments (10 g of starch, 
3.4 g of sodium glutamate, 0.4 g of KH2PO4, 1.2 g of K2HPO4, 1.0 g of MgSO4·7H2O, 2.0 
g of NaCl, 1.0 g of CaCO3, 0.01 g of FeSO4·7H2O, 1.5 mg CuSO4·5H2O, 3.0 mg 
ZnSO4·7H2O, 1.5 mg CoSO4·7H2O, 1.5 mg of MnSO4·H2O, and 1.0 mg of 
NaMoO4·2H2O per liter of water). This medium was used for all SIL precursor conditions, 
except for the [1-15N] glutamate and the corresponding unlabeled glutamate control. For 
these conditions the same minimal medium was prepared with 50% of the standard 
amount of unlabeled sodium glutamate (1.7 g/L instead of 3.4 g/L), and the remaining 
50% was replaced with either [1-15N] glutamate or unlabeled glutamate by sterile 
filtration at the time of inoculation.  
Stable isotopically labeled compounds were purchased from Cambridge Isotope 
Laboratories, Inc. The corresponding unlabeled compounds were purchased from 
ThermoFisher Scientific. The SIL feedstock compounds, [99% 1-13C]acetate, [99% 1-
13C]propionate, [99% methyl-13C]methionine, and [98% 1-15N]glutamate, and unlabeled 
version of each compound were prepared as stock solutions in Milli-Q water and 
sterilized by filtration (0.2 uM filter). The same culture was used as inoculum for all 
replicate wells of every feedstock condition in a given experiment. The 24-well microtiter 
plates and sandwich covers used for micro-scale bacterial cultures were purchased from 
Enzyscreen B.V. (The Netherlands) and the protocol for microtiter well plate 
fermentations was adapted from Duetz et al.38  
The 24-well microtiter plates were cleaned and sterilized according to Duetz et 
al.,38 and 2 mL of minimal media was added to each well. The first and last columns in 
each 24-well plate were left with sterile media and the inner 16 wells were inoculated 
with 80 µL of bacterial inoculum. Following inoculation, either an SIL compound or the 
corresponding unlabeled compound was added to each well by sterile filtration. Four 
replicate wells were prepared and inoculated for each condition, including unlabeled 
controls. Unlabeled control cultures were included for each feedstock condition to 
account for metabolic changes that may occur as a result of adding the precursor 
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compound. Stock solution concentrations were adjusted according to the final desired 
concentration of each SIL or unlabeled precursor in the culture so that a minimal volume 
of 20-100 µL of stock solution was added to each well. The replicate cultures were 
fermented and analyzed separately and therefore account for technical variation in both 
the fermentation experiment as well as the analytical variation in the MS data.  
 Microtiter plates containing SIL supplemented bacterial cultures were 
shaken at 200 rpm and maintained at 23.0 °C for five days. On the fifth day the cultures 
were extracted by adding 2 mL of Optima methanol to each well. The contents of each 
well were then transferred to Eppendorf tubes, sonicated for 5 minutes, and centrifuged 
for 1 minute at 16,000 g. Methanol/water extracts were injected directly onto the UPLC-
qTOF system, or diluted to maintain the most intense signals in the chromatogram in an 
optimal range for both sensitivity and mass accuracy.  
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Chapter 4.  
 
IsoAnalyst Case Studies: Connecting Chemical 
Phenotypes to Biosynthetic Gene Clusters of Model 
Organisms 
4.1. Introduction  
In this chapter I will demonstrate how the accurate detection of SIL incorporation 
described in Chapter 3 aligns with the biosynthesis of known compounds. IsoAnalyst 
enables the categorization of compounds detected in MS metabolomics experiments by 
their biosynthetic origin. I initially tested the IsoAnalyst platform on the type strain 
organisms Saccharopolyspora erythraea and Amycolotopsis mediterranei, which I 
selected for their efficient production of erythromycin A and rifamycin SV respectively.1,2 
The BGCs and biosynthetic machinery that produce these two compounds have served 
as model systems for understanding polyketide biosynthesis for decades.3 I selected 
these systems in order to apply IsoAnalyst to a full MS metabolomics dataset where I 
was confident that sufficient SIL incorporation would occur. These type strains are 
optimized for production of their respective polyketide antibiotics, although their 
genomes both reveal various other BGCs that have not been investigated extensively.1,2 
Using IsoAnalyst I identified families of biosynthetic intermediates and analogues of both 
erythromycin A and rifamycin SV, as well as siderophore production in both organisms.  
4.1.1. Differentiating Direct and Indirect SIL Incorporation 
 As I discussed in Chapter 2, a main challenge in using simple SIL precursors is 
that they can be transformed as substrates in primary metabolism prior to incorporation 
into natural products. [1-13C]Acetate is particularly promiscuous due to its direct 
incorporation into the TCA cycle through acetyl-CoA (Figure 4.1). [1-13C]Acetate has 
been added as a supplement to fermentations for the detection and analysis of 
polyketide structures for decades, however these studies often focus on specific 
compounds rather than looking at incorporation across the entire metabolome.4–7 Indirect 
incorporation of [1-13C]acetate into amino acids and other TCA-derived substrates is 
significant but variable under different metabolic conditions and therefore requires 
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careful consideration. To account for common SIL precursor turnover in primary 
metabolism, I created a Substrate Labeling Table (Table 4.1) by considering the 
metabolic fate of [1-13C]acetate, [1-13C]propionate, [methyl-13C]methionine, and [1-
15N]glutamate in common central metabolic pathways. The rows correspond to a list of 
common biosynthetic substrates in natural product biosynthesis and the columns to each 
SIL condition used in this study (Table 4.1). The Substrate Labeling Table designates 
the maximum theoretical incorporation events of each SIL precursor into each substrate.  
 
Figure 4.1 [1-13C]Acetate Incorporation in the TCA Cycle 
Red filled circles represent 13C derived from [1-13C]acetate following its direct transformation to 
acetyl-CoA. Open circles represent positions where the location of the 13C atom is ambiguous 
due to the symmetry of succinate. Only one position represented by an open circle may be 
labelled in a molecule. Amino acids derived from TCA cycle intermediates are indicated.  
 The amino acids that are derived from TCA cycle intermediates (Figure 4.1) are 
designated in Table 4.1 to be labeled by [1-13C]acetate a maximum of one or two times. 
Terpenes may be labeled by [1-13C]acetate only in organisms with the mevalonate 
pathway8 (Table 4.1).  The [1-15N]glutamate SIL condition is intentionally designed to be 
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promiscuous and label all amino acids and other subunits derived from amino acids 
(Table 4.1). Although the [1-15N]glutamate condition is designed to incorporate 15N into 
any substrate, in theory some amino substrate acids will be much more easily labeled 
than others. Amino acids that have an a-nitrogen that is derived directly from 
transamination by glutamate, are more likely to be labeled by [1-15N]glutamate. The 
biosynthesis of some amino acids are more tightly regulated than others such as 
histidine, arginine, and tryptophan due to their higher ATP demand.9 These amino acids 
are more likely to be derived from recycled sources and will potentially have less 15N 
incorporation from [1-15N]glutamate than other amino acids. The growth medium used in 
this experiment is quite limited in terms of nitrogen metabolism, as either unlabeled or [1-
15N]glutamate are the only nitrogen sources. Although this was designed with the 
intention of labeling any nitrogen position with 15N, the fact that glutamate is the sole 
nitrogen source in the media restricts the metabolism such that not all amino acids will 
be supplied in high quantities. This medium was selected for the optimization of [1-
13C]acetate incorporation, as described in Chapter 2, but may not be ideal for optimal 15N 
incorporation into all amino acids. It is likely that under these conditions the organism is 
limited by amino acid supply, and therefore this media is probably not optimal for eliciting 
biosynthesis of amino acid-containing natural products such as NRPSs. These 
limitations highlight the importance of considering the test organism’s ability to 
synthesize essential building blocks when optimizing the IsoAnalyst approach to that 
particular organism’s metabolism.   
 Unlike [1-13C]acetate and [1-15N]glutamate, [1-13C]propionate and [methyl-
13C]methionine are expected to label only specific substrates (Table 4.1). [1-
13C]Propionate is directly incorporated into propionyl-CoA and methylmalonyl-CoA, 
which are both common PKS substrates. [1-13C]Propionate may also label succinyl-CoA 
by the conversion of methylmalonyl-CoA to succinyl-CoA.10 [methyl-13C]Methionine 
labels compounds which have a methyl group derived from S-adenosyl methionine 
(SAM). The SIL incorporation events referenced in this table are based on current 
knowledge of the metabolism of the four SIL precursors used here, but they are by no 
means a comprehensive overview of all the potential metabolic pathways that these four 
compounds can undergo. There is long standing evidence that alternative pathways for 
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Table 4.1 Substrate Labelling Table 
Substrate A P M G 
Glu 2   1 
Gln 2   2 
Arg 2   4 
Pro 2   1 
Orn 2   2 
Asp 1   1 
Met 1  1 1 
Thr 1   1 
Ile 1   1 
Asn 1   2 
Lys 1   2 
Ala    1 
Leu    1 
Val    1 
Phe    1 
Tyr    1 
Trp    2 
Ser    1 
Gly    1 
Cys    1 
His    3 
Unknown amino acid    1+ 
Acetyl or Malonyl-CoA 1    
Propionyl-CoA  1   
Methylmalonyl-CoA 1 1   
Methoxymalonate   1  
Hydroxymalonate     
Methyl   1  
IPPa 2    
DMAPPa 2    
GPPa 4    
FPPa 6    
Succinyl-CoA 1 1   
Amino-saccharide    1 
Amino group    1 
amevalonate pathway only 
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amino acid and PKS monomer biosynthesis can not only be influenced by genetics but 
environmental factors.11 Other common pathways such as the glycoxylate cycle, and 
gluconeogenesis should be considered under metabolic circumstances where they are 
relevant. The Substrate Labeling Table (Table 4.1) can be modified to account for other 
such pathways or to include more SIL precursors. 
4.1.2. Application of IsoAnalyst to the Full Metabolome 
The summary output file of IsoAnalyst described in Chapter 3 contains every 
feature from the ground truth feature list, and the corresponding SIL incorporation for 
each condition. This summary file was filtered automatically to contain only those MS 
features that had detected isotope incorporation in two or more of the SIL conditions. 
This initial filtering reduces the number of primary metabolites present in the output. 
Although a compound with labeling in only one SIL condition may be a natural product, 
this is not sufficient to hypothesize which BGC is responsible for producing the labeled 
compound. There is an inherent bias in the selection of SIL precursors as to which types 
of natural products will be able to be identified. This element of the experimental design 
is flexible and can be adapted to different BGC classes. I then manually interrogated the 
summary file to filter features based on chromatographic peak shape and signal 
intensity. Features were eliminated if either of these factors interfered with the accuracy 
of the SIL detection. I manually grouped features that represented adducts or fragments 
of the same compound, and further compared SIL incorporation patterns between 
different compounds to relate compounds originating from the same BGC. Compound 
identities were confirmed by a combination of SIL incorporation, MS/MS fragmentation, 
and NMR when applicable. I did this for a full parallel SIL experiment using [1-
13C]acetate, [1-13C]propionate, [methyl-13C]methionine, and [1-15N]glutamate in S. 
erythraea and A. mediterranei.  
4.2. Saccharopolyspora erythraea  
S. erythraea has had a massive impact on biosynthesis research.12 Much of the 
basis for what we know about polyketide synthases today began with preliminary work 
on the 6-deoxyerythronolide B synthase (DEBS). Early studies on the biosynthesis of 
erythromycin A used [14C]-, [13C]-, [18O]-, and [2H]- labeled substrates to elucidate the 
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steps of the biosynthetic pathway, before the BGC had even been discovered.13 It was 
not until the genetic characterization of DEBS that the complex biochemical basis of 
polyketide formation was beginning to be understood.14,15 Complete heterologous 
expression of erythromycin A has been accomplished16 and this well-understood 
pathway has been manipulated countless times for drug development.17 Furthermore, 
due to the extensive studies of this biosynthetic pathway, each biosynthetic intermediate 
has been characterized and described in the literature.16 I have used the example of 
erythromycin A throughout the last two chapters because it is so often used as a model 
system for biosynthesis and there is strong evidence for the expected SIL incorporation 
pattern. Here I will focus on the overall metabolome of S. erythraea.  
The SIL incorporation into erythromycin A was used as the primary example in 
Chapter 3 to confirm the accurate detection of SIL incorporation into a known compound. 
This example demonstrated that the full expected labeling of each SIL precursor could 
be detected in all of the ion adducts and in-source fragments of erythromycin A. In this 
section I will look at the full MS metabolomic dataset for S. erythraea as generated by 
the SIL experiment and data analysis described Chapter 3. The ground truth feature list 
for this S. erythraea experiment contained 786 unique features, and IsoAnalyst identified 
147 which had SIL incorporation in two or more conditions. I further filtered this to 94 
features with reliable SIL detection on the basis of chromatographic peak shape. I 
identified 71 of these features corresponding to erythromycin A and five additional 
compounds with SIL incorporation patterns related to erythromycin A (Figure 4.2). The 
differential labeling in the biosynthetic intermediates of the erythromycin pathway 
demonstrate the strength of IsoAnalyst to efficiently relate MS features corresponding to 
the same BGC. Furthermore, seven of the labeled features detected by IsoAnalyst 
corresponded to a siderophore, erythrochelin, which has previously been isolated from 
S. erythraea18 (Figure 4.2).  
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Figure 4.2 Overview of Labelled Ions Detected from S. erythraea  
IsoAnalyst profiles and structures for selected labeled ions detected in the S. erythraea 
metabolome. Seventy-seven m/z features are shown which were identified as having SIL 
incorporation in two or more conditions, and having realistic ion intensity and chromatographic 
peak shape. Seventy-one features indicated as diamonds were identified as erythromycin A or 
related structures, and seven features indicated as circles were identified as erythrochelin. The 
IsoAnalyst results for selected ions are shown.   
4.2.1. Erythromycin Family  
The 14-member polyketide macrolide core, 6-deoxyerthronolide B, is 
biosynthesized from a propionyl-CoA starter unit and six methylmalonyl-CoA extender 
units by the large multi-domain PKS, 6-Deoxyerythonolide B Synthase (DEBS)12 (Figure 
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4.3). All of the erythromycin compounds identified using IsoAnalyst had identical SIL 
incorporation in the [1-13C]acetate and [1-13C]propionate conditions, indicating this 
shared polyketide core. By contrast, labeling in [methyl-13C]methionine and [1-
15N]glutamate varied between the five products, suggesting different degrees of 
decoration of the polyketide core (Figure 4.2). The polyketide product produced by 
DEBS, 6-deoxyerythronolide B (Figure 4.3), was not observed in this experiment. 
However, using IsoAnalyst I putatively identified the subsequent six biosynthetic 
intermediates, erythronolide B (4.1), O-α-mycarosylerythronolide B (4.2), erythromycin D 
(4.3), B (4.4), C (4.5), and A (4.6) (Figures 4.2, 4.3).  
 
Figure 4.3 Biosynthesis of Erythromycin A  
Biosynthetic scheme showing the steps in the biosynthesis of erythromycin A. The direct product 
of DEBS, 6-deoxyerythronolide B, is the only intermediate shown which was not detected in this 
experiment. All of the subsequent biosynthetic products have varying degrees of hydroxylation, 
methylation, and glycosylation, but contain the same polyketide core.  
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Erythronolide B (4.1) was not labeled by either [methyl-13C]methionine or [1-
15N]glutamate, consistent with the proposed structure containing only the core 
macrocycle (Figure 4.2). 3-O-α-Mycarosylerythronolide B (4.2) contained a single 
labeled position in [methyl-13C] methionine, consistent with the addition of the mycarose 
sugar, which contains a single site of SAM methylation. I isolated and confirmed the 
identity of 4.1 and 4.2 by NMR and UPLC-MS co-injection (Appendix A, Figures A1-A6). 
Erythromycin D (4.3) was putatively identified having three labeled positions in the 
[methyl-13C]methionine condition and one position in the [1-15N]glutamate condition, due 
to the addition of the desosamine sugar (Figures 4.2, 4.3). The final two reactions in the 
erythromycin pathway consist of a hydroxylation at C-12 of the macrolactone core and 
3”-O-methylation on the mycarose sugar (Figure 4.3). These reactions may occur in a 
variable order resulting in the products 4.4 and 4.6, which have one additional position 
labeled by [methyl-13C]methionine compared to 4.3, and 4.5, which has the same SIL 
incorporation as 4.3 in all four conditions (Figure 4.2). Erythromycin A (4.6) was also 
discussed in detail in Chapter 3, the same SIL incorporation results are shown here 
(Figure 4.2). The identity of 4.6 was confirmed by UPLC-MS co-injection with an 
authentic standard (Appendix Figure A7). These data align with what is known about 
erythromycin biosynthesis and support the putative identification of 4.3, 4.4, and 4.5. 
4.2.2. Erythrochelin 
 Erythrochelin (4.7) is a hydroxomate siderophore which has previously been 
isolated from S. erythraea.18 Erythrochelin is produced by the tetramodular nonribosomal 
peptide synthase (NRPS) ErcD.18,19 The core substrates used in the biosynthesis of 
erythrochelin are L-ornithine (3), L-serine (1), and acetyl-CoA (3) (Figure 4.4). L-
Ornithine is first hydroxylated by the d-N-ornithine monooxygenase, ErcB. L-d-N-
hydroxyornithine is acetylated twice in the starter unit of erythrochelin, followed by the 
condensation of serine, L-d-N-hydroxyornithine (hOrn) and L-d-N-acetyl-d-N-
hydroxyornithine (haOrn). Direct 13C incorporation into acetyl-CoA by [1-13C]acetate, and 
15N incorporation into ornithine and serine by [1-15N]glutamate, would result in an 
expected incorporation of three 13C atoms from [1-13C]acetate, and seven 15N atoms 
from [1-15N]glutamate (Figure 4.4). However, Table 4.1 indicates that ornithine is derived 
from the TCA intermediate a-ketoglutarate, which can also be labeled in two positions by 
[1-13C]acetate. This results in a theoretical maximum labeling of erythrochelin by nine 13C 
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positions derived from [1-13C]acetate, with six of these incorporation events occurring via 
labeling of the ornithine carbon skeleton (Figure 4.4).  
 
Figure 4.4 Biosynthesis of Erythrochelin 
Scheme showing the biosynthetic substrates that make up erythrochelin. Expected positions of 
SIL tracer incorporation are indicated by colored circles. Ornithine is first hydroxylated to produce 
hOrn and three units of hOrn are later acetylated to produce haOrn. The NRPS condenses three 
units of haOrn and one serine to generate the final product, erythrochelin.  
 Both the iron-chelated and protonated adduct ions of 4.7 were detected by 
IsoAnalyst to have eight positions labeled by [1-13C]acetate, and six positions labeled by 
[1-15N]glutamate (Figure 4.5). A more detailed interrogation of the SIL data confirmed the 
identity of compound 4.7 through a combination of fragment m/z values, which matching 
those previously reported for erythrochelin18 (Figure 4.6). The two larger fragment ions 
differ by the loss of a serine residue18 and each fragment had detectable 15N enrichment 
in 4 out of 5 positions and 3 out of 4 positions respectively (Figure 4.6a,b). This indicates 
that relative differences in SIL incorporation are detectable using IsoAnalyst, even when 
the SIL incorporation is not complete for every available position in the compound. The 
expected [1-13C]acetate labeling was for 5 positions in both of these fragment ions, as 
serine does not have expected labeling by [1-13C]acetate (Table 4.1). Four out of five 
positions were detected as having enrichment in [1-13C]acetate for both fragment ions in 
Figure 4.6a and Figure 4.6b. The smaller fragment ions are the L-d-N-acetyl-d-N-
hydroxyornithine subunit (Figure 4.6c) and d-N-hydroxyornithine (Figure 4.6d).18 These 
fragments show 13C enrichment in three positions for L-d-N-acetyl-d-N-hydroxyornithine, 
and two positions for the d-N-hydroxyornithine fragment (Figure 4.6c,d). Although the M1 
isotopologue is the most intense isotopologue peak in the [1-13C]acetate mass spectrum 
in Figure 4.6d, the 13C enrichment in the M2 isotopologue peak was determined to be 
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statistically significant for 13C enrichment using IsoAnalyst. These data confirm that two 
positions of ornithine are labeled by [1-13C]acetate as predicted in the Substrate Labeling 
Table (Table 4.1), even though the M2 isotopologue peak has a lower relative intensity 
than the M0 and M1 peaks (Figure 4.6d).  
 
Figure 4.5 SIL Incorporation in Erythrochelin 
(a) Substrates used in the biosynthesis of 7, and both the expected and observed labeling of 
erythrochelin. (b) Structures and mass spectra for the iron adduct (m/z 657.2064) and the 
protonated adduct (m/z 604.2950) of 7 in the [1-13C]acetate and [1-15N]glutamate conditions. [1-
13C]Propionate and [methyl-13C] methionine conditions are not shown as 7 was not produced 
under the [1-13C] propionate condition and no SIL incorporation occurred under the [methyl-
13C]methionine condition. 
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Figure 4.6 SIL Tracer Incorporation in Erythrochelin Fragment Ions 
Mass spectra of fragments m/z 390.1990 (a), m/z 303.1666 (b), m/z 173.0932 (c) and m/z 
131.0827 (d) under [1-13C]acetate and [1-15N]glutamate conditions indicate that the detected SIL 
incorporation is within the expected labeling maximums for the biosynthetic subunits derived from 
ornithine and acetyl-CoA. 
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4.3. Amycolatopsis meditteranei 
A. meditteranei produces the antibiotic rifamycin SV, which was first isolated with 
a mixture of rifamycins in 1959 when the organism was classified as Streptomyces 
meditteranei.20 Although rifamycin SV is the more potent antibiotic, it is a biosynthetic 
precursor of rifamycin B, and two A. meditteranei strains have been sequenced for 
specialization in producing either rifamycin B or SV.2,21 A. meditteranei U32 is the 
commercial producer of rifamycin SV, as it contains a mutation in the P450 gene 
responsible for converting rifamycin SV to rifamycin B.2 The biosynthesis of the 
rifamycins have been well-studied as a model PKS system making this organism a 
suitable test case for assessing SIL incorporation using IsoAnalyst 
4.3.1. Rifamycin 
Rifamycin SV is a macrocyclic polyketide which is biosynthesized from the starter 
unit 3-amino-5-hydroxybenzoic acid (AHBA), followed by chain extension with eight units 
of methylmalonyl-CoA and two units of malonyl-CoA.22 The rifamycin BGC contains 
genes for the biosynthesis of AHBA22 and this starter unit is only expected to be labeled 
by [1-15N]glutamate. The rifamycin backbone undergoes a rearrangement to form a five-
membered ring and ketal structure.23 In the process of this transformation, the methyl (C-
3) of one propionate unit is lost,23 however, this does not affect the number of expected 
positions labeled in my experiment, as the SIL tracer [1-13C]propionate is labeled in the 
carbonyl (C-1) position (Figure 4.7). Finally, the core polyketide is methylated by SAM, 
and acetylated to form rifamycin SV (Figure 4.7). Using Table 4.1 to account for both 
direct and indirect SIL incorporation, I determined the expected labeling of rifamycin SV 
to be 11 x [1-13C]acetate, 8 x [1-13C]propionate, 1x [methyl-13Cmethionine], and 1 x [1-
15N]glutamate positions (Figure 4.7). While rifamycin SV is most commonly discussed in 
the literature, I only observed the oxidized form, rifamycin S in the following experiments. 
I confirmed the presence of rifamycin S by co-injection with a commercial standard 
(Appendix Figure A8).  
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Figure 4.7 Biosynthesis and Expected SIL Incorporation in Rifamycin S 
Biosynthetic scheme showing the building blocks and positions which are expected to have SIL 
incorporation in rifamycin S (4.8). Eight units of methylmalonyl-CoA, two of malonyl-CoA and one 
AHBA are used to make the polyketide core, followed by an acetylation and methylation by SAM 
to form 4.8.  
Unlike the S. erythraea experiment, I was unable to detect different biosynthetic 
precursors or analogues to rifamycin S. However, I did detect a series of in-source 
fragments of rifamycin S which demonstrate how IsoAnalyst can assist in interpreting the 
positions of SIL incorporation by analyzing fragment ions. In addition to the [M+H]+ 
adduct (m/z 696.2994), I observed the subsequent loss of the O-methyl group (m/z 
664.2709), the acetyl group (m/z 604.2562), and H2O (m/z 586.2454) (Figure 4.8). The 
[M+H]+ adduct had the exact expected SIL tracer incorporation in the [1-13C]propionate, 
[methyl-13C]methionine, and [1-15N]glutamate conditions, but slightly less labelling (9 out 
of 11 expected positions) in the [1-13C]acetate condition Figure 4.8). As was the case 
with the erythromycins, this discrepancy is likely due to the indirect incorporation of [1-
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13C]acetate into the methylmalonyl-CoA subunits of rifamycin S. The fragment ions had 
decreased SIL incorporation in the [1-13C]acetate and [methyl-13C]methionine conditions, 
as expected from the loss of the O-methyl and acetyl groups (Figure 4.8).  
 
 
Figure 4.8 SIL Tracer Incorporation in Rifamycin S and Fragment Ions 
Four MS features were detected with SIL tracer incorporation patterns corresponding to the in-
source fragment ions of rifamycin S (4.8). The m/z 696.2994 is the [M+H]+ ion. The m/z 664.2709 
fragment has a loss of the O-methyl group. The m/z 604.2562 fragment has an additional loss of 
the acetate group, indicated by the decrease from 7 to 6 detected 13C positions in the [1-
13C]acetate condition. The m/z 586.2454 has a further dehydration.   
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4.3.2. Unknown Siderophore 
I detected a group of interesting MS features in the A. meditteranei experiment 
which had related labeling patterns and an iron adduct, similar to erythrochelin (Figure 
4.9). In addition to the iron (m/z 700.2448) and protonated (m/z 647.3337) adducts, I 
detected three smaller in-source fragments at the same retention time with similar SIL 
incorporation patterns (Figure 4.9). SIL incorporation was detected for 5 x [1-13C]acetate, 
2 x [1-13C]propionate, 3 x [methyl-13C]methionine, and 6 x [1-15N]glutamate units in the 
protonated adduct of this unknown siderophore (Figure 4.9). The iron adduct had more 
SIL tracer detected in the [1-13C]acetate and [1-15N]glutamate conditions, however, this 
method does not account for the contribution of 54Fe to the isotopologue ratios, so the 
SIL tracer incorporation in the protonated adduct is likely more reliable. Notably, this 
siderophore has three methylated positions, only one of which is lost in the smallest 
fragment ion detected (m/z 475.2508, Figure 4.9).  
The current antiSMASH database contains the complete BGC analysis output for 
A. meditteranei U32 performed in antiSMASH 5.0.24,25 I identified a candidate BGC for 
the production of the unknown siderophore, of which 80% of the genes present share 
similarity to genes in the BGC for the known siderophore, scabichelin (4.9, Figure 4.10). 
These similarity metrics are automatically generated in antiSMASH, to link to related 
BGCs in the MIBiG database.26 The scabichelin BGC contains five NRPS modules, two 
of which contain N-methyltransferase domain27 (Figure 4.10a). The scabilchelin BGC 
has been previously characterized and associated with scabilchelin through mutation 
studies.27 The diagram in Figure 4.10a is of the scabilchelin BGC modules which are 
provided in the MIBiG database.26 The BGC located in ‘region 18’ of the A. meditteranei 
U32 genome also contains five modules, although the predicted amino acids are slightly 
different. Three N-methyltransferase domains were detected in region 18, consistent 
with the [methyl-13C]methionine incorporation detected in the unknown siderophore 
(Figure 4.10). Additionally, two units of [1-13C]propionate were consistently  
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Figure 4.9 SIL Tracer Incorporation into an Unknown Siderophore 
Five MS features were detected with SIL tracer incorporation patterns corresponding to an 
unknown siderophore which eluted at 1.27 min. The m/z 700.2448 feature is an [M-2H+Fe]+ ion 
and the m/z 647.3337 feature is an [M+H]+ ion. The remaining m/z features are unidentified in-
source fragment ions.  
detected in all of the fragment ions associated with the unknown siderophore, 
suggesting the presence of an amino acid that can be biosynthetically derived from [1-
13C]propionate. Observation of the raw MS data indicates that the M0 peak of the 
protonated adduct (m/z 647.3337) was the base peak in the [1-13C]propionate condition, 
despite the fact that the M2 isotopologue peak was detected as having statistically 
significant SIL incorporation (Figure 4.11). This highlights both an advantage of 
IsoAnalyst, in that is it is sensitive to detecting SIL incorporation in higher isotopologues, 
as well as a limitation in the interpretation of the IsoAnalyst output. Observation of the 
raw data in this case clearly indicates that the 2 x [1-13C]propionate incorporation occurs 
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at a much lower ratio than the 3 x [methyl-13C]methionine incorporation into the same 
molecule (Figure 4.11). These data suggest that the [1-13C]propionate labelling in this 
siderophore originates from an indirect source, and orthogonal metabolomic approaches 
such as fluxomics or transcriptomic methods would assist in identifying the metabolic 
pathways involved. I was not able to determine the exact structural identity of this  
 
Figure 4.10 Comparison of Scabichelin BGC and Region 18 in A. meditteranei 
(a) Modules of the scabilchelin BGC taken from the MIBiG database.26 Substrates of each 
enzymatic module are indicated. Structure of scabichelin has been identified and associated with 
the BGC through genetic mutation studies.27 (b) Modules and enzymatic substrate predictions 
from BGC region 18 in the A. meditteranei genome taken from the antiSMASH database.25 
Subatrate abbreviations: L-N5-formyl-N5-hydroxyornithine (L-fhOrn), L-N5-hydroxyornithine (L-
hOrn),  L-N5-acetyl-N5-hydroxyornithine (L-haOrn)  
siderophore, however it is likely a hydroxamate siderophore containing two units of L-d-
N-acetyl-d-N-hydroxyornithine, one N-methylated L-serine, and two unknown amino 
acids that may be indirectly labelled by [1-13C]propionate. Further investigation of this 
compound may reveal a novel structure, and would provide evidence for the association 
of this siderophore with the BGC identified in region 18 of the A. meditteranei U32 
genome.  
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Figure 4.11 Unlabeled and SIL MS Spectra for m/z 647.3337 
Unlabeled and SIL MS data for protonated adduct (m/z 647.3337) of the unknown siderophore 
from A. meditteranei. SIL incorporation in [1-13C]acetate and [1-15N]glutamate resemble the 
isotopologue distributions I observed for other siderophores such as erythrochelin. However, SIL 
incorporation for [methyl-13C]methionine was distinctly efficient, showing very little isotopologue 
peak intensity for isotopologues below M3.  
4.4. Conclusion 
These case studies in commercially available type strain bacteria demonstrated 
promising results for the application of IsoAnalyst to PKS and NRPS biosynthetic 
pathways. In S. erythraea, IsoAnalyst identified nearly all of the known biosynthetic 
intermediates of erythromycin A and accurately detected variable SIL incorporation 
across these compounds. Furthermore I identified the siderophore erythrochelin, and 
IsoAnalyst accurately detected SIL incorporation into the fragments ions, supporting the 
putative identity of these molecules. The ability to groups related MS features together 
and to interpret the positional SIL incorporation through fragmentation are currently 
manual processes which I have implemented here. However, both of these approaches 
to working with the IsoAnalyst output may be automated in the future, as adduct 
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matching and fragmentation pattern association are already applied to unlabeled MS 
metabolomics data.28,29 Overall, the SIL incorporation patterns detected by IsoAnalyst 
could assist greatly in associating related adducts and fragments as well as facilitate 
structural interpretations of MS metabolomics data. I also detected SIL incorporation in 
the polyketide antibiotic rifamycin S, and related in-source fragment adducts. 
Surprisingly, I was able to identify an unknown labeled compound in the metabolome 
data for A. meditteranei, although this organism has been exploited for natural product 
production for many years. This compound appears to be a hydroxymate siderophore 
which is related to scabeichelin, on the basis of the SIL incorporation pattern and BGC, 
further validating the utility of IsoAnalyst in indicating the biosynthetic origin of 
compounds prior to compound isolation and structure elucidation.  
The examples shown here are limited as they represent only a narrow window of 
what is currently known about natural product biosynthesis. I selected these type strains 
which produce well-known polyketides and also identified siderophore NRPS 
compounds. While I have shown that the IsoAnalyst experimental design applied here 
works well for identifying these molecules, additional optimization would be needed to 
include a wider range of SIL tracers and biosynthetic pathways. Nonetheless, the 
generalizable SIL tracers used in combination with the IsoAnalyst data analysis platform 
have great potential for compound identification and biosynthetic grouping of MS 
features. 
4.5. Methods 
4.5.1. Parallel SIL Fermentation Experiments 
 Saccharopolyspora erythraea ATCC 11635 (NRRL 2338) and Amycolatopsis 
meditteranei ATCC 13685 were purchased from ATCC (USA). The parallel SIL 
fermentation protocols used in this chapter for S. erythraea and A. meditteranei were 
performed exactly as described in Chapter 3. The sample extraction, preparation, and 
UPLC-MS analysis were also performed as described in Chapter 3. Each experiment 
was analyzed using IsoAnalyst to generate a summary file of all ions with SIL 
incorporation detected in two or more conditions. The data were interrogated manually to 
identify the compounds described in this chapter.  
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4.5.2. Large Scale Fermentation and Extraction of 4.1 and 4.2 
Four large-scale S. erythraea cultures were grown in 2.8 L Fernbach flasks 
containing 20.0 g of Amberlite XAD-16 adsorbent resin, a stainless steel spring, and 1 L 
of the same minimal media used in the SIL experiments. The large scale fermentation 
was done without the supplementation of SIL precursors. Cultures were shaken at 200 
rpm for 6 days, at which time the cultures were filtered by vacuum filtration on Whatman 
glass microfiber filters. The cells and resin were collected and extracted with 250 mL of 
1:1 methanol/dicholormethane. The organic extract was collected by vacuum filtration 
and dried by rotary evaporation. The crude organic extract was initially separated into 
seven fractions by a stepwise methanol/water elution (10, 20, 40, 60, 80, 100 vol/vol) 
and an additional ethyl acetate wash step on a RediSep Rf C18 cartridge (Teledyne 
Isco) using a Teledyne Isco CombiFlash Rf flash chromatography system. 
4.5.3. Isolation and Characterization of 4.1 and 4.2 
Purification of compounds 4.1 and 4.2 was performed on a Waters 
autopurification system with a SQ Detector 2 quadrupole MS detector. Both compounds 
were purified from the 60% methanol extract fraction. For all HPLC purification of 4.1 
and 4.2 solvent A was water with 0.02% formic acid and solvent B was acetonitrile with 
0.02% formic acid. The 60% methanol pre-fraction was separated by HPLC (Waters 
Atlantis T3 prep OBO column 5 µm, 19 x 250 mm) using an elution gradient of 45-83% B 
over 21 minutes, at a flow rate of 20 mL/min. Erythronolide B (4.1) was collected at 6.5 
minutes by mass detection for the ion m/z 425.4 and 3 was collected at 9.5 minutes by 
mass detection for the ion m/z 529.4. 3-O-α-mycarosylerythronolide B (4.2) was further 
purified using an isocratic gradient of 42% B, with MEB eluting from the column at 11.8 
minutes. 2.5 mg of 4.1 and 4.5 mg of 4.2 were isolated in total and analyzed by NMR for 
comparison to authentic standards (Appendix A). 
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Chapter 5.  
 
IsoAnalyst Coupled to Whole Genome Analysis as a 
Tool for Natural Product Discovery 
5.1. Introduction 
The ultimate goal of the IsoAnalyst platform is to facilitate natural product 
discovery through the characterization of complex chemical phenotypes produced by 
BGCs. In Chapter 4, I showed how IsoAnalyst can be used to accurately interpret the 
biosynthetic pathway of known compounds and how the various analogues and 
biosynthetic precursors of erythromycin A can be associated on the basis of related SIL 
incorporation patterns. In this chapter, I apply this workflow to an environmental strain to 
demonstrate how IsoAnalyst can reduce a complete untargeted MS metabolomics 
dataset to a manageable number of labeled MS features. Whole genome sequences can 
be analyzed for BGC presence by open source online tools and the growing availability 
of genome data further allows for large-scale comparisons between BGCs across 
thousands of strains.1,2 I have developed a generalizable method for interpreting how 
BGC products will be labeled by specific SIL tracers on the basis of the enzymatic 
substrate predictions generated in antiSMASH1 and investigation of literature about 
related BGCs from MIBiG.2 I collaborated with the developers of these platforms to 
generate the manually curated substrate predictions, but I created the process for 
interpreting the data and associating the substrate prediction with the SIL incorporation 
profiles from IsoAnalyst. Using this complete workflow, I show how IsoAnalyst can 
quickly associate both known metabolites and unknown analytes to elucidate the 
complex chemical phenotypes of known BGCs.  
5.2. Whole Genome BGC Analysis of Micromonospora sp.  
In order to test the capacity of IsoAnalyst to identify natural products in a 
sequenced environmental strain, I applied the complete workflow to Micromonospora sp. 
RL09-050-HVF-A. This Micromonospora sp. was isolated from marine sediments in 
Point Lobos, California and produced the macrolactam, lobosamide A, which 
demonstrated submicromolar antitryposomal activity against Trypanosoma brucei and 
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the related analogues lobosamide B and C.3 In order to fully solve the configurational 
analysis of the hydroxyl groups present in the lobosamides, our laboratory had this 
Micromonospora sp. sequenced at the Institute of Genome Science sequencing facility 
(IGS, University of Maryland, Baltimore) using a Pacific Bioscience Sequencing machine 
and a 10KB insert library. The Micromonospora sp. RL09-050-HVF-A genome was 
uploaded to NCBI under the accession number JAGKQP000000000 and the BioProject 
ID PRJNA718589. 
5.2.1. Curated antiSMASH Output 
In order to apply the IsoAnalyst workflow to the full metabolome of 
Micromonospora sp., BGC mining was performed on the full genome using antiSMASH 
version 5.2.0-8ecc354. Our collaborators used the antiSMASH to perform sequence 
analysis of the BGCs, including automated substrate predictions. They further developed 
a protocol using MIBiG to manually interpret these substrate predictions using both 
sequence analysis and literature review. The antiSMASH output offers substrate 
predictions for a broad cross-section of biosynthetic classes using a suite of prediction 
algorithms including SANDPUMA,4 NRPSPredictor2,5 and RODEO.6 These substrate 
predictions have a fair degree of accuracy, but manual interpretation is nearly always 
required, as not all enzymes yield equally likely substrate predictions. For example, type 
I and II PKS and NRPS enzymes have more predictable substrates while special 
algorithms have been developed for other classes such as type III PKS.7 It is important 
to manually inspect every BGC substrate prediction in antiSMASH, as these predictions 
are potentially less accurate for more novel BGCs, and some BGCs have no substrate 
predictions at all. The antiSMASH output also indicates the most closely related BGC 
sequences that are available in the MIBiG database.2 Using the antiSMASH substrate 
prediction for the detected enzymatic domains, in combination with literature information 
from related BGCs in MIBiG, our collaborators developed a protocol for curating 
enzymatic substrate prediction information with the highest possible accuracy. This 
protocol is described in more detail in the methods section at the end of this chapter. 
The curated antiSMASH output for Micromonospora sp. is shown in Tables 5.1 and 5.2. 
Table 5.1 contains metadata and comments about each BGC. The BGC type is 
determined automatically in antiSMASH, and the comments are based on manual 
interpretations of related BGCs by comparison with the MIBiG database. The columns of 
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Table 5.2 contain predicted substrate counts for a single gene cluster from a list of 
commonly encountered biosynthetic substrates that are expected to be labeled by one 
or more SIL precursors. 
Table 5.1 BGCs Detected in Micromonospora sp. Genome 
Cluster Type Product # Comments 
1a NRPS 1  
1b RiPP 1  
1b RiPP 2  
2 PKS 1 galbonolides 
3 PKS 1  
4 PKS-NRPS 1  
5 RiPP 1  
6 NRPS 1+ desferrioaxamines 
7 & 21 terpene 1 sioxanthin - cluster 7 & 21 work together 
8 lantipeptide 2 very similar to SapB 
9 type II PKS 1 core PKS similar to frankiamycin type II PKS 
10 type I PKS 1 similar to maduropeptin 
11a PKS-NRPS 1  
11b lasso peptide 1  
12a NRPS 1  
12b PKS 1  
13 NRPS 1 indigoidine 
14 PKS 1  
15 phenazine 1  
16 NRPS 1 similar to Fruilimicin 
17 RiPP-like 1 no relevant predictions to be made 
18 terpene 1  
19 NRPS-like 1  
20 type III PKS 2 alkyl-O-dihydrogeranyl-methoxyhydroquinones 
21   see 7 
22 PKS-like 1 paulomycin without paulomycose 
23 indole 1 prenylated indole 
24 terpene 1  
25 NRPS 1  
26 NRPS 1 one AA is probably aromatic, possibly Phe 
27 NAGGN 1 N-acetylglutaminylglutamine amide 
28 lantipeptide 1  
29 RiPP-like 1 no relevant predictions to be made 
30a PKS-NRPS 1 similar to Tirandamycin 
30b terpene 2  
30c PKS 3 lobosamide 
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Table 5.2 Curated AntiSMASH Output for Micromonospora sp. 
Cluster 1a 1b 1b 2 3 4 5 6 7 & 21 8 8 9 10 11a 11b 12a 12b 13 14 15 16 17 18 19 20 20 22 23 24 25 26 27 28 29 30a 30b 30c 
Product # 1 1 2 1 1 1 1 1+ 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 2 3 
Glu                                                                         1 
Gln                     1             2                           2           
Arg   2 2             1                                                       
Pro   3 3                       1           2                                 
Orn                                                                           
Asp                   1 1       3           2                       5         
Met     2                                                                     
Thr   4 3             3 3       1                                   2         
Ile   1                                                                       
Asn           1       1 1       1 1                                           
Lys               3                                                 1         
Ala   8 9             1 1       1                                   2         
Leu   3 1             4 4       3                                   2         
Val   7 5     1       1 1       1           1                       1         
Phe   1 1                                                                     
Tyr                                         1                                 
Trp                                                       1                   
Ser   1       1       5 5       1                                   1         
Gly   8 5             4 4       7 1         6                       2   1     
Cys                   2 2                           1               2         
His     1                                                                     
Unk. Amino Acid 1         1 1+                                             1 2             
Acetyl-CoA               1         2                                     1           
Malonyl-CoA         3+ 1           12 12+ 1+     1   8           3 3                 5   8 
Methylmalonyl-CoA       4 3+                       1   1                               5   3 
Methoxymalonate       4                                                                   
Hydroxymalonate                                                                           
Methyl group         1 1                           1         1 1                   1   
IPP                 8                           3           1+             2   
DMAPP                                                       1                   
GPP                                                 2                         
FPP                                                   2                       
Succinyl-CoA               2                                                           
Unknown fatty acid                       1 1     1         1   1 1                       1   
Amino saccharide                         1       1     1 1                                 
Amino group                                                                           
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5.2.2. BGC Labeling Prediction 
In Chapter 4 I introduced the Substrate Labeling Table (Table 5.3) to show how 
the SIL tracer incorporation detected by IsoAnalyst can be aligned with the substrates 
used in the biosynthesis of compounds in S. erythraea and A. medietteranei. This table 
can further be used to predict SIL tracer incorporation into the products of the BGCs 
shown in Table 5.2. To predict the labeling patterns for each BGC, I integrated data from 
the curated antiSMASH output (Table 5.2) and the Substrate Labeling Table (Table 5.3) 
to create a table of predicted precursor labeling for all BGCs in the genome (Table 5.4).  
Not all of the BGCs detected in the genome of Micromonospora sp. are equally 
amenable to SIL incorporation in our experiment. Some well-characterized BGC classes, 
such as terpenes, do not have sufficient SIL incorporation by the SIL tracers used in this 
experiment. On the other hand, some natural products may be labeled by the SIL 
precursors used, but cannot be easily connected to the BGC due to the lack of 
biochemical knowledge about the BGC. I used two criteria to determine the likelihood of 
identifying the product of a BGC with the SIL precursors used in this study. Firstly, the 
predicted product of a BGC should be labeled in two or more conditions, as it is not 
possible to differentiate products of related BGCs on the basis of labeling in a single 
condition. Additionally, the product must be labeled three or more times in at least one of 
the conditions, as minor SIL incorporation is likely to occur in off-target compounds 
involved in primary metabolism. In Table 5.4 BGCs that meet both criteria are 
highlighted in dark gray, while BGCs that meet only one of the criteria are highlighted in 
light gray. 
The BGC substrate analysis indicates that NRPS and PKS BGCs are most well 
suited to discovery using this approach. There are several reasons for this bias. BGC 
identification and annotation tends to be most reliable for these two well-studied 
biosynthetic classes. Future improvements in BGC informatics, particularly in the area of 
substrate prediction for less well studied BGC classes, will increase the coverage of the 
IsoAnalyst method. Likewise, SIL precursor selection has a significant impact on BGC 
class coverage. Additional SIL precursors could be included to provide labeling for 
specific biosynthetic classes. For example, terpenes will only have robust SIL 
incorporation with [1-13C] acetate if the organism possesses the mevalonate pathway. 
Inclusion of 13C labeled IPP as an additional SIL precursor would significantly improve 
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coverage of compounds in this class. Similarly, chorismate-derived precursors are also 
common and 13C labeled chorismate or shikimate could help to prioritize specific BGC 
products containing these substrates. In applying this tool to environmental organisms, 
substrate analysis of the BGCs present ideally should be done in advance to guide the 
precursor selection process and optimize coverage of that particular organism’s 
metabolism.  
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               Table 5.3 Substrate Labelling Table 
Substrate A P M G 
Glu 2   1 
Gln 2   2 
Arg 2   4 
Pro 2   1 
Orn 2   2 
Asp 1   1 
Met 1  1 1 
Thr 1   1 
Ile 1   1 
Asn 1   2 
Lys 1   2 
Ala    1 
Leu    1 
Val    1 
Phe    1 
Tyr    1 
Trp    2 
Ser    1 
Gly    1 
Cys    1 
His    3 
Unknown amino acid    1+ 
Acetyl or Malonyl-CoA 1    
Propionyl-CoA  1   
Methylmalonyl-CoA 1 1   
Methoxymalonate   1  
Hydroxymalonate     
Methyl   1  
IPPa 2    
DMAPPa 2    
GPPa 4    
FPPa 6    
Succinyl-CoA 1 1   
Amino-saccharide    1 
Amino group    1 
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       Table 5.4 BGC Labelling Prediction for Micromonospora sp. 
Cluster Type A P M G 
8 lantipeptide 7     27 
28 lantipeptide 8     19 
11b lasso peptide 7     20 
1b RiPP 16     44 
5 RiPP       1+ 
17 RiPP-like         
29 RiPP-like         
6 NRPS 6 2   6 
12a NRPS 1+     3 
13 NRPS 4     4 
16 NRPS 7+     13 
1a NRPS       1+ 
25 NRPS       1+ 
26 NRPS       2+ 
19 NRPS-like 1+       
4 PKS-NRPS 2   1 4 
30a PKS-NRPS 10 5   1 
11a PKS-NRPS 1+       
10 type I PKS 14+     1 
9 type II PKS 12+       
20 type III PKS 15   1 1 
2 PKS 4 4 4   
3 PKS 6+ 3+ 1   
12b PKS 2 1   1 
14 PKS 9 1     
30c PKS 11 3   1 
22 PKS-like         
7 & 21 terpene 16       
18 terpene 6+       
24 terpene 2+       
30b terpene 2+       
23 indole 3     1 
15 phenazine     1 3 
27 NAGGN 5     5 
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5.2.3. Micromonospora sp. Complete IsoAnalyst Results 
I performed parallel SIL culture, UPLC-MS analysis and data processing with the 
IsoAnalyst pipeline on Micromonospora sp. The summary file from IsoAnalyst initially 
contained 246 m/z features that were labeled in two or more SIL conditions. I then 
manually interrogated this file to filter features based on chromatographic peak shape 
and signal intensity. Features were eliminated if either of these factors interfered with the 
accuracy of the SIL detection. This manual filtering step resulted in 100 features that 
could be grouped into two major compound classes based on their isotope labeling 
patterns (Figure 5.1). Forty-nine features corresponded to the desferrioxamine family of 
hydroxamate siderophores and 51 features corresponded to the lobosamide 
macrolactam polyketides previously discovered in our lab. Both classes could be 
confidently linked to their BGCs on the basis of their SIL incorporation patterns and 
showed remarkable diversity in labeled products despite originating from only two 
distinct BGCs.  
5.3. Desferrioxamines 
The first group of similarly labeled features possessed significant labeling by [1-
13C]acetate (2-6 positions), [1-13C]propionate (1-2 positions), and [1-15N]glutamate (5-6 
positions), but not labeling by [methyl-13C]methionine (Figures 5.1, 5.2). The only BGC 
in Table 5.4 containing two or more [1-13C]propionate labels and six or more [1-
15N]glutamate labels is BGC 6. This group of labeled MS features was consistently 
associated with iron-adducts and related fragment ions, suggesting a family of related 
siderophores. BGC 6 was predicted to produce a siderophore by antiSMASH, and had 
100% match with the BGC responsible for producing desferrioxamine B (5.1) and E 
(5.2).  
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Figure 5.1 Overview of IsoAnalyst Results from Micromonospora sp. 
Diagram showing all MS features with detected SIL incorporation in two or more conditions, 
following manual filtering and grouping according to SIL incorporation profiles. (a) known 
desferrioxamines, (b) known lobosamides, (c) new desferrioxamine, (d) new lobosamide. 
Diamonds represent features with SIL incorporation patterns related to the lobosamides, and 
circles represent features with SIL incorporation patterns related to the desferrioxamines.  
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5.3.1. Known Desferrioxamine Siderophores 
 Desferrioxamines are hydroxymate siderophores that are made up of three 
subunits of N-hydroxycadaverine, which are acylated by the acyl-dependent acyl 
transferase, DesC, with either acetyl-CoA or succinyl-CoA.8 Des D catalyzes the 
oligomerization of either two units of N-hydroxy-N-succinylcadaverine (HSC) and one N-
hydroxy-N-acetylcadaverine (HAC) to yield the linear 5.1, or three units of HSC to yield 
the cyclized compound 5.2.9 N-Hydroxycadaverine is derived from lysine, which has two 
nitrogen atoms than can be labeled by [1-15N]glutamate and one carbon atom that can 
be labeled by [1-13C]acetate (Table 5.3). Succinyl-CoA can be labeled in one position by 
[1-13C]acetate through the TCA cycle, and one position by [1-13C]propionate through the 
transformation of methylmalonyl-CoA to succinyl-CoA (Table 5.3). In both cases, the 
position of the SIL incorporation is ambiguous due to the symmetry of succinate (Figure 
5.1). These positions are represented by open circles in Figure 5.1, but only one of the 
two indicated positions may be labeled in a given molecule. In all, 5.1 is expected to be 
labeled in six positions by [1-13C]acetate, two postions by [1-13C]propionate, and six 
positions by [1-15N]glutamate (Figure 5.1). Enrichment of SIL in compound 5.1 was 
detected for all six nitrogen atoms derived from lysine in the [1-15N]glutamate condition, 
four of the six expected subunits in the [1-13C]acetate condition, and one of the two 
expected subunits in the [1-13C]propionate condition (Figure 5.1). The cyclized 5.2 has 
one additional position expected to be labeled by [1-13C]propionate due to an additional 
incorporation of succinyl-CoA, however, 5.2 demonstrated slightly less SIL incorporation 
in both [1-13C]acetate and [1-15N]glutamate compared to 5.1 (Figure 5.1). These 
differences are likely due to a lower signal intensity for the isotopologue peaks of 5.2 
rather than biosynthetic differences between 5.1 and 5.2.  
 In addition to 5.1 and 5.2, four desferrioxamine derivatives that have been 
reported in the literature were identified based on MS spectra, database matching, and 
the manual interpretation of SIL patterns. The identities of all compounds were 
confirmed by co-injection with authentic standards (Figure 5.2, Appendix A Figures A9-
14). Desferrioxamine D2 (5.3) contains one ornithine-derived subunit instead of the 
lysine derived N-hydroxycadaverine, due to the substrate promiscuity of the lysine 
decrarboxylase DesA.10 Although ornithine is expected to have one more position 
labeled by [1-13C]acetate than lysine (Table 5.3), we detected less [1-13C]incorporation in 
5.3 compared to 5.2 (Figure 5.2). This discrepancy can again be attributed to a 
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difference in signal intensity, indicating that the variable intensities between 
biosynthetically related compounds is often a limiting factor in the exact interpretation of 
SIL incorporation in this study.  
 
Figure 5.2 SIL Incorporation in Desferrioxamines 
(a) Diagram showing all MS features with detected SIL incorporation in two or more conditions, 
following manual filtering and grouping according to SIL incorporation profiles. (b) SIL 
incorporation detected by IsoAnalyst in desferrioxamine B and related analogs. SIL incorporation 
shown for MS features indicated as filled circles.  
 Most of the structural variability in the desferrioxamine family is derived from the 
substrate flexibility of DesC which has been shown to also accept larger acyl substrates 
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besides acetyl-CoA and succinyl-CoA.8 N-Acylated desferrioxamine derivatives have 
been described in a few studies.11–14 A paper previously published in our lab describes 
microferrioxamines A (5.4), B (5.5), and C (5.6), which are linear aliphatic siderophores 
containing acyl chains of varying lengths15 (Figures 5.2, 5.3). Due to the varying lengths 
of the acyl tail, the number of maximum theoretical positions labeled by [1-13C]acetate 
cannot be accurately predicted (Figure 5.3). Despite this, the microferrioxamines have  
 
Figure 5.3 SIL Incorporation in Microferrioxamines and Fragment Ions 
Expected (left) and observed (right) labeling for microferrioxamines A (a), B (b), C (c), and their 
corresponding b-ion and y-ion fragments. The b-ion contains the acyl tail group and retains more 
[1-13C]acetate incorporation which varies across the different analogues. The SIL incorporation 
across the y-ion was consistent in all SIL tracers, except [1-15N]glutamate (c), which is likely due 
to differences in ion intensity. The [1-13C]acetate incorporation cannot be fully predicted for these 
molecules, as the length of the acyl chain varies and cannot be directly predicted from the BGC, 
and these positions are represented by ‘x’ in the expected labeling by [1-13C]acetate for each 
compound.  
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clearly related SIL incorporation patterns in the [M+H]+ and [M-3H+Fe]+ ions (Figure 5.2) 
as well as the detected fragment ions (Figure 5.3). The same y-ion (m/z 319.2342) was 
detected for all three microferrioxamines, and the corresponding b-ions have higher [1-
13C]acetate incorporation, indicating the relative position of the acyl tail. While the 
substrate variation among these derivatives does produce minor differences in detected 
SIL patterns, additional data such as mass fragmentation patterns and the presence of 
iron adducts assist in categorizing these compounds as a biosynthetically and 
structurally related family.  
5.3.2. New Desferrioxamine Siderophore 
Review of the remaining members of this compound group identified one 
molecule with a diagnostic ferrioxamine labeling pattern and iron-adduct that had no 
match in existing natural products databases (Figure 5.1c). This new molecule 
possessed an [M+H]+ adduct at m/z 575.3752 corresponding to the molecular formula 
C26H50N6O8 suggesting an analogue of 5.1 containing an additional CH2 subunit. This 
putative desferrioxamine derivative (5.7) showed related labeling to 5.1, with a nearly 
identical labeling pattern in the [1-15N]glutamate condition, but decreased labeling by [1-
13C]acetate, and increased labeling by [1-13C]propionate (Figure 5.4a). This suggested 
that the additional CH2 subunit present in 5.7 derived from substitution of one [1-
13C]acetate subunit with an additional [1-13C]propionate moiety. To further understand 
the structural differences between these compounds, we examined the MS/MS 
fragmentation data. The y-ion m/z 319.2343 was detected as an MS feature for both 5.1 
and 5.7 and possessed identical SIL patterns in both cases (Figure 5.4b). The 
corresponding b-ion fragments m/z 243.1342 and m/z 257.1505 were detected for 5.1 
and 5.7 respectively. These b-ions have identical labeling in the [1-15N]glutamate 
condition, but relative to each other, m/z 243.1342 is enriched in [1-13C]acetate, while 
m/z 257.1505 is enriched in [1-13C]propionate (Figure 5.4b) The combination of the mass 
difference of 14.0 Da, corresponding to CH2, and the enriched [1-13C] propionate labeling 
in comparison to the analogous fragment in 5.1, indicates that propionyl-CoA replaces 
acetyl-CoA in the acylation of the terminal N-hydroxycadaverine residue, confirming the 
identification of this molecule as a new member of the hydroxamate siderophore family 
of natural products. Together, these results show that this strain can produce a large 
suite of desferrioxamine derivatives, and that these ions can be easily grouped together  
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Figure 5.4 SIL Incorporation in Desferroxamine B and Unknown 
Desferrioxamine 
(a) Structure of desferrioxamine B (5.1), and the mass spectra of the [M+H]+ ion, the b-ion and y-
ion fragments of 5.1. (b) Putative structure of the new desferrioxamine (5.7) and the mass spectra 
of the [M+H]+ ion, the b-ion and y-ion fragments of 5.7.  Expected (left) and observed (right) SIL 
incorporation for each ion are shown in boxes. 
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by relating SIL patterns detected using the IsoAnalyst platform. In total, I identified seven 
compounds produced by the desferrioxamine BGC, including the novel desferrioxamine 
analogue 5.7. 
5.4. Lobosamides 
5.4.1. Lobosamide Biosynthetic Gene Cluster 
The second major class of labeled molecules in this dataset also had closely 
related labeling patterns in the [1-13C]acetate, [1-13C]propionate, and [1-15N]glutamate 
conditions (Figure 5.1). Comparison of these labeling patterns (8 x [1-13C]acetate, 3 x [1-
13C]propionate, 1 x [1-15N]glutamate) to the annotated BGC list identified two BGCs with 
an appropriate combination of biosynthetic modules; clusters 30a and 30c (Table 5.4). 
Both BGCs include a single [1-15N]glutamate incorporation, with BGCs 30a and 30c 
incorporating five and three [1-13C]propionate units respectively. Based on these data 
alone, the molecules could derive from either BGC 30a or 30c because incomplete SIL 
incorporation or incomplete detection of isotope labeling could limit our ability to 
accurately define the number of SIL incorporations in each molecule. From the [1-
13C]acetate predictions in Table 5.4 we see that both BGCs have a higher theoretical 
maximum for acetate incorporation than the eight [1-13C]acetate units detected in this 
compound class. BGC 30a includes a maximum of ten [1-13C]acetate incorporations 
while BGC 30c includes a maximum of eleven (Table 5.4). However, these predictions 
include both direct and indirect incorporation pathways. Specifically, the methylmalonyl-
CoA building blocks that are predicted to be labeled by [1-13C]propionate in these BGCs 
are also expected to be labeled indirectly by [1-13C]acetate. Considering only the direct 
incorporation of [1-13C]acetate through malonyl-CoA and not methylmalonyl-CoA, BGCs 
30a and 30c incorporate five and eight labeled precursors respectively (Table 5.4). The 
strong and consistent incorporation of a minimum of eight acetate units in the molecules 
of this class thus prioritizes BGC 30c as the cluster responsible for the production of this 
compound family. This prediction is further strengthened by the observation that the 
predicted direct incorporation for BGC 30c (8 x [1-13C]acetate, 3 x [1-13C]propionate, 1 x 
[1-15N]glutamate) exactly matches the observed SIL patterns in the compound family 
(Figure 5.1).  
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5.4.2. Diversity of Detected Lobosamides 
BGC 30c has previously been shown to produce the lobosamide family of natural 
products.3 All the major compounds in this group displayed diagnostic m/z features and 
distinctive [M+H-H2O]+ in-source fragments consistent with the lobosamide family. The 
presence of lobosamide C (5.8) was confirmed by HPLC purification and NMR 
comparison, while lobosamide A (5.9) was identified in the extracts by UPLC-MS 
comparison to an authentic standard (Appendix A Figures A15-A18). Known lobosamide 
structures only accounted for 6 of the 51 MS features with related SIL patterns. Most of 
the remaining features were produced in low titer and had mass differences related to 
the degree of unsaturation and varying oxidations of the known lobosamide scaffold, 
suggestive of a suite of lobosamide analogues. These features were detected across 
more than half of the chromatographic separation time, indicating a wide range of 
polarities despite having the same structural units (Figure 5.1). I also noticed that despite 
the large number of features with lobosamide-like SIL incorporation, many of these 
features shared the same m/z value but were eluted at different retention times, further 
suggesting that the lobosamide BGC produces a variety of isomers. Aside from 
substrate flexibility, these configurational isomers add to the complexity of the chemical 
phenotype of a BGC. Although not all isomers are produced in isolable quantities, the 
IsoAnalyst approach allows for the easy detection and association of these related 
features for further investigation and optimization for compound isolation.  
5.4.3.  Isolation and Characterization of Lobosamide D 
I isolated a representative molecule from this class with an [M+H]+ m/z feature at 
500.3012 and a calculated molecular formula of C29H41NO6. This molecule did have a 
[M+H-H2O]+ adduct, however it demonstrated a slightly different distribution of ion 
adducts than the known lobosamide compounds (Figure 5.5). These distinctive in-source 
dehydration fragments also appeared in the MS/MS spectra, however, no structurally 
informative MS/MS fragments were detected for any of the lobosamides. The 1H NMR 
spectrum of the isolated compound bore low similarity to the 1H spectra for the known 
lobosamides (Figure 5.6a). While the initial chemical characterization data provided 
ambiguous evidence for the structural relatedness of my isolated compound with other 
lobosamides, it was clear from the SIL incorporation data that the new compound was 
derived from the same biosynthetic pathway. Using a combination of 1D and 2D NMR 
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experiments (Appendix B) I determined the planar structure of this new metabolite as a 
5-5-6 fused ring system variant of 5.9 which  we named lobosamide D (5.10) (Figure 
5.7a). The full absolute configuration of this new molecule was determined using a 
combination of extensive 1D-selective and 2D ROESY experiments, coupled with 
configurational assignments based on sequence data for selected keto-reductase (KR) 
domains3 (Figure 5.7b). A detailed description of the NMR experiments used to solve 
this structure is provided in the methods section at the end of this chapter.  
 
Figure 5.5 MS Adduct and In-Source Fragment Ions of Lobosamides 
Adducts and in-source fragment ions corresponding to 5.8, 5.9, and 5.10, which had SIL 
incorporation detected by IsoAnalyst. The dehydration and multi-dehydration ions are present for 
nearly all of the detected lobosamides, however the increased fragments and adduct ions of 5.10 
could not be accounted for by increased ion intensity.   
The proposed biosynthesis of this new member of the lobosamide family via 
epoxidation followed by intramolecular cyclization (Figure 5.6b) is analogous to the 
production of dracolactams A and B from a common macrolactam precursor16 and the 
production of mirilactams C-E from the macrocyclic precursor mirilactam A.17 It has been 
proposed that the key epoxidation step in this proposed biosynthetic pathway is 
catalyzed by a cytochrome P450 epoxidase that is encoded outside of the macrolactam  
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Figure 5.6 Comparison of NMR and SIL Incorporation in Lobosamides 
(a) Comparison of the 1H NMR spectra and IsoAnalyst profiles of lobosamides 5.8, 5.9, and 5.10. 
(b) Biosynthetic scheme for post-PKS tailoring reactions which transform 5.8 to 5.10. This 
biosynthetic scheme is a hypothesis put forth by the Abe group, where a variety of similar 
cyclized macrolactams have been discovered.18 
core BGC.18 This transformation has been observed in other macrolactam BGCs, but no 
epoxidase is found in any of the BGCs that are known to produce these cyclized polyene 
macrolactam compounds, supporting this hypothesis.16–21 This complicates the process 
of predicting intramolecular cyclization events and other complex late-stage structural 
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rearrangements for structures such as 5.10 based solely on the BGC sequence. 
Importantly, IsoAnalyst is able to identify biogenetic relationships between molecules, 
even for those which have significant structural rearrangements, highlighting a key 
advantage of this new platform for linking molecules to their cognate BGCs. 
 
Figure 5.7 Key NMR Correletions for Lobosamide D (5.10) 
(a) COSY correlations indicated by bold bonds. Key HMBC correlations indicated by red solid 
arrows. (b) Key ROESY correlations indicated by dashed red arrows. 
5.5. Conclusion 
In this chapter I have demonstrated how a complete genome sequence can be 
analyzed for BGCs and manually curated based on expected substrates using freely 
available computational tools. This BGC analysis workflow was developed in 
collaboration with our colleagues Dr. Marnix Medema and Dr. Justin van der Hooft, and 
represents the utilization of the most recent tools and databases available. The complete 
BGC analysis described in this chapter would allow for the careful selection of SIL 
tracers to optimize discovery of compounds from a given organism. This flexibility sets 
IsoAnalyst apart from many currently available tools that require multiply labeled or 
specialized precursors to identify SIL incorporation, and allows for a wide range of both 
targeted and untargeted experimental designs. Using four general SIL tracers that are 
widely applicable to multiple biosynthetic classes, I successfully identified two compound 
families present by their SIL incorporation patterns and further characterized ten specific 
compounds from within these groups. This analysis significantly reduced the number of 
interesting m/z features to manually investigate, and easily associated m/z features 
across the entire run on the basis of SIL incorporation.  
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Although I show in Table 5.4 that the general SIL tracers used in this study do 
have good coverage of the BGCs present in the Micromonospora sp. genome, I only 
succeeded in identifying novel compounds within known classes. The application of 
IsoAnalyst to different growth conditions, perturbations, or genetically modified 
organisms offers future opportunities for novel compound class discovery through the 
characterization of novel or unknown BGCs. Despite this, I have shown that novel 
chemistry can be discovered from known BGCs and many unknown m/z features with 
identifiable SIL incorporation detected by IsoAnalyst can also be associated with a 
known biosynthetic class.  
5.6. Methods 
5.6.1. Parallel SIL Fermentation with Micromonospora sp.  
The parallel SIL fermentation protocol, sample extraction, and UPLC-MS method 
used to analyze Micomonospora sp. in this chapter were performed exactly as described 
in Chapter 3. 
5.6.2. BGC Analysis of Complete Micromonospora sp. Genome 
The genome of the Micromonospora sp. isolate was first mined for BGCs using 
antiSMASH version 5.2.0-8ecc354, resulting in 26 BGCs. AntiSMASH can predict 
numerous natural product compound classes including non-ribosomal peptides, type I, II, 
or III polyketides, lanthipeptides, and terpenes. These predicted BGCs were used to list 
the type and number of substrates needed to biosynthesize the product. In some cases, 
such as for NRPS, our analysis provided input for the predicted substrate specificity of 
each BGC domain detected, which helped to list the various expected amino acids used 
as a substrate. Likewise, the PKS domain architecture information was used to assess 
the number of expected acetate, malonate, methoxymalonate, and methylmalonate 
substrate building blocks incorporated into the polyketide. In some cases, the output 
from this analysis was further investigated by looking at the closest associated MIBiG 
entry for each BGC to find more information on the expected substrates and other 
chemical moieties likely to be incorporated based on similarity of enzyme-coding genes 
to those found in experimentally characterized pathways. Literature information and 
uniqueness of enzymatic domains present were taken into consideration in generating 
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the substrate predictions shown in Table 5.2 ultimately a result of computationally 
predicted substrates where possible and expert knowledge on biochemical pathways 
where needed and possible based on known enzyme functions, for example in the case 
of methylations by SAMs. 
5.6.3. Large-Scale Fermentation and Extraction of Micromonospora 
sp.  
Micromonospora sp. was grown in 2.8 L Fernbach flasks containing 20.0 g of 
Amberlite XAD-16 adsorbent resin, a stainless steel spring, and 1 L of the minimal media 
as described above for use in the SIL experiments. Four large scale fermentations were 
performed without the supplementation of SIL precursors. Cultures were shaken at 200 
rpm for 6 days, at which time the cultures were filtered by vacuum filtration on Whatman 
glass microfiber filters. The cells and resin were collected and extracted with 250 mL of 
1:1 methanol/dicholormethane. The organic extract was collected by vacuum filtration 
and dried by rotary evaporation. The crude organic extract was initially separated into 
seven fractions by a stepwise methanol/water elution (10, 20, 40, 60, 80, 100 vol/vol) 
and an additional ethyl acetate wash step on a RediSep Rf C18 cartridge (Teledyne 
Isco) using a Teledyne Isco CombiFlash Rf flash chromatography system. 
5.6.4. Isolation and Characterization of Lobosamide C and D 
Purification of 5.8 and 5.10 was carried out using an Agilent 1200 series HPLC 
system. Lobosamide C (5.8) (0.7 mg) was isolated from the 100% methanol pre-fraction 
by HPLC (Phenomenex Kinetix XB-C18 5µm, 250 x 4.6 mm) using an isocratic 
separation (45% methanol + 0.02% formic acid, 45% H2O + 0.02% formic acid, and 10% 
isopropyl alcohol with 0.02% formic acid) with a flow rate of 1.2 mL/min for 20 minutes. 
Lobosamide C (5.8) was eluted from the column at 34.4 min and was collected by UV 
detection at 300 nm. Lobosamide D (5.10) (0.4 mg) was isolated from the 40% methanol 
pre-fraction by HPLC (Phenomenex Kinetix XB-C18 5µm, 250 x 4.6 mm) using an 
isocratic separation (23% acetonitrile + 0.02% formic acid and 77% H2O + 0.02% formic 
acid) with a flow rate of 1.2 mL/min for 20 minutes. Lobosamide D (5.10) was eluted 
from the column at 15.0 min and was collected by UV detection at 280 nm.      
Lobosamide D: [α]D = -166.7 (c 0.042, MeOH); UV (MeOH), λmax 275 nm, log Ɛ = 3.45; 
HRMS (m/z): [M+H]+ calcd. for C29H41NO6, 500.3007; found, 500.3012. (see Appendix B 
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Table B1 for NMR shifts), SMILES: 
C[C@H]1C[C@@H](O)[C@]2([H])[C@@]3([H])[C@]4(C)/C=C(C)/C=C/C=C\[C@H](O)C
[C@H](O)[C@@H](O)[C@H](O)[C@@H](C)/C=C/[C@@H]4C=C[C@]3([H])C(N12)=O 
5.6.5. Full NMR Characterization of Lobosamide D 
 The molecular formula C29H41NO6 was calculated from the [M+H]+ ion detected at 
m/z 500.3012 (calcd. 500.3007, ∆ppm = 1.0), indicating 10 degrees of unsaturation. 
Review of the 1H and phase-sensitive HSQC spectra revealed 4 x CH3, 2 x CH2, and 20 
x CH including 9 olefinic signals. Further evaluation of the 13C and HMBC spectra 
identified a further 3 x qC signals, including one olefinic carbon, and one amide carbonyl. 
These components accounted for all carbons, 36 of 41 protons, one oxygen and one 
nitrogen from the molecular formula. The remaining five oxygens and five protons were 
assigned as hydroxy groups, based on the presence of five broad exchangeable signals 
in the proton spectrum and five signals in the HSQC (1H 3.35 - 4.61 ppm, 13C 65.5 - 75.7 
ppm) consistent with oxygenated methines. This completed the detection of all the 
elements in the molecular formula in the spectral data. 
 To solve the planar structure the COSY spectrum was used to identify one large 
spin system that incorporated all but two of the protonated carbons in the molecule. 
Starting from an olefinic doublet at 6.07 ppm (H17) sequential COSY correlations to 6.16 
(H16), 5.84 (H15) and 5.48 (H14) ppm identified a diene motif. COSY signals from 5.48 
(H14) sequentially to 4.61 (H13), diastereotopic methylene protons at 1.23 and 1.62 
(H12), and oxygenated methine protons at 3.97 (H11), 3.35 (H10), and 2.92 (H9) 
indicated a polyhydroxylated region which in turn was connected to another olefin 
through COSY correlations sequentially from 2.29 (H8) to 5.47 (H7) and from 5.47 (H7) 
to 5.10 (H6). This completed the linear portion of the spin system highlighted in red in 
Figure 5.8a.  
 The next section of the structure elucidation was complicated by the presence of 
a large number of aliphatic methine signals, suggestive of a complex fused ring system. 
From the last olefinic proton (H6) a series of sequential COSY signals connected 
protons at 2.88 (H5), 5.32 (H4), 5.75 (H3), 3.10 (H2), 2.09 (H21), 3.62 (H22), 3.96 (H23), 
a diastereotopic methylene at 1.58 and 2.42 (H24), 3.71 (H25) and a terminal methyl  
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Figure 5.8 Key NMR Correlations for Configurational Analysis 
(a) Key COSY and HMBC correlations used to solve the planar structure of lobosamide D (5.10). 
(b) Diagram of key ROESY correlations used in the configurational analysis of lobosamide D 
(5.10).   
signal at 1.16 ppm. This completed the second component of the spin system illustrated 
in blue in Figure 5.8a.  
 Assembly of the tetracyclic ring system in 5.10 required extensive use of HMBC 
data. This was complicated by severe signal overlap for two of the methyl signals (H28 
and H29). Key HMBC signals from H2 and H3 to the amide carbonyl carbon (C1) at 
172.2 placed the carbonyl at C2. This left a total of five carbons; 1 x aliphatic CH3, 1 x 
vinylic CH3, 1 x olefinic CH, 2 x qC. This was suggestive of a trisubstituted olefin, which 
was supported by the presence of a methyl singlet at 1H 1.76 13C 16.1 ppm (H27) which 
showed HMBC correlations to the olefinic methine (C19) and a quaternary carbon at 
134.9 (C18). In addition, this vinyl methyl signal (H27) showed a strong HMBC 
correlation to C17, placing it at the terminus of the major spin system. The olefinic 
methine signal (H19) showed reciprocal HMBC correlations to C17, C18 and C27, 
confirming this assignment. H19 possessed two additional HMBC correlations, one to 
the remaining quaternary carbon at 38.9 ppm (C20) and the other to the remaining 
methyl carbon at 19.4 ppm (C28). Closer examination of the quaternary carbon at 38.9 
(C20) revealed an HMBC correlation from H21, closing the macrocyclic ring. Finally, a 
strong HMBC correlation from methyl H28 to C20 placed the remaining methyl group on 
carbon 20. Additional HMBC correlations from this methyl group to C5 and C21 
confirmed the presence of the 6, 5 fused ring system, and completed all of the carbon-
carbon bond connections in the molecule.  
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 The five hydroxyl groups were located on carbons 9, 10, 11, 13 and 23 based on 
COSY correlations from each broad OH proton to its associated methine proton 
(Appendix B Figure B4). Finally, the remaining nitrogen atom on the amide functional 
group was connected to the two remaining open positions in the molecule (C22 and 
C25). This assignment was supported by the chemical shifts for these two carbons (65.5 
and 47.1 respectively) and completed the planar structure assignment, accounting for all 
of the degrees of unsaturation. 
 Lobosamide D (5.10) was isolated from the same strain, Micromonospora sp. 
RL09-050-HVF-A, which was previously published by our laboratory as the producing 
organism of lobosamides A-C. To determine the complete absolute configurations of 
lobosamides A-C we previously obtained a full genome sequence for this strain and 
identified the lob PKS biosynthetic gene cluster. This sequence data, in conjunction with 
extensive dipolar coupling NMR experiments, defined the absolute configuration at every 
position in the molecule.3  
 Given the common polyketide core precursor between lobosamides A-C and 
lobosamide D (5.10) and the absence of any other relevant polyketide BGCs in the 
genome of the producing organism we hypothesize that this same BGC also produces 
lobosamide D. The absolute configurations of positions 9, 11, and 13 of lobosamides A-
C were previously determined by genetic analyses of three ketoreductase (KR) domains 
responsible for these hydroxyls. The relative configurations of the methyl at position 8 
and the hydroxyl at position 10 were determined experimentally and the configurations 
were fully assigned through comparison to the hydroxyl stereocenters (9,11, and 13) 
produced by KR domains. The stereocenter at position 25 in all of the lobosamides and 
related compounds including salinilactam and micromonolactam, is derived from a 3-
aminobutyrate starter unit. The enzymatic mechanism that produces this starter unit was 
characterized for incednine and demonstrated stereospecificity in producing (S)-3-
aminobutyrate. This stereospecificity helped assign positions 25S for lobosamides A-C, 
and this conserved stereospecificity for compounds containing the (S)-3-aminobutyrate 
starter unit has been shown experimentally in other related natural products (mirilactam, 
micromonolactam, etc). The same absolute configuration is assigned to position 25 in 
lobosamide D. Based on these previously established data, we determined the absolute 
configuration of the following positions of lobosamide D to be 8S, 9R, 10R, 11S, 13R, 
25S.  
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 The double bond configurations in lobosamide D (5.10) are also expected to 
match the configurations in the lobosamides. Double bond configurations were 
consistent in lobosamides A-C except for the olefin at C14-C15, which is 14E in 
lobosamide B and 14Z in lobosamides A and C. Evaluation of key coupling constants 
between olefinic protons in lobosamide D confirmed that it matched the configuration of 
lobosamide A in all positions including C14 (3JH14-H15 = 10.1 Hz). The full double bond 
configurations for lobosamide D are 3Z, 6E, 14Z, 16E, and 18E (3JH3-H4 = 9.8 Hz, 3JH6-H7 = 
14.6 Hz, 3JH14-H15 = 10.1 Hz, and 3JH16-H17 = 15.7 Hz) The double bond at position 18E 
was corroborated by ROESY correlations between H19/H21 and H5/H27, indicating that 
H19 and H27 are on opposite sides of the 6-membered ring.  
 The full absolute configuration of the 5-5-6 fused ring system was determined 
using ROESY correlations. When possible, ROESY correlations from 2D ROESY 
experiments were confirmed by selective 1D ROESY experiments. ROESY correlations 
between H21/H6, H21/H19, and H21/H23 indicated that protons H6, H19, H21, and H23 
were all located on the same face of the ring system (Appendix B Figures B7-8, Figure 
5.8b) A ROESY correlation between H2/H28 and the trans relationship between H2 and 
H21 (3JH2-H21 = 13.0 Hz) indicated that H2 and H28 are located on the same face of the 
six membered ring (Appendix B Figure B7, Figure 5.8b).  
 The absolute configuration at position 25S was previously determined by BGC 
analysis which indicated the starter unit (S)-3-aminobutyrate. However, no correlations 
could be observed in the 2D ROESY spectra between H23 and H25 or H29 in order to 
establish the relationship between the fused ring system and the known configuration at 
position 25. To address this, we performed a 1D ROESY experiment selectively 
irradiating H25 and observed a correlation to H23 (Appendix B Figure B10). This 
connected the known absolute configuration at position 25 to the relative configurations 
in the 6,5,5 ring system determined by ROESY experiments and allowed us to assign 
the full absolute configuration of lobosamide D as 2R, 5S, 8S, 9R, 10R, 11S, 13R, 20R, 
21S, 22S, 23R, 25S. 
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Chapter 6.  
 
Conclusions 
In this thesis I have described the development, optimization, and validation of an 
MS-based workflow for the untargeted characterization of complex chemical phenotypes 
produced by BGCs in microorganisms. The ultimate goal of this work is to provide a 
hypothesis-generating workflow for connecting compounds to BGCs using parallel SIL 
experiments. I have demonstrated various limitations to the IsoAnalyst approach, and 
highlighted important factors to consider when applying this approach to different 
microorganisms. I have shown the IsoAnalyst can accurately detect SIL incorporation 
into compounds with well-established biosynthetic pathways, and identify novel variants 
of compounds from known classes. The flexibility of this tool will offer opportunities for 
the creative application towards understanding natural product biosynthesis and novel 
compound discovery.  
6.1. Limitations  
The metabolic limitations of SIL incorporation need to be considered and 
optimized prior to SIL feeding and I have shown that considerations of both core minimal 
media components and SIL tracer selection are essential to experimental optimization. 
In Chapter 2 I discussed the steps that went into developing the minimal medium used 
throughout this thesis. However, this optimization overall resulted in a lack of diversity in 
the compounds produced by Micromonospora sp. in the full application of the workflow 
in Chapter 5. The application of this medium with the four SIL tracers I selected was 
sufficient for the initial development of this method, but a further expansion of both 
growth media and SIL tracers is necessary to expand upon the types of compounds 
identified. Although the use of minimal media is often limited in eliciting natural products, 
I demonstrated in Chapter 2 that a rich media can also be used and still result in 
sufficient SIL incorporation for some SIL tracers. The IsoAnalyst workflow lends itself to 
the parallelization of many conditions and would be especially complementary to one-
strain many compounds (OSMAC) approaches which test different types of media or 
elicitors of biosynthesis.  
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The MS signal intensity is the main technical limiting factor in the IsoAnalyst 
platform. I showed in Chapter 3 that signal intensity was a significant factor in the 
reliability of statistical measurements of heavy isotopologue peaks. This was further 
addressed in Chapter 5, as both the desferrioxamine and lobosamide families had more 
variability in SIL incorporation among different analogues due to signal intensity than 
enzymatic substrate flexibility. This limitation underpins the fact that IsoAnalyst does not 
provide an exact interpretation of the biosynthesis of every detected compound. Rather, 
it is a general way of associating MS features with related biosynthetic origins and 
generating hypotheses about the BGC responsible for compound production. Factors 
such as MS signal intensity, chromatographic peak shape, and overlap of related 
compounds greatly influence the data interpretation and currently still require manual 
interrogation to interpret. 
While signal intensity is the biggest limitation in determining SIL incorporation, 
BGC analysis and substrate prediction also restrict our ability to connect the compounds 
identified with the correct BGC. In Chapter 5, I demonstrated how a few simple criteria 
can be used to qualitatively assess the likelihood of identifying a compound from a given 
BGC using a given set of SIL precursors. This is a generalizable approach that can be 
used to optimize SIL selection on the basis of the BGCs present in the genome. This 
process also entails many manual data curation steps, however the current rate of 
growth of BGC databases will likely increase the automation and confidence of these 
predictions as more BGC sequences are discovered and their cognate product 
structures confirmed.1 Still, there are many BGCs that are detectable in the genome but 
have unreliable substrate predictions, and little resemblance to other BGCs which are 
not likely to be discovered using IsoAnalyst alone. IsoAnalyst is a complementary 
technique that can be used alongside more established approaches such a molecular 
networking, heterologous expression, and correlation-based BGC discovery to draw 
connections between compounds and BGCs.  
6.2. Future Perspectives 
There are many intriguing ideas about how this platform can be applied to natural 
product discovery and MS metabolomics in general. Using IsoAnalyst, one can focus on 
the entire chemical phenotype produced by a BGC, and assess how this phenotype 
changes under different environmental or genetic conditions. Rather than looking at a 
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single product of a BGC, IsoAnalyst can assess the differences in the full profile of 
compounds produced by a BGC in a sample. This can be used to detect optimal 
conditions for production of specific analogues, or to better understand how substrate 
flexibility influences the ecological function of specialized metabolism. Evolutionary 
pressures may select for more highly specific biosynthetic enzymes to produce the most 
potent compound structure, much like structure-activity relationships are established in a 
laboratory setting during drug development. Yet we find more often than not that 
biosynthetic enzymes employ this substrate flexibility to produce a variety of related 
structures. IsoAnalyst represents a step towards understanding natural product 
discovery from a more holistic biosynthetic and ecological perspective. By catering the 
experimental design to a particular organism and compound class, IsoAnalyst can be 
used to observe whole phenotypic changes from different conditions, including co-
culture. IsoAnalyst takes a systematic approach to understanding natural product 
biosynthesis with the assumption that BGCs are not hard-coded to produce bioactive 
compounds, but rather interact adaptably with the environment to produce different 
chemical compositions. In heterologous expression, and other genetic techniques used 
to induce compound production in native hosts, identifying the target compound 
structure can still be difficult while optimizing the system.2 IsoAnalyst can identify related 
compounds that are significantly structurally modified but derived from the same 
biosynthetic precursors, such as in the case of lobosamide D, and could assist in the 
identification of unexpected biosynthetic products in heterologous host systems.  
Advances in genomic sequencing, publicly available computational tools, and 
BGC databases have motivated large scale studies of BGC sequences and products.3 
Both correlation and feature based approaches are used separately and together to 
make connections between specific BGCs and compounds, and to draw big-picture 
conclusions about the distribution and variation of BGCs and the natural products they 
produce.1,4,5 IsoAnalyst can be used in conjunction with correlation based approaches by 
comparing SIL incorporation in organisms with related BGCs to identify products. This 
allows for the comparison of not just single products, but overall phenotypic variation 
between organisms with similar biosynthetic potential. These insights will further our 
understanding of BGC convergent and divergent evolution by offering a chemistry-
centric perspective of BGC diversity orthogonally to well-established genetic 
comparisons. IsoAnalyst is also complementary to feature-based approaches which 
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focus on metabolite detection in MS1 but often in MS/MS features as well. Molecular 
networking has become one of the most widely used MS metabolomics tools for 
identifying related compounds and associating structures on the basis of related 
fragmentation.6 IsoAnalyst can support the conclusions drawn from molecular 
networking analysis and contribute to structural hypotheses on the basis of which 
fragment ions retain or lose isotopic enrichment from specific SIL tracers. Overall, 
IsoAnalyst fills a gap in both correlation and feature based approaches by offering 
complementary biosynthetic information about m/z features that can be used to generate 
hypotheses and guide follow-up studies on specific compound classes.  
IsoAnalyst can also be applied to microbial culture in other creative ways. 
Detection of SIL tracer incorporation into natural products over time can be used to 
observe compound production throughout the growth phase, or as a result of introducing 
a metabolic perturbation. By applying IsoAnalyst as a targeted workflow to observe 
specific groups of compounds, the timing and influence of environmental factors on 
chemical phenotype can be more carefully interrogated. Addition of SIL tracers at 
different time points can also be used to optimize the efficiency of SIL incorporation and 
directly observe the timing of biosynthetic activity throughout the growth phase. These 
applications are possible because of the flexibility of the IsoAnalyst experimental 
approach, and the statistical application used to detect SIL incorporation. By determining 
the number of detectable SIL tracers incorporated into m/z features, IsoAnalyst simplifies 
the data interpretation compared to metabolic flux measurements and other untargeted 
methods that compare overall SIL incorporation between conditions. The IsoAnalyst 
approach focuses on natural product biosynthesis in terms of the substrates used rather 
than the metabolic flux through the pathway to identify the entire metabolic phenotype in 
a single MS metabolomics experiment. The novelty and flexibility of this approach will 
offer many new opportunities for applications in natural product discovery, biosynthesis, 
and ecological function.  
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Appendix A.   
 
MS and NMR Data for Known Compounds and 
Commercial Standards 
 
Figure A1. Erythronolide B Standard Co-Injection and MS 
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Figure A2. 1H NMR Spectra of Erythronolide B acquired in DMSO-d6 at 600MHz 
Commercial standard (top) and isolated compound (bottom) 
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Expansion of Figure A2. 
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Figure A3. 13C NMR Spectra of Erythronolide B acquired in DMSO-d6 at 150 MHz 
Commercial standard (top) and isolated compound (bottom) 
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Figure A4. 3-O-α-mycarosylerythronolide B Standard Co-Injection and MS  
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Figure A5. 1H NMR Spectra of 3-O-α-mycarosylerythronolide B acquired in DMSO-d6 at 600MHz 
Commercial standard (top) and isolated compound (bottom) 
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Expansion of Figure A5 
 
0.51.01.52.02.53.03.54.04.55.05.5
δ
(ppm)
0.51.01.52.02.53.03.54.04.55.05.5
δ
(ppm)
O
O
O
O
OH
OH
OH
O OH
OH
168 
 
Figure A6. 13C NMR Spectra of 3-O-α-mycarosylerythronolide B acquired in DMSO-d6 at 150 MHz 
Commercial standard (top) and isolated compound (bottom) 
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Expansion of Figure A6 
 
0510152025303540455055606570758085
δ
(ppm)
O
O
O
O
OH
OH
OH
O OH
OH
0510152025303540455055606570758085
δ
(ppm)
170 
 
Figure A7. Erythromycin A Standard Co-Injection and MS  
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Figure A8. Rifamycin S Standard Co-Injection and MS  
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Figure A9. Desferrioxamine B Standard Co-Injection and MS  
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Figure A10. Desferrioxamine E Standard Co-Injection and MS  
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Figure A11. Desferrioxamine D2 Standard Co-Injection and MS  
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Figure A12. Microferrioxamine A Standard and extract MS  
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Figure A13. Microferrioxamine B Standard and extract MS  
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Figure A14. Microferrioxamine C Standard and extract MS  
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Figure A15. Lobosamide C Standard and extract MS  
 
 
Figure A16. Lobosamide A Standard and extract MS  
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Figure A17. 1H NMR Spectra of Lobosamide C acquired in DMSO-d6 at 600MHz 
Standard (top) and isolated compound (bottom) 
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Figure A18. 13C NMR Spectra of Lobosamide C acquired in DMSO-d6 at 150MHz 
Standard (top) and isolated compound (bottom) 
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Appendix B.   
 
MS and NMR Data for Lobosamide D  
 
Figure B1. Lobosamide D Chromatogram and MS  
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 Table B1. NMR Signals for Lobosamide D 
Position d H (ppm) m J(Hz) d C 
1    172.2 
2 3.10 d 13.0 44.1 
3 5.75 d 9.8 121.1 
4 5.32 m  132.3 
5 2.88 d 9.8 52.6 
6 5.10 dd 9.8,14.6 127.5 
7 5.47 dd  134.4 
8 2.29 m  37.2 
9 2.92 dd 8.0,8.0 74.4 
10 3.35   75.7 
11 3.97 m  70.9 
12a 1.23 m  40.4 
12b 1.62 m   
13 4.61 m  68.8 
14 5.48 dd  138.1 
15 5.84 dd 10.1,10.1 125.2 
16 6.16 dd 10.1,15.7 122.3 
17 6.07 d 15.7 137.9 
18    134.9 
19 6.10 s  136.9 
20    38.9 
21 2.09 dd 9.3, 13.0 53.2 
22 3.62 dd 6.6, 9.3 65.5 
23 3.96 m  73.5 
24a 1.58 m  45.0 
24b 2.42 m   
25 3.71 m  47.1 
26 0.80 d 6.7 12.2 
27 1.76 s  16.1 
28 1.17 s  19.4 
29 1.16 d  21.0 
OH(9) 4.35    
OH(10) 4.34    
OH(11) 4.16    
OH(13) 4.60    
OH(23) 5.30    
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Figure B2. 1H NMR Spectrum of Lobosamide D acquired in DMSO-d6 at 600MHz 
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Expansion of Figure B2 
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Figure B3. 13C NMR Spectrum of Lobosamide D acquired in DMSO-d6 at 150MHz 
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Figure B4. COSY of Lobosamide D in DMSO-d6 at 600MHz 
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Figure B5. HSQC of Lobosamide D in DMSO-d6 at 600MHz 
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Figure B6. HMBC of Lobosamide D in DMSO-d6 at 600MHz 
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Figure B7. ROESY of Lobosamide D in DMSO-d6 at 600MHz 
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Figure B8. Selective 1D ROESY for H21 of (2.09 ppm) in DMSO-d6 at 600MHz 
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Figure B9. Selective 1D ROESY for H2 of (3.10 ppm) in DMSO-d6 at 600MHz 
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Figure B10. Selective 1D ROESY for H25 of (3.71 ppm) in DMSO-d6 at 600MHz 
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